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1“Sometimes I am scared because I think that if I lose this kidney, I’ll regret that I didn’t take my medication”(Kidney transplant patient)
“When you miss a dose you presume it is ok and you move on and nothing happens. 
And so on, until I went to the outpatient clinic to check my kidney function and it 
wasn’t ok anymore”
(Kidney transplant patient after graft loss)
In my work as a nurse practitioner, I see a lot of patients who have difficulties with taking 
immunosuppressive medication after kidney transplantation. They struggle to fit the 
medication into their daily life. This phenomenon intrigued me, why do patients act in 
a certain way that can lead to rejection of their graft. How do patients think about their 
medication and how does this affect their behavior?
End stage renal disease
Patients with end stage renal disease (ESRD) have various options for renal replacement 
therapy. Patients can undergo dialysis or kidney transplantation. While dialysis is a 
lifesaving treatment, transplantation, if possible, is the best option due to the advantages 
for patient survival and quality of life (www.renine.nl) (1). There are two choices in renal 
transplantation; a living donor kidney transplantation (LDKT) or a deceased donor kidney 
transplantation (DDKT). A LDKT is the most favourable, because of the advantages for graft 
and patient survival (2-4). Moreover it can be performed before dialysis has to be instituted. 
Thus dialysis related morbidity and mortality can be circumvented. With a kidney transplant 
a patient can live a relatively normal life without the limitations of dialysis, however the 
patient must take lifelong immunosuppressive medication to prevent rejection of the graft. 
Because of this medication regime they receive specific lifestyle recommendations. 
Therapy and lifestyle after kidney transplantation
Kidney transplant patients have to take immunosuppressive drugs every twelve-hours. A 
recent development is monotherapy once a day (5, 6). Most patients have a medical regime 
of two intake moments a day. In many cases patients have to take other medications in 
addition to their immunosuppressive drugs. Immediately after kidney transplantation when 
patients have to take medication, this consists of on average of at least 6 pills in the morning 
depending on the co-morbidity of the patient. Each medication can have specific conditions 
under which it can be taken, such as not in combination with other drugs or after food, 
the entire regime as a whole can be complex. The complexity of the regime is suggested 
to influence adherence (7-9). Because of the immunosuppressive medication patients are 
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more vulnerable for infections, and therefore have recommendations for diet to prevent 
a bacterial infection. Their diet is similar to the diet of pregnant women. Rates of skin 
cancer after kidney transplantation are high, the immunosuppressive medication makes 
the skin more vulnerable. Almost 40% of the post-transplant malignancies are skin cancer 
(10). Patients are therefore advised to avoid direct sun exposure. Also immunosuppressive 
medications have many side effects, including diabetes, cosmetic side effects, diarrhea, 
and tremors (11). This can have an effect on patient’s quality of life after transplantation. 
Because patients can experience side effects while benefits of the medication are not always 
evident this can influence their adherence. This can be likened to blood pressure medication 
whereby patients do not feel/experience benefits but do experience side effects (12, 13). 
These could be factors, which may affect medication adherence after kidney transplantation. 
Medication Adherence
According to the World Health Organization (WHO) adherence is defined as “the extent to 
which a person’s behavior corresponds with the agreed recommendations from a health 
care provider” (7). Nonadherence to the medication regime in chronically ill patients 
is related to poorer clinical outcomes (7, 14). After kidney transplantation we now see 
evidence that nonadherence has a negative influence on graft survival in the long term (15-
17). Nonadherence is also associated with increased healthcare costs (18, 19). 
One of the difficulties with adherence research is the issue of measurement. The gold-
standard to measure nonadherence is direct observation that medication was consumed 
(20). However this is not a realistic tool, you cannot always be there to observe your patient, 
especially after discharge from hospital. As each type of measurement has limitations, 
combining several measures of adherences, so called ‘triangulation’, is recommended (21). 
According to the WHO there are five interacting dimensions that affect adherence. The 
first is ‘social and economic factors’, for example poverty, race and age, insurance of the 
patient. The second dimension is ‘the health care team and system-related factors’, such as 
patient-provider relationship. The third dimension ‘condition-related factors’ is the severity 
of symptoms or severity of the disease and how they influence patients’ perception of risk 
if they deviate from the prescribed regime. The fourth dimension is ‘therapy-related factors’ 
like the complexity of the medical regime and the side effects of that regime. The fifth 
and last dimension is ‘patient-related factors’ which represents the resources, knowledge, 
attitudes, beliefs, perceptions, and expectations of the patient. 
Most studies on non-adherence focus on ‘therapy-related factors’ (22, 23). Less is known 
about the second dimension ‘the health care team and system-related factors’ or the fifth 
dimension ‘patient-related factors’. Examples of patient-related factors are the attitudes 
and beliefs of the patients. In other patient groups, evidence suggests that these patient-
related, psychosocial factors influence adherence (24, 25). Moreover, most of the research 
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1on nonadherence is cross-sectional (15); consequently there is a great variation in time since kidney transplantation. Adherence and factors that cause it may be different at different phases after transplantation. There is thus a need for prospective studies to investigate the rate of nonadherence immediately after transplantation and changes over time as well as 
potential determinants of nonadherence. 
A meta-analysis showed that in kidney transplantation there is a nonadherence rate of 
35.6 cases per 100 persons per year (15). Nonadherence is more common among adolescents 
compared to other age groups (26, 27). Many studies focus mainly on the adolescent in 
paediatric care (aged 12-18 years) and the effect of transition from paediatric to adult care 
on adherence (28-30). However, less is known about nonadherence rates of the young adult 
in adult care (>18 years) and who of the young adults are at risk. To our knowledge, there is 
also hardly any evidence about elderly (>65 years) and their non-adherence rate in kidney 
transplantation. Research among elderly and nonadherence in antihypertensive medication 
showed that half of patients forget their medication (31). Patients that are classified as 
nonadherent can have problems with the taking, dosing, and timing of the prescribed 
medicines (32). The complexity of the regime is suggested to have influence on adherence 
(7-9). When patients get older (>65 years) this can even be more difficult due to their aging 
process.
Graft survival in kidney transplantation 
After transplantation the survival of the graft depends on different factors. Patients who are 
transplanted with a LDKT have significant patient and graft survival benefits when compared 
with DDKT (2). In DDKT there is damage due to type and length of cold storage and therefore 
the quality of the kidney (33). In contrast, living donor nephrectomy is planned in an 
optimized setting. Moreover, the donor is screened and therefore is in an excellent state 
of health. Patients who are transplanted pre-emptively (prior to initiation of dialysis) with 
a living donor kidney have the best clinical outcomes (34, 35). Also the least mismatches 
on the human leukocyte antigen (HLA)-A, -B, -DR contributes to a better graft survival (3, 
35). Since the 1990’s more effective immunosuppressive drugs with fewer side effects 
are available to prevent rejection. Nevertheless rejection can occur after transplantation 
and can influence graft survival. Patients with a previous transplant or sensitized patients 
with a high level of a panel-reactive antibodies can develop an early and aggressive form 
of rejection, termed AMR (36). For this type of rejection there is no standard treatment. 
The most common form of immunological rejection in the early post-transplant period is 
acute cellular rejection; the impact of acute cellular rejection on graft survival depends on 
the response to treatment (37). Younger patients have a more vigorous immune system, 
resulting in more rejection (23, 38). The immunosuppressive drugs, especially calcineurin 
inhibitors, can cause nephrotoxicity. The avoidance of clinical or subclinical episodes of 
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nephrotoxicity may be important in terms of long-term allograft histology and function (39). 
Recurrence of original disease, infections with bacteria or virus, can also play a role in the 
graft survival. The short term survival has increased over recent years, 1-year graft survival 
rates are typically above 90%, while the long-term graft survival rates have remained 
unchanged at 4% graft loss per year (40, 41). Risk factors for chronic allograft loss are donor 
organ quality, immune factors, but also recipient factors like hypertension, proteinuria, 
smoking and medication non-adherence (42). Late acute rejection is often seen in the clinic 
and it may be the result of medication non-adherence. The rejection is often severe and 
is associated with de novo donor specific antigen (DSA) and vascular rejection that can 
result in graft loss. However there is little evidence of prospective studies investigating if 
medication nonadherence (in timing) has influence on rejection rate or graft survival. More 
important we still do not know the characteristics, behavior and beliefs of patients at risk for 
nonadherence and therefore for graft loss.
Aim and outline of this Thesis
The overarching aim was to gain a better understanding of medication nonadherence and 
in particular the psychosocial aspects of behavior after kidney transplantation in order to 
inform the care that nurse practitioners can offer in the clinic. To understand how patients 
cope with their medication regime in daily life, it is important to understand how they 
perceive their illness and medication as well as how this medication regime fits into, or 
conflicts with, their daily life. What can we, as healthcare professionals, contribute to the 
care of our patients so that they become more adherent, how can we achieve the best graft 
survival in kidney transplant patients with the best quality of life. 
Research questions were: 
(1) What is the rate of nonadherence among our population of kidney transplant recipients 
and does this change over time?
(2) What are the attitudes, beliefs and goals of kidney transplant recipients towards the 
medication regime?
(3) To what extent are these attitudes, beliefs and goals related to nonadherence? 
(4) To what extent is nonadherence related to graft survival?
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1The research questions were answered in the following chapters:Chapter 2:  Describes a mixed-methods Q-methodology study that investigate attitude to nonadherence among young adult renal recipients.
Chapter 3:  A descriptive study about attitudes and behavior of young adults towards 
the medical regime.
Chapter 4:  A q-methodological study into the attitudes towards medication non-
adherence in elderly kidney transplants patients.  
Chapter 5:  Describes a prospective cohort study on the role of goal cognitions, illness 
perceptions and treatment beliefs in self-reported adherence up to 6 
months after kidney transplantation. 
Chapter 6:  Describes a prospective cohort study into immunosuppressive medication 
adherence up to 18 months after kidney transplantation.
Chapter 7:  Attitudes to medication after kidney transplantation and their association 
with medication adherence and graft survival: a 2-year follow-up study.
Chapter 8:  General discussion & Clinical implications
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Abstract
Background: Young adult renal transplant recipients may display patterns of behavior that 
affect graft survival. The present study aimed to identify young adults at risk of non-adherent 
behavior by investigating their attitudes about post-transplant health lifestyle.
Method: A Q-methodological study was conducted. Participants were asked to rank-order 
statements on issues potentially associated with (non-)adherence, according to agreement. 
Factor analysis was applied to uncover similar patterns in the ranking of statements. The 
resulting factors represent attitudes and are described using a composite ranking of the 
statements. As a first test of discriminated validity, a different group of 34 young patients 
was asked how well the factor descriptions fitted them. 
Results: 26 young adults (18-25 years) participated in the study. They were remarkably 
willing to discuss sensitive issues when confronted with statements on the cards. Four 
distinct attitude profiles concerning post-transplant health lifestyle were found among 
young adults: (i) concerned & controlled, (ii) appearance orientated, (iii) opinionated & 
independent, and (iv) easy going & pliable. Self-categorization discriminated well in 67% of 
the respondents between the four attitude profiles. 
Conclusions: Using Q-methodology, four attitude profiles about post-transplant health 
lifestyle were uncovered. Self-categorization on these attitudes seems feasible and may be 
a useful screening aid to identify young adults at risk of non-adherence. 
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2
Introduction
Many studies have indicated that renal graft survival is significantly worse in young adults 
when compared with adults [1,2]. Also in our center we found a lower graft survival in 
patients of 18 to 25 years of age compared to older recipients (Fig 1) [3]. 
Figure 1 Graft survival censored for death after kidney transplantation (no exclusions) in 
Rotterdam stratified for age.
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It is generally assumed that young adults have a more vigorous immune system, resulting in 
more rejection [1,4]. This may, however, not be the only explanation for the difference in graft 
survival with the adult population. Nonadherence to the post-transplant therapeutic regimen, 
especially nonadherence to medication, was demonstrated to be a major source of graft loss 
and morbidity among young adult renal transplant recipients [5-8]. This illustrates, as Dobbels 
et al. [9] also argued, that young adult transplant recipients should be regarded as a chronically 
ill patient population in whom behavioral and psychosocial management is equally important as 
It is generally assumed that young adults have a more vigorous immune system, resulting 
in more rejection [1,4]. This may, however, not be the only explanation for the difference in 
graft survival with the adult populati . Nonadh rence to the post-transplant therap utic 
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graft loss and morbidity among young adult renal transplant recipients [5-8]. This illustrates, 
as Dobbels et al. [9] also argued, that young adult transplant recipients should be regarded 
as a chronically ill patient population in whom behavioral and psychosocial man gement is 
equally important as state-of-the-art medical management. Some studies have attempted 
to categorize transplant recipients according to adherence, mostly using self-reports of 
medication intake, observational data of blood levels, or medical staff opinion [e.g.,7,10-
14]. These studies confirmed the association between non-adherence and adverse effects 
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for the patient. Other studies have investigated associations between adherence and 
individual and contextual variables [e.g.,8,11-13,15,16]. These studies found associations 
between adherence and, among others, gender, satisfaction with appearance, symptoms of 
posttraumatic stress disorder, self-awareness, denial, and various parental and young adult-
parent relationship variables. 
These studies provided valuable insights into possible characteristics of young adult 
transplant recipients at risk of non-adherence and their environment. Many of these 
authors recommended further investigation into instruments that help identify patients at 
risk of non-adherence, as necessary aid for the design of effective interventions to increase 
patient survival and well being [8,11,13,15]. However, such investigations have not been 
conducted yet. The present study aimed to identify young adults at risk for non-adherent 
behavior by investigating their attitudes about posttransplant health lifestyle, and to explore 
the usefulness of the composite profiles in daily practice.
Methodology
To investigate young adults’ attitudes about their health lifestyle, a Q-methodological 
study was conducted. Q-methodology is a hybrid qualitative–quantitative method that 
provides a foundation for the systematic study of subjectivity, peoples’ viewpoints, beliefs, 
attitudes, feelings, opinions and the like [17-19]. It combines the strengths of qualitative 
and quantitative research [20], and is regarded a more robust technique than alternative 
methods for the measurement of attitudes and subjective opinion [21]. Q-methodology was 
used before to investigate health lifestyle attitudes among youths [22].
In a Q-methodological study, people typically are presented with a sample of statements. 
Respondents are asked to rank-order these statements according to their point of view, in 
this case according to agreement, using a quasi-normal distribution (Fig 2). 
The individual rankings of statements are factor-analysed so as to reveal a limited 
number of corresponding patterns in the way the statements were sorted by respondents. 
Correlation between individual rankings of statements is viewed as an indication of similar 
viewpoints. Therefore, the results of a Q-methodological study can be used to describe 
a population of viewpoints, not a population of people [23]. Q-methodology research 
emphasizes the qualitative ‘how’ and ‘why’ people think the way they do; the methodology 
does not count ‘how many’ people think a certain way. The goal of Q-methodology is, first 
and foremost, to uncover different patterns of thought and not their numerical distribution 
among the larger population [24]. Finally, it is a small sample methodology: “Q does not 
need large numbers of subjects as does survey analysis, for it can reveal a characteristic 
independently of the distribution of that characteristic relative to other characteristics” [25].
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The current study consisted of four phases. First, possible self-referent statements young 
adults can make about posttransplant health lifestyle were collected, through participant 
observation in the clinic and scientific literature. The statements should be matters of 
opinion only, not fact; Q-methodology assumes that opinions are subjective and can be 
shared, measured and compared [17]. A total of 72 statements were collected. Secondly, 
a broadly representative subset of statements was selected using the WHO dimensions of 
adherence [26]: socioeconomic-related factors, health care team- or health system-related 
factors, condition-related factors, treatment-related factors and patient-related factors. This 
was done by the authors, based on an iterative procedure and consensus. The final Q-set 
consisted of 37 statements (Table 1), which were randomly numbered and printed on cards. 
Third, respondents were recruited and Q-sort interviews were conducted. All kidney 
transplant patients in our outpatient clinic, aged between 18 and 25 years (January 1st 
2006), were invited to participate in this study (n=46). Those with a failed kidney graft were 
included to prevent bias toward compliant patients without graft loss. Patients were not 
selected, but we excluded two patients with an intellectual disability (n=44). In total 26 
young adults responded (response rate of 59%). The main reason for nonparticipation was 
travel distance to the clinic. Other young adults had no interest in this research arguing they 
did not want to be reminded of their disease. Patient characteristics are shown in Table 2. 
Table 2  Patient characteristics
                     Q-study
Respondents 
(n=26)
Non-respondents 
(n=20)
Follow-up
(n=34) 
Age, median (range)(yr) 22.5 (18-25) 22 (18-25) 22.5 (18-25)
Time after transplantation, median (range)(yr) 2.5 (0-17) 5.5 (0-17) 3(0-19)
Gender
   Female
   Male
10 (38.5%) 
16 (61.5%) 
6 (30.0%) 
14 (70.0%)
10 (29.4%)
24 (70.6%)
Graft
   Functioning
   Failure
22 (84.6%)  
4 (15.4%)
18 (90.0%)  
2 (10.0%)
32 (94.1%)
2 (5.9%)
Education
   High
   Middle
   Low
8 (30.8%) 
8 (30.8%) 
10 (38.4%) 
n.r. n.r.
Ethnicity
   Caucasian
   Other
19 (73.1%) 
7 (26.9%) 
16 (80.0%) 
4 (20.0%)
21 (61.8%)
13 (38.2%)
Living environment
   Independent
   With parents
9(34.6%)
17(65.4%)
 
n.r. n.r.
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There were no statistically significant differences between respondents and 
nonrespondents for age, gender, functioning graft, or ethnicity. All one-to-one interviews 
were conducted by a trained nurse practitioner (M.T.) in a private room in the outpatient 
clinic at the hospital. During the interview, participants were asked to rank-order the 37 
cards containing the statements, using a score sheet (Fig. 2). They were first asked to read 
through all statements and to sort them into three piles: cards containing statements with 
which they agreed, disagreed, and had no opinion about or were considered irrelevant. 
Next, they were instructed to take the pile with cards they agreed with, read through them 
again, and to select the two they agreed with most. These were placed in the two spots 
at the extreme right of the score sheet (Fig. 2). From the remaining cards in the pile they 
selected the four they agreed most with, et cetera, until all cards in the pile were placed on 
the score sheet. These steps were repeated for the pile with cards they disagreed with, now 
working from the left of the score sheet. Finally, the cards in the last pile were rank-ordered 
in the remaining spots on the score sheet, as felt suited by the respondent. At the end of 
the interview, participants were asked to reflect on their rank-ordering of the statements 
and to motivate their preferences. The interviews were audio-taped and transcribed. 
Finally, the data were analyzed and interpreted. The individual rankings of statements were 
analyzed using common factor analysis (extraction method: centroid/rotation method: 
varimax). Q-analysis differs from conventional factor analysis only in the sense that the 
Q-sort(er)s are taken as variables. Consequently, respondents are clustered according to 
(dis)similarity in their ranking of the statements, and the resulting factors represent clusters 
of young adult transplant recipients who share a posttransplant attitude about their health 
lifestyle. For each factor a composite sort was calculated, which is a weighted ranking of 
the statements based on the underlying Q-sorts and their correlation coefficients with the 
factors as weights. This composite sort represents how a young renal transplant recipient 
correlating 100% with that factor would have rank-ordered the statements, and is the basis 
for interpretation and description of the factor. Data were analyzed using PQMethod 2.11 
(software and manual are available at www.qmethod.org or www.rz.unibw-muenchen.de/
p41bsmk/qmethod).
Then, as a first test of these results as a potential screening instrument, a convenience 
sample of 34 young renal transplant recipients categorized themselves on the factors: six 
patients who had recently been transplanted (between January 2006 and April 2007), 
three patient who came from the pediatric department, 19 respondents from the main 
study (of whom 12 loaded on one of the four factors), and six nonrespondents from the 
main study who agreed to participate in the follow-up. For this purpose, four short factor 
descriptions were developed, highlighting the important distinguishing characteristics of 
each attitude profile (see Table 1). These 34 young adults were asked how well each of the 
factor descriptions fitted them, using a 5-point Likert scale ranging from “totally not” to 
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“very well”. This was done in an interview setting, by the same trained nurse practitioner 
(M.T.) during a regular visit to the same outpatient clinic in the period January to April 2007. 
Spearman correlations were computed to assess discriminate validity.
The study was approved by the Medical Ethics Review Committee of the Erasmus 
University Medical Center of Rotterdam. 
Results 
Twenty-six young renal transplant recipients (18-25years) participated in the study. We 
observed that they were willing to discuss sensitive topics in response to the statements 
printed on the cards. Analysis of their Q-sorts resulted in a four factor solution, that is, 
four distinct young adult posttransplant health lifestyle attitude profiles (Table 1). The four 
factors were defined by 17 participants (65%); four participants did not load statistically 
significantly on any of the factors and five participants were confounded. 
Young adults loading on the first factor (a) worry that their kidney will be rejected 
(statement 2 gets a +3 score; Table 1), are concerned about their future (statement 20), 
and think it is important that the outpatient clinic monitors their kidney function regularly 
(statement 34). Like someone said: “I wish I could see a doctor every week instead of once 
in two months” or “If I feel something different, I am scared that my kidney will reject.” They 
are careful about their medication (statement 18, 27) and their health behavior (statement 
36), and find it more important to be adherent than to have a good life now (statement 26). 
The post-sort interview indicated that these young adults prefer to be in control of their 
regime, but also wish to be monitored regularly by professionals. Non-adherence leads to 
feelings of guilt, and the regime and their prospects make them at higher risk of depression 
and gloominess than other groups. Factor (a) was labeled “concerned & controlled”. 
Young adults loading on the second factor (b) are appearance-orientated (statement 
11 and 21), “I can’t control my weight, due to the medication, that affects me a lot,” do 
not wish their life to evolve around their disease (statement 35), and believe that after 
transplantation they can live a normal life (statement 19 and 31). They do not tell others 
they are transplanted (statement 1). “I never tell someone I have a transplant.” Young adults 
with this attitude most fear being transplanted may interfere with getting into a normal 
relationship (statement 10), “Dialysis is at some point inevitable, a partner should know 
that,” and feel least guilty about behaving unhealthily (statement 36). The risk for non-
adherence seems relatively small in these young adults, but the fear for cosmetic side-effects 
of immunosuppressants, and the tendency to be incommunicative about their transplant in 
their social environment, may interfere with adherence to their regime in some occasions. 
Factor (b) was labeled “appearance-orientated”. 
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Young adults loading on the third factor (c) believe strongly about not wanting to go 
back on dialysis again (statement 9) “I never want to go back (on dialysis), I can’t maintain 
all those rules,” and do not wish their life to evolve around their disease (statement 35). 
They feel they can live a normal life (statement 31), do not feel less fit than their peers 
(statement 14), do not seek contact with other transplant recipients (statement 23), are not 
afraid about getting into a relationship (statement 10), and are rarely gloomy or depressed 
(statement 30). These young adults appear pretty well informed about the medication 
they take (statement 25), think it is important that the outpatient clinic monitors their 
kidney function regularly (statement 34), and indicate that health care professionals should 
confront them if they do not adhere to their regimen (statement 28). They seek a normal 
life, with the least possible limitations from their regime. More than in other groups, these 
young adults are scared of a former rejection because of nonadherence and, although they 
try to comply better now, think it is important to be monitored by professionals. Factor (c) 
was labeled “opinionated & independent”. 
Finally, young adults loading on the fourth factor (d) find it more important to live a good 
life now than to be compliant (statement 26), find it hard to say no to friends (statement 17), 
and think nothing bad will happen if they forget their medication (statement 29). “When 
I don’t take that pill I will not die, I’m not that punctual with my medication.” Although 
they have no problems telling others they are transplanted (statement 1), they, least of all, 
believe they can live a normal life after transplantation (statement 31), least of all think it is 
important that the outpatient clinic monitors their kidney function regularly (statement 34), 
and most of all indicate to experience side effects (statement 24). In addition, they are not 
at all concerned about going back on dialysis (statement 9) and do not worry that their life 
evolves around their disease (statement 35). These young adults seems to be uninformed 
or uninterested in their illness and regime, and not to foresee or accept the risks of their 
nonadherent behaviour. Their risk for nonadherence therefore is high. Like one of them 
quoted: “I know I am a kidney transplant patient, I know that some day I will probably 
become so ill that I can die within a week. So for now, I want to try it all.” Factor (d) was 
labeled “easy going & pliable”.
In the follow-up analysis, we tried to identify the population at risk for non-adherence; 
therefore, we asked 34 young adult transplant recipients how well the four posttransplant 
health lifestyle attitudes suited them (patient characteristics; Table 2). Discriminating 
answers were obtained from 23 of 34 respondents (67%): nine respondents self-selected as 
attitude concerned and controlled, two as attitude appearance-orientated, nine as attitude 
opinionated and independent, and three as attitude easy going and pliable. The remaining 
respondents provided non-discriminating answers by eliciting equal highest scores on more 
than one item. We found two attitude scores to be correlated: a sizeable (.46) negative 
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correlation between the scores for attitudes concerned and controlled and easy going and 
pliable (p<0.01). In this relatively small sample, girls (4.2 vs. 3.0; p<0.05) and younger patients 
(ρ = -.35; p<0.05) scored higher on the attitude concerned and controlled. No statistically 
significant differences were found for the age at transplant and living or deceased donor 
kidney. 
Finally, we can compare the results for young adults who participated in both studies: 
12 of these 17 respondents loaded on one of the four factors in the Q-methodological study 
and self-selected one of the four profiles. Of the three respondents loading on the factor 
concerned and controlled in the Q-methodological study, two indicated that the description 
fitted them well in the follow-up exercise, and one very well. Of the two respondents loading 
on appearance orientated, one self-selected as fairly well and one as very well. Of the six 
loading on “opinionated and independent”, one self-selected as not really, two as fairly well, 
one as well, and two as very well. Finally, the one loading on easy going and pliable self-
selected as very well in the follow-up exercise. The results of both studies therefore seem 
fairly similar. 
Discussion
This Q-methodological study revealed four distinct health lifestyle attitudes among young 
adult transplant recipients: (a) concerned and controlled, (b) appearance orientated, (c) 
opinionated and independent, and (d) easy going and pliable. The primary differences and 
similarities between these four attitudes have been discussed. 
Some remarks need to be made regarding these results, however. First, unexpectedly, 
parents do not seem to play a significant role in any of the attitudes. This differs from former-
related research among adolescents with chronic disorders in the Netherlands, which 
revealed a distinct attitude profile for their parents supporting and even taking over control of 
their regime [27]. This difference probably relates to the older age of our participants. In the 
present study, peers seem much more influential on posttransplant health lifestyle attitudes. 
Unfortunately, from the perspective of treatment adherence, peers had not a beneficial 
influence, especially in the case of young adults with attitude (d). Second, appearance is 
a hot topic in all attitudes, though most explicit in attitude (b). This concern seems mainly 
related to social acceptance by peers and the ability to get into relationships. The strongest 
implication to be considered in clinical practice is adherence to immunosuppressive drugs 
with cosmetic side-effects. Third, attitudes (a), (b) and (c) seem positively associated with 
adherence, but at least in two of them, (b) and (c), the need for monitoring by professionals 
is emphasized. This indicates that these young adults acknowledge the importance of 
adherence, try their best to comply, but still are unsure or would appreciate feedback on 
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how they are doing. Young adults with attitude (d) also emphasize the need for monitoring 
the functioning of their kidney by professionals, especially to be informed about the extent 
of the negative side-effects of their nonadherent behaviour. Finally, while depression 
previously has been indicated as a risk factor for nonadherence [12], here – in attitude (a)– 
we found the opposite. The gloominess of these young adults seems to be associated with 
the regime and their prospects, but translates into need for high control and monitoring 
than nonadherence.
Some remarks also need to be made regarding the methodology applied in this study. 
First, the sorting of the cards was perfectly feasible for these young adults and the postsort 
interviews indicated that they comprehended the task and the contents very well. In 
that sense, the postsort interview also served as a validity check, because incongruence 
between the sorting of the cards and explanations of the sort could be remedied. Either 
statements could be re-shifted on the score sheet in case they were misunderstood, or the 
explanation could be clarified to the interviewer. But this was rarely necessary, which is an 
indication for the validity of the results. This may also be helped by the fact that the principal 
investigator (M.T.) was familiar to the patients. The participants appeared open and frank 
about their behavior and underlying motivations, and did not experience the interview as 
an infringement on their privacy. 
Second, we found the statements were of help in communication with these young 
adults. Adolescents are more vulnerable and less approachable for various psychological 
reasons [16]. Strikingly, young adults were talking easily about sensitive issues when 
confronted with the task to rank-order statements on a card, because it helped them raise 
issues they had not thought of or were reluctant about before. One of the participants even 
asked if he could have the cards so he could communicate better with his family about the 
different subjects coming with his disease. Participating in the study was not only enjoyable, 
but even empowering for participants. On the other hand, it is important to realize that this 
study was conducted among a small population in a single center. Although the size of our 
population is no worry to Q-methodology, we would applaud replication of this study in 
other centers. 
The results of the follow-up exercise in which participants self-selected their factor 
membership using concise factor descriptions were promising. The discriminant validity 
was fair: 67% of respondents could be assigned to a single attitude, and we observed 
low correlations between attitude scores and in expected directions. In addition, the 
congruence between factor membership in the Q-methodological study and self-selection 
in the follow-up study among 12 respondents who participated in both was good. All in 
all, most participants seem to be able to distinguish themselves using such short profile 
descriptions, possibly better than they would in a direct interaction with a healthcare 
professional. Therefore, self-selection can support the quality and efficiency of patient-
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professional interactions. It may help as a first screening tool concerning adherence, as a 
means to direct the communication, and a way to help tailor the regime to the needs and 
concerns of patients. However, to determine the prevalence of these attitudes within this 
population and how this affects graft survival, conventional survey analysis using a larger, 
representative sample of patients is required. 
Nevertheless, in our outpatient clinic the process and results of this Q-methodological 
study have been experienced as informative and contributing to patient-oriented care. 
Although the value of the results as a screening tool remains to be investigated, the 
Q-sorting exercise and the self-selection exercise have proved to be helpful in increasing the 
interaction with this sometimes difficult and incommunicative group. 
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Abstract
Background: In our center we encounter serious problems with a number young adult (18-
25yrs) renal transplant recipients that are non-compliant to the medication regime. This 
could well be one of the reasons for the significantly worse unadjusted 10 years kidney graft 
survival in this patient group compared to that in recipients > 25 years: 47.2% versus 64.0%. 
This paper focuses on the attitudes and behavior of young adults towards compliance with 
the immunosuppressive drugs.
Method: We used Q-methodology to identify attitude profiles associated with noncompliant 
behavior. Adolescent renal transplant recipients (n=25) sorted a set of 37 statements (Q-set) 
along a continuum of preferences to reveal categories of individuals who shared common 
viewpoints. The same Q-set was also used as a topic list for an in-depth interview. In this 
paper, we focus on the interview results of four statements, related to compliance with 
immunosuppressive drugs. Each interview was fully written down, using the software 
program Atlas.Ti® for coding and labeling.
Results: Almost half of respondents (40%) think that forgetting medication will not lead to 
serious consequences. They feel they took so much medication over the years that they had 
developed a certain reserve immunity against rejection. Others state that they had become 
indifferent after experiencing that ‘nothing happened’ after forgetting their medication. 
Most adolescents declare having no problems taking their medication when going out with 
friends. They do not feel ashamed, but some lose track of time and simply forget taking 
medication when they are out with friends. Remarkably, 18 of the 25 young adults (72%) 
admit to not always taking their medication on time. When they sleep late, only 7 of them 
set the alarm clock in order to take their medication as prescribed.
Conclusion: Using the Q-set statements as interview topics triggered young adults to 
ventilate their opinion and reveal their medication practice. Confronting statements on 
cards appeared to be very useful in communicating with adolescents about difficult subjects 
such as noncompliance. This helps caretakers in the outpatient clinic to explore and discuss 
reasons for nonadherence to immunosuppressive drugs. Many young adults are not very 
accurate in taking medication on time, and 40% even think nothing bad will happen when 
they forget their immunosuppressive drugs. Healthcare professionals should be aware of 
this grossly underestimated problem.
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Introduction
Young adults try to establish their identity and autonomy and want to be independent while 
at the same time they are dependent on the help from adults and healthcare professionals 
when they are chronically ill [1]. This struggle for independency in a situation of dependency 
often leads to non-compliance which may result in graft rejection. In our experience, non-
compliance is a major problem in young adult patients. In our outpatient clinic we often 
see young male adults who appear indifferent and careless, whom we sometimes call ‘the 
baseball caps’. The impact of non-compliance is more obvious in adolescent transplant 
recipients than in the older transplant population. We analyzed renal graft survival of all our 
kidney transplant patients between 1971-2005. We stratified them according to age: older 
and younger than 25 (Fig.1). 
Figure 1 Graft survival censored for death of all kidney transplants performed in Rotterdam from 
 1971-2005
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n=1596 
n=169 
P<0.0001 
We found, as has also been suggested in literature, a significant worse graft survival for young 
adults compared with older adults [2,3,4]. While young adults may have a more vigorous 
immune system resulting in more rejection [5], this is probably not the only explanation. 
Non-adherence can also be a cause of late graft loss [1,6,7]. In a previous study we used 
Q-methodology to identify 4 behavior patterns in young adults [8]. These four profiles are 
A; Concerned & Controlled, profile B; Appearance orientated & Uncommunicative, profile 
C; Opinioned & Independent and profile D; Easy going & Pliable. The young adults in profile 
A have the lowest risk of noncompliance and the young adults in profile D have the highest 
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risk. One of the key issues in non-compliance concerns proper taking of immunosuppressive 
drugs as prescribed. Therefore, in this paper we focus on the ideas of young adults regarding 
this sensitive topic.
Methodology
The goal of Q-methodology is, first and foremost, to uncover different patterns of thought 
(not their numerical distribution among the larger population) [9,10]. Q-methodology 
exists of three stages: first, to develop a set of statements to be sorted (called a Q-sample), 
second, to require participants to sort the statements along a continuum of preference, 
and last, to analyze and to interpret the data [11,12]. We made a list of 37 statements 
(Q-set). The statements are matters of opinion only, not facts. All statements are related to 
issues related to non-compliance. We followed the different dimensions of non-adherence 
described by WHO [13]. Adolescent renal transplant recipients (n=25) sorted the Q-sets 
along a continuum of preferences (‘disagree most’ to ‘agree most’) to reveal categories of 
individuals who shared common viewpoints. (Fig. see page 21).
Afterwards, we performed an in-depth interview about all the statements, using the 
statements as a topic list. We asked the respondent to comment on each statement. 
The interviews were recorded and later transcribed ad verbatim. For qualitative analysis, 
consisting of coding and labeling followed by thematic analysis using constant comparison, 
we used the computerprogramme Atlas.Ti®. This paper focuses on the responses to four 
statements concerning compliance to immunosuppressive drugs:
1. “If you forget your medication, nothing really bad will happen”
2. “I never forget my medication”
3. “When I stay in bed late, I just take my medication later”
4. “When I am out with friends, I am not very punctual with medication
Results
Patients’ characteristics of the 25 participants are shown in table 1. 
Table 1       Patient Characteristics (n=25)
Patient characteristics Respondents
Age 18-25yrs
Sex 10 (40%) female/ 15 (60%) male
Graft 21 (84%) functioning graft/4 (16%) failures
Education level 8 (32%) high/ 8 (32%) middle/ 9 (36%) low
Ethnicity 18 (72%) Caucasian/ 7 (28%) others
Type of transplant 18 (72%) living donor kidney/ 7 (28%) deceased donor kidney
Living environment 9 (36%) independent/ 16 (64%) with parents
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Ten recipients felt that forgetting medication would not lead to serious consequences (Table 
2). 
Table 2       Agree and disagree of the 4 statements
Statement Agree Disagree
“When you forget your medication nothing bad will really happen” 40% (n=10) 60% (n=15)
“I never forget my medication 48% (n=12) 52% (n=13)
“When I am out with friends, I am not very punctual with medication” 20% (n=5) 80% (n=20)
“When I stay in bed late, I just take my medication later” 72% (n=18) 28% (n=7)
One girl said: “I did it a few times (forgetting medication) and nothing happened. I take my 
pills on Tuesday, Wednesday, Thursday and Friday, on Saturday I do not. And then I take them 
again”. When asked if she wasn’t scared her kidney would reject, she said: “Sometimes I am 
scared because I think if I lose this kidney, I will regret that I did not take my medication”.
Some recipients thought that after taking so much medication over the past years, a certain 
reserve immunity against rejection had been developed. Others stated they had become 
indifferent after experiencing that ‘nothing happened’ after forgetting their medication. One 
young man thought that, because he was prescribed a low dose of immunosuppressive 
drugs, he could more easily forget his medication than someone who needed a higher dose 
of immunosuppressants. Two of the eight young men who all disagreed with the statement 
“when you forget your medication nothing bad will really happen” had learned this the hard 
way; one went through an acute rejection from which he fully recovered and the other had 
experienced graft loss due to non-compliance. From the ten recipients who admitted to 
non-compliance, five had received a deceased donor- and five a living donor kidney.
In contrast, the responses to the statement “I never forget my medication”, were quite 
different. Half of the respondents (48%) stated that they never forget their medication. They 
are so used to take medication, a girl said: “I can’t imagine how people can live without any 
medication, I have medication everywhere, in the car, with friends, if I forget, then I have 
them everywhere”. But half of the interviewed forget their medication sometimes, however 
not intentionally: they are too occupied or in a hurry. One young man, who sometimes 
forgets his medication, says he does not feel like taking medication at that time and then 
simply forgets. Another one states: “When I forget my medication, I am really angry [with 
myself], when it happens twice a week I think it goes really bad and I have to focus more”. 
One respondent thinks it is important to take his medication since he received a transplant 
kidney. When he was still on dialysis he intentionally forgot his medication, because he did 
not feel like it and did not see the point of taking medication all the time. Most adolescents 
say they have no problem taking medication when going out with friends (80%). They claim 
not to feel ashamed, but some lose track of time and simply forget taking medication when 
they are out with friends. A young man explained it was hard to remember his medication 
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when he was on holiday with friends, because there was ‘no structure’. But a young woman 
said: “You do crazy things when you are on holiday, but I always take care of my kidney, even 
when I drink a lot of alcohol, I think about my kidney, you never forget your kidney”.
Remarkably, 18 of the 25 young adults (72%) admit to not always taking their medication 
on time (Table 2). Especially after going out with friends the day before, they forget to take 
their medication on the prescribed time. Only seven respondents claim to set the alarm 
clock when they are sleeping late, in order to take their medication as prescribed. After 
taking the pills, they go back to sleep. One girl said she took her medication regularly when 
admitted to hospital, but when at home, she preferred to look at a television program and 
postpone her medication with one or two hours. Especially during the weekend young 
adults experience problems with the regular intake of immunosuppressive drugs. A girl said: 
“In the past, my parents used to wake me up. I was always mad because of that, nowadays 
I do it myself, but I don’t care to take the medication later”.
Discussion
To better detect and understand non-compliance, Q-methodology was used to gather 
information about various issues regarding non-compliance. After the sorting of the cards 
with statements (Qset), young adults were asked to give their opinion about each statement. 
Statements in the middle had a ‘neutral’ meaning for them (issues not so important to young 
adults as compared to the other issues on the cards put at the extremes). Remarkably, 
these neutral statements turn out to be of special interest to healthcare professionals. 
Rianthavorn and Attenger described a group of invulnerable non-compliers, i.e. recipients 
who don’t think that missing medication can hurt them [1]. They feel invulnerable to the 
effects of discontinuing of immunosuppressive drugs. In our study, we found a similar 
group of invulnerable non-compliers. The statement: “Forgetting medication will not lead 
to serious consequences” turned out to be a distinguishing and characteristic statement in 
Q-profile D, the most non-compliant group [8]. In contrast, almost every young adult put 
the card with the statement: “When I sleep till late, I just take my medication later” in the 
middle, neutral zone. The interview afterwards revealed that young adults think it is normal 
to take medication much later when they sleep late. Russel et al. also discovered patterns 
in patients who take medication later or missed a dose [14]. Apparently, young adults are 
not too accurate with the medication, especially when it does not fit in with their life style 
and with important social activities such as going out with friends. Adolescents are more 
vulnerable and less approachable for various psychological reasons [15].
Strikingly, young adults were willing to talk easily about sensitive issues when confronted 
with statements on a card. The interviewer in this study (M.T.) is a nurse practitioner familiar 
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with and also slightly older then the respondents. This could, on theoretical grounds, be a 
disadvantage because of a possible infringement on their privacy. However, we feel it turned 
out to be an advantage, as the respondents felt comfortable with her, which resulted in 
frank answers.
Conclusion
Q-methodology was used to create attitude profiles among young adults. In this study, we 
discovered that using these statements as interview topics proved to be of great help in 
communication with adolescents. The cards triggered them to ventilate their opinion and 
reveal their ideas and their medication practices. This is extremely relevant for healthcare 
professionals in their attempt to understand the motivation of young adults. Discussing 
these sensitive issues may very well help young adults to better comply with their strict 
medication regime. Many young adults are not very accurate with taking medication on 
time, and a lot of them think nothing bad will happen if they forget their immunosuppressive 
drugs. Healthcare professionals should be aware of this grossly underestimated problem.
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Abstract
Background: Non-adherence to the post-transplant regime is a common problem in kidney 
transplant patients and may lead to rejection or even graft failure. This study investigated 
attitudes towards the post-transplant regime of immunosuppressive medication among the 
ever growing population of elderly kidney recipients. 
Methods: Q-methodology was used to explore attitude profiles. Participants (>65yrs) were 
asked to rank-order opinion statements on issues associated with (non)-adherence. The 
rankings were subject to by-person factor analysis, and the resulting factors were interpreted 
and described as attitudes. 
Results: Twenty-six elderly renal transplant recipients participated in the study. All passed 
the Mini-Mental State Examination. Two attitude profiles were found: (i) satisfied and easy-
going (attitude A), and (ii) reserved and concerned (attitude B). Elderly patients with attitude 
A want to enjoy the new life following their kidney transplant, are not very concerned 
about having to recommence dialysis, now and then even forget their regime, but do not 
really worry about it. Elderly patients with attitude B feel more insecure about their kidney 
transplant, are fairly concerned over issues like rejection or going back on dialysis, and try 
to adapt their way of life to the regime. One-third of these elderly patients forget their 
medication at least once a month, but there was no difference between attitude groups. 
Conclusions: Attitudes about the post-transplant regime differ among elderly patients, 
implying different needs for assistance, monitoring and risk of non-adherence to the regime. 
The proportion of elderly that forgets their medication is considerable, but may be much 
higher among those with mild and severe cognitive limitations. 
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Introduction
Kidney transplantation is the optimal treatment for end stage renal disease. Life expectation 
is significantly improved among transplant patients compared to that of the age-matched 
wait-listed patients on dialysis (1-5). Also elderly patients may benefit as they experience 
a better quality of life after transplantation compared to dialysis treatment (6). Therefore 
the number of transplanted elderly patients is increasing. At the same time we are not 
informed how elderly view their post transplant lifestyle. Moreover still little is known about 
their adherence to the medication regime. Non-adherence has been shown to be related to 
rejection and even graft failure (7-10). Non-adherence to medication is a common problem 
in young kidney transplant patients, but this issue has yet to be studied in elderly transplant 
recipients. Risk factors of non-adherence are depression, less structure in daily life and 
social isolation (11). We hypothesized that these risk factors are likely to play an important 
role in adherence among the elderly population. Also other problems specific to the elderly 
may also interfere with medication adherence e.g. label-reading and interpretation, child-
resistant containers and short-term memory (12). Non-adherence to immunosuppressive 
medication may add to older age related risk factors such as cardiovascular complications 
and psycho geriatric morbidity. The way in which patients think about their medication 
and lifestyle is suggested to be linked to their behavior. It is supposed that attitudes are 
concealed and not directly observable in themselves, but they cause actions and behaviors 
that are observable, i.e. health-related behaviors (13). The present study investigated elderly 
kidney transplant recipients’ attitudes towards their post-transplant immunosuppressive 
medication regime. This study is comparable to a similar study conducted among young 
renal transplant recipients (10). We expected to discover a limited number of attitude 
profiles specific for elderly transplant patients that would be related to medication taking 
behavior and ultimately to adherence. Understanding patients’ perspectives might help 
predict health behaviors and implement more effective interventions.
Subjects and Methods
Q-methodology was used to investigate attitudes towards post-transplant health lifestyle. 
Participants are presented with a sample of opinion statements and are asked to rank-order 
these statements according to the extent to which they agree with the statement. The 
individual rankings of statements are subject to by-person factor-analysis so as to reveal 
corresponding patterns in the way the statements were ranked by respondents. The results 
of a Q-methodological study can thus be used to describe a population of viewpoints, not 
a population of people (14). Q-methodology emphasizes the qualitative ‘how’ and ‘why’ 
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people think the way they do, but does not count ‘how many’ people think a certain way. 
For this purpose, Q methodology does not need large numbers of subjects (15,16).
The current study consisted of four phases. First, self-referent statements that elderly 
patients can make about post-transplant health lifestyle were collected through interviews 
with elderly transplant patients, observations in the clinic and studying the literature (10). 
The WHO defined different dimensions of non-adherence (17): socioeconomic-related 
factors, health care team or health system-related factors, condition-related factors, 
treatment-related factors and patient-related factors. The second step was therefore to 
categorize the collected statements according to these dimensions by experts and condense 
them to a manageable set for the population under study. Statements were chosen that 
represented the pertinent issues within each dimension. The final set consisted of 35 
statements (Table 1) that were randomly numbered and printed on cards. Many studies 
have indicated that depression is a risk factor for non-adherence (7,11,18,19). Therefore we 
have included statements 1, 2 and 5, that we used as indicators of depressive symptoms in 
the Q-set (Table 1). 
Third, all patients who had been transplanted at the department of Internal Medicine, 
Erasmus MC, had received their transplant after their 65th birthday, and with a follow up 
of at least one year, were selected to participate in this study (n=72). We included only 
these patients because they experienced this major life event at an older age. Of these, 
46 patients had an outpatient clinic appointment during the period of inclusion and were 
therefore invited to participate. The other 26 patients were not invited because they had no 
appointment during the study period or some (n=5) were lost to follow up. In total 26 elderly 
patients of the 46 who were invited to participate, responded (response rate of 56.5%). 
The main reasons for non-participation were limitations in vision or hearing impeding 
participation in the study, and children of the elderly declining participation of their parent 
because of admission to a nursing home or cognitive limitations. The characteristics of 
participants are shown in table 2. There were no statistically significant differences between 
respondents and non-respondents in age, gender, or ethnicity. 
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Table 2  Patient characteristics
Patient characteristics Respondents (n=26) Non-respondents (n=20)
Age (years) 67-82 (median 73) 67-84 (median 72,5)
Time after transplantation (years) 1-10 (median 5) 1-16 (median 4,5)
Gender 5 F / 21 M 7 F / 13 M
Education level 1 university, 5 high, 2 middle, 18 low Unknown
MMSE score 25-30 (median 29) Unknown
Ethnicity Caucasian 16 Caucasian, 3 Asian, 
1 African
Kidney transplant 14 living/ 12 post mortal 11 living/ 9 post mortal
Living status All living independently Unknown
Civil status 21 married/ 2 single/ 3 widowed Unknown
All interviews were conducted in a private room in the outpatient clinic. During the interview, 
participants were asked to rank-order the 35 cards containing the opinion statements, using 
a score sheet (figure, page 21). 
Furthermore, as a way of checking for completeness of the statement set, respondents 
received two additional blank cards on which they could indicate an aspect they missed 
in the set; these cards could be ranked at the bottom of any of the columns of the score 
sheet. In post-sort interviews participants were asked to explain the reasoning behind their 
choices, in particular the cards positioned on the extreme ends of the score sheet.
Finally, in phase four, the data was analyzed and interpreted. The individual rankings 
of statements were analyzed using common by-person factor analysis (extraction method: 
centroid; rotation method: varimax). Data were analyzed using PQMethod 2.11 (dedicated 
software and manual are available via http:///www.rz.unibw-muenchen.de/p41bsmk/
qmethod). The resulting factors represent clusters of elderly transplant patients whose 
attitudes about their post-transplant health lifestyle are similar. 
Q-methodology is an established method that can be used to study subjectivity in a 
systematic way, such as peoples’ viewpoints, beliefs, and attitudes (20,21). It combines the 
strengths of qualitative and quantitative research, and is regarded a more robust technique 
than alternative methods for the measurement of attitudes and subjective opinion (13, 22). 
Mini-Mental State examination
All 26 patients were asked to complete a standardized mini mental state examination (23). 
Patients scoring less than 25 points (of the maximum attainable 30 points) were considered 
cognitively unable to participate in the study. 
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Self-reported non-adherence
All respondents answered four questions of the Siegal Scale (24), in order to assess 
adherence to immunosuppressive drugs during the last month and the reason why they 
were non-adherent (25). In a non-accusatory, information seeking way participants 
were asked how often they (i) had not taken their immunosuppressive drugs (IS), (ii) had 
forgotten to take their IS, (iii) had not taken their IS because they believed that they did not 
need them and (iv) had reduced the prescribed amount of IS. Frequency of these factors 
was measured using a 7-point scale ranging from 0 (never) to 6 (daily). Patients answering 
“never” were considered to be adherent. All other scores (i.e. once a month, twice a month, 
three times, or more) indicated non-adherence with medication taking. To test convergent 
validity a Pearson’s’ correlation was conducted between the Siegal scale and the following 
statements: “I sometimes forget my medication”, “When I stay in bed late, I just take my 
medication later”, and “If I’m not sure whether I have taken my pills already, I just take them 
again” [statements 16, 31, and 35 in table 1]. 
Results
Twenty-six elderly kidney transplant recipients (67-82 years) participated in this study. All 
participants were included because they had a MMSE score of ≥25; median score was 29. 
Analysis of their Q-sorts resulted in a two factor solution (Eigen value > 1), indicating there 
were two distinct post-transplant health lifestyle attitudes (Table 1). Twelve elderly patients 
defined factor 1 and 14 elderly patients defined factor 2. 
The elderly patients who defined the first factor were not worried that their kidney will 
be rejected (statement 4; see Table 1) but nonetheless think it is important that their kidney 
function is monitored regularly (statement 29). If dialysis is necessarily, they are not afraid 
of it (statement 6). They are sometimes forgetful (statement 9), but are not concerned 
about the consequences of forgetting their medication once in a while (statement 14), and 
take their medication later if they sleep late (statement 16). They do not evidence signs of 
depression (statements 1, 5), do not want life to revolve around their disease (statement 15) 
and are of the opinion that after transplantation they can lead a normal life (statement 17). 
They experience few side effects of their medication (statement 33). This factor was labeled 
“Satisfied & Easy-going”. The post-sort interviews indicated that these elderly patients are 
satisfied with the new life that was made possible thanks to their kidney transplant. They 
find it important to have their kidney function checked regularly, to confirm that they are 
doing well. They tend to forget their medication now and then, but don’t make a big deal or 
feel guilty about it. The following quotes illustrate this attitude profile: “I sometimes think 
I don’t need my medication and I would like to try not taking them” and “I don’t mind 
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forgetting my medication, I would like to have less medication anyway”. Another respondent 
said: “Sometimes I take my medication later, the nurses did not give me a hard time when I 
forgot, so why should I mind”. 
The elderly patients who defined the second factor were worried that their kidney could 
be rejected (statement 4) and were afraid of going back to dialysis (statements 6, 24). They 
were of the opinion that forgetting medication will have harmful consequences for them 
(statement 14), but also indicated that they experienced some negative side effects from 
their medication (statement 33). These elderly patients appeared less happy and comfortable 
with their post-transplant life than the elderly in the other factor (statements 1, 5, 17), 
and generally felt more tired than their peers (statement 21). They were more sensitive to 
their doctor’s opinion about their health lifestyle (statement 28). This factor was therefore 
labelled “Reserved & Concerned”. The post-sort interviews confirmed these findings. These 
elderly patients did not want to go back on dialysis, “It was horrible to lay there for four 
hours”. Some of these elderly said they would rather die than go back on dialysis, but at the 
same time contemplated that they might change their opinion if this happened, depending 
on their partner still being alive. Because they worried about the consequences of forgetting 
their medication, they tried to be accurate (“I had a clock for my medication, when it was 
broken it was really hard for me”) and compliant to their doctor’s advice (“My doctor is my 
teacher, so I change something if he thinks that is necessarily”). Based on this combination 
of attitudes we would expect adherence to be high among these patients. 
We observed consensus about several issues between elderly patients with the two 
different attitudes. Firstly, elderly patients trusted and had a lot of faith in their doctor, and 
were satisfied with the way they are treated by hospital staff (statements 23, 25, 26, 27). In 
addition, despite the some worries, all elderly seemed happy with their kidney transplant 
(statements 3, 8). One respondent for instance said: “If I would need another kidney 
transplantation tomorrow, I would not hesitate”. Finally, social isolation was not a serious 
issue in these elderly patients, and they appreciated the support they got from friends and 
family (statement 20). Almost all patients (n=21) were married, and indicated that their 
partner supported and sometimes even managed their medication regime.
The Siegal scale revealed that 8 of the 26 (30.8%) respondents had not taken their 
medication, once or more, over the last month; the main reason for not taking medication 
was forgetfulness (r=1.000, p<0.000). Although the number of respondents is small, there 
was no significant difference (r=0.162, p<0.43) in adherence to the mediation regime 
between the two attitude profiles, 3 of the 12 elderly with the “Satisfied & Easy going” 
attitude, and 5 of the 14 with the “Reserved & Concerned” attitude. Elderly with both 
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attitudes tended to forget their medication now and then, but unintentionally. We observed 
convergent validity between the statement (31); “I sometimes forget my medication” and 
the Siegal scale with a significant correlation (r=0.416, p<0.034). There was no significant 
difference on socio-demographic factors like age or time since transplantation.
Our elderly participants showed little signs of depression; because statements 1, 2 and 
5 were generally placed negatively (i.e. they disagreed with these statements). Only 3 of 26 
patients agreed with the statement “I think about the death a lot” (statement 2).
Discussion
Prior to this study, little was known how elderly experienced problems with adherence to 
the post-transplant medication regime. This study revealed two distinct attitudes among 
elderly transplant recipients: “Satisfied & Easy going” and “Reserved & Concerned”. Satisfied 
and easy-going patients focus on leading a normal and enjoyable life and are not fearful or 
worried about the consequences of not taking their medication correctly. Reserved and 
concerned elderly patients experience more psychical and psychological complaints are 
more fearful of consequences of not taking their medication correctly. Elderly with both 
attitudes tend to forget their medication now and then, but unintentionally -like found 
among young transplant recipients (10).
We observed a substantial level of non adherence (30%) in our study population. This 
is comparable to the findings from a systematic review of the literature that 28% of the 
adult renal population is non adherent (7). Non adherence is associated with poor clinical 
outcomes; however death with a functioning graft is still the most common cause of death 
in the elderly renal transplant population. The two most common causes of death in the 
elderly are cardiovascular diseases and infection-related mortality after transplantation (46, 
48). Although the attitudes towards the post-transplant regime in our study population of 
elderly patients differed within the sample, a comparable non-adherence score was found 
for the two groups with distinct attitudes. These results are remarkable because our study 
population was cognitively well functioning as they were screened for this in the MMSE-
test. One consistent determinant of non adherence is social isolation (49). The patients in 
our study were all living independently and were active in their social network. The risk of 
non-adherence could be far higher among elderly transplant recipients not enrolled in the 
present study, those with visual or auditory impairment or moderate to severe cognitive 
limitations. This indicates that the non-adherence observed here, although considerable, 
could very well be just the “tip of the iceberg”.
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The sorting of the cards was feasible for these elderly transplant patients and the post-sort 
interviews indicated they comprehended the task and the contents. Because the elderly 
patients had a tendency to be very accurate, the sorting of the cards took a lot of time. In 
that sense, the post-sort interview also served as a validity check, because any incongruence 
between the sorting of the cards and explanations of the sort could be remedied. But this 
was rarely necessary, which is an indication of the validity of the results. The statements and 
placing them on a score sheet stimulated open communication about the topic. Respondents 
talked freely and easily about sensitive issues (i.e. death, loneliness), when confronted with 
these statements. This indicates that the process of sorting a set of opinion statements may 
also be a helpful instrument in clinical practice to commence and deepen discussions with 
patients. In doing so they may be able to learn more about how elderly kidney transplant 
patients experience and deal with their disease, their treatment and their prospects after 
treatment, and what constitutes these attitudes.
Limitations of the study
Although this sample was sufficient to be able to discover attitude profiles, further research 
with a larger non selected sample is needed to explore and confirm the relationship with 
adherence. In particular investigating the attitude profiles and adherence patterns of hard 
to reach elderly patients who are less independent or have greater co morbidity would 
be interesting. However this is another argument that the real non-adherence in elderly 
patients is probably higher than the 30% we observed. In addition, if we want to conduct 
further studies in this patient population, we should develop methodologies that facilitate 
participation of vision or hearing impaired patients so we can study the elderly in a broader 
sense. In this study the Siegal scale was used, which has been criticized for its lack of 
sensitivity, as self-reporting scales have the tendency to underestimate adherence. Future 
studies should follow current recommendations in the literature to use multiple measures 
of adherence (68).
Notwithstanding these limitations, this study offers a unique insight into the attitudes of 
elderly transplant patients and how these may relate to medication adherence. 
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Abstract
Objective: Nonadherence to immunosuppressive medication (IM) after kidney transplantation 
is related to poorer patient and graft outcomes; therefore research into modifiable factors 
associated with nonadherence is a priority. In this prospective cohort study we investigated 
whether changes in goal cognitions, illness perceptions, and treatment beliefs were related 
to self-reported medication adherence six months after kidney transplantation. 
Methods: Interviews were conducted with patients in the out-patient clinic six weeks (T1: 
n = 113) and six months (T2: n = 106) after transplantation. Self-reported adherence was 
measured using the Basel Assessment of Adherence to Immunosuppressive Medications 
Scale (BAASIS© Interview). The Brief Illness Perceptions Questionnaire, Beliefs about 
Medicines Questionnaire and questions on goal cognitions were also administered at both 
time points. 
Results: Self-reported nonadherence increased significantly between 6 weeks and 6 months 
after transplantation from 17% to 27%. Importance of medication adherence as a personal 
goal and self-efficacy to successfully carry out this goal decreased significantly over time. 
Perceived necessity of immunosuppressive medication was high but significantly decreased 
over time. Concerns about the medicines were low. There were no significant changes in 
illness perceptions or concerns over time. An increase in perceived graft longevity (timeline) 
was related to higher likelihood of nonadherence six months post-transplant. Furthermore, 
younger adult patients were more likely to be nonadherent six months after transplantation. 
Conclusion: The self-reported nonadherence levels found in this study so soon after 
transplantation demonstrate the need for early and continued intervention after kidney 
transplantation in order to maximize adherence and consequently clinical outcomes. 
Changes in (unrealistic) beliefs regarding the longevity of the graft may offer a potential 
target for intervention among nonadherent patients.
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Introduction 
Adherence to immunosuppressive medication (IM) is an integral component of self-
management after kidney transplantation (KT); however, supporting optimal adherence is 
often a major challenge for health care professionals [1–3]. Results from a meta-analysis 
suggested 36 cases per 100 patients per year are nonadherent to IM after KT [4]. Evidence 
suggests that adherence immediately after KT is often high and gradually declines over time 
[5], although some authors suggest nonadherence is ‘early and pervasive’ among kidney 
transplant patients [6]. Failure to take the correct dose at the correct time is a risk factor for 
(late) acute rejection, (late) graft failure, and patient mortality [5–8]. Graft failure results in 
(re)initiation of dialysis and the associated reduction in quality of life. Even small deviations 
from this strict, lifelong regime can result in poorer outcomes [9]. Nonadherence to as little 
as 5% of prescribed doses has been associated with significantly higher acute rejection and 
graft loss [10,11]. For this reason the definition of adherence among this population tends 
to be strict [12]. Unfortunately, there are many side-effects of IM ranging from excessive 
hair growth to increased risk of skin cancer. In addition to the clinical consequences, 
nonadherence is associated with increased health care costs and thus has a negative impact 
on the cost-effectiveness of renal transplantation [13,14]. 
Within health psychology, various theoretical models have been developed to explain 
adherence to health behaviors. Of particular relevance to adherence is Leventhal’s Common-
Sense Model (CSM). This model describes how cognitive and emotional representations, 
so-called illness perceptions, are generated in response to a health threat [15]. Illness 
perceptions consist of perceived causes, consequences, identity (name and symptoms), 
timeline, emotional response, coherence, and personal and treatment control. Patients 
generate goals to cope with the health threat and/or associated emotions. Actions are 
undertaken in order to reduce either the threat itself or the associated emotions. On-going 
appraisals evaluate response efficacy and feed into subsequent representations in an on-
going iterative process. The CSM model has been expanded to incorporate the beliefs that 
patients hold about their treatment: the perceived necessity for and concerns about the 
effects of the medication. In the context of kidney transplantation, one of the threats to 
health is (fear of) graft rejection and adherence to IM can be seen as an action to cope with 
this threat. 
Research among end stage renal disease patients undergoing dialysis has suggested 
support for a relationship between adherence and illness representations [16,17] and 
beliefs about medicines [18]. However, to date, few studies have applied the CSM model 
to adherence after kidney transplantation. In a cross-sectional study among liver, lung and 
heart transplant recipients in New Zealand, lower treatment control, lower comprehension, 
greater emotional response, greater experienced symptoms, greater impact on their 
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lives, lower perceived necessity and greater concerns were related to greater medication 
nonadherence [19]. Among kidney transplant recipients in the US and UK respectively, greater 
nonadherence has been related to lower perceived necessity and higher concerns about the 
medication [20,21]. In contrast, a study on Swedish kidney transplant patients found no 
relationship between treatment beliefs and adherence [22]. There appears therefore to be a 
gap in the literature concerning the relationship between adherence and illness perceptions 
and contradicting evidence regarding treatment beliefs among kidney transplant patients. 
Furthermore, there is little information on how the medication regime is integrated into and 
aligned with other personal goals the patient has. Self-regulation theory stipulates that all 
behavior is goal-directed [23]. Therefore cognitions such as relative importance and self-
efficacy for medication taking are likely to offer insights into why this goal-directed behavior 
is or is not being carried out. For example, behavior is less likely to be consistently carried 
out if it conflicts with achievement of other personal goals [24]. Finally, studies to date have 
been cross-sectional resulting in considerable variation in time since transplantation. Given 
the dynamic character of adherence behavior, prospective measurement is preferable [12]. 
Therefore the aim of this study was to prospectively investigate the relationships between 
goal cognitions, illness representations, and treatment beliefs on the one hand and self-
reported adherence after kidney transplantation on the other. We formulated the following 
research question: To what extent are changes in (a) illness perceptions, (b) beliefs about 
medication (necessity and concerns), and (c) goal cognitions related to self-reported IM 
adherence? We hypothesized that a decrease in symptoms, emotional response, perceived 
impact on daily life, goal conflict and an increase in comprehension, perceived personal and 
treatment control, and self-efficacy would be related to greater adherence. Research into 
modifiable factors associated with adherence among kidney transplant patients is essential 
in order to identify potential targets for intervention. 
Methods 
Participants 
Consecutive patients who received a kidney transplant at the Erasmus University Medical 
Centre, Rotterdam, between 24th August 2010 and 26th October 2011 were invited to 
participate. In total 212 patients underwent transplantation during this period. Participants 
were required to meet the following inclusion criteria: over 18 years of age, a functioning 
graft six weeks post-transplant, sufficient physical and mental ability to be able to participate, 
and sufficient command of the Dutch language. Forty-four patients did not meet these 
inclusion criteria and were therefore not approached for participation. Specific reasons for 
exclusion were: language (n = 23), physical or mental disability (n = 9), graft loss (n = 4), 
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death (n = 4), primary non-function (n = 3) and emigration (n = 1). Of the remaining 168 
patients who were invited to participate, 113 agreed (T1: 67% response rate). Reasons for 
refusal included fatigue (n = 26), no interest (n = 20), logistical reasons (n = 7), and other (n = 
2). Six months after transplantation, 106 patients remained in the study (T2: 94% retention 
rate) as 2 patients had died, 2 had graft failure, and 3 had health issues or did not wish to 
participate any longer. 
Procedure 
Patients who met the inclusion criteria received a Patient Information Form and Informed 
Consent Form (ICF) during a consultation with the nurse practitioner prior to discharge 
from the hospital. Patients who signed and returned the ICF were contacted to make an 
appointment for the interview. Those who did not return the ICF within 2 weeks of discharge 
were contacted to ascertain whether or not they wished to participate. Interviews at 6 
weeks and 6 months after transplantation were conducted by either a nurse practitioner 
(MT), a psychologist (EM, ML) or a psychology student (RK, DB). The one-to-one interviews 
(without the presence of family or other caregivers) took approximately 45– 60 min and 
were combined with the scheduled visit to the outpatient clinic to avoid extra travel, costs 
or inconvenience. All measures were administered at both time points. The study was 
approved by the Medical Ethics Committee of the Erasmus Medical Centre (MEC-2010-257) 
and procedures were in accordance with the Declaration of Helsinki. 
Measurements 
Medication adherence 
Adherence to the IM regime was measured using the Basel Assessment of Adherence 
to Immunosuppressive Medications Scale (BAASIS© Interview) [25,26]. Part 1 of this 
instrument consists of 5 questions on the taking and timing of medication, drug holidays, 
reduction of the dose and persistence. An affirmative answer to any of the first 3 questions 
results in assignment to the nonadherent group. This scoring is intentionally strict due to 
an assumption of underreporting of nonadherence [27]. Part 2 consists of a continuous 
overall adherence rating scale ranging from 0 (medication never taken as prescribed) to 100 
(medication always taken as prescribed). The BAASIS measure was selected as it is short, 
reliable, valid and sensitive to both timing and taking which is of particular importance 
for IM after transplantation [26]. A number of studies have demonstrated support for the 
validity of both parts [28,29]. Specificity and sensitivity of part 2 has been shown to be high 
[28]. 
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Goal cognitions 
Goal cognition items were adapted from the study by Pomaki and colleagues [30]. The extent 
to which patients endorse IM adherence as an important personal goal was measured using 
2 items: ‘Taking my medication at the correct time is an important goal for me’, and ‘Taking 
the correct dose of my medication is an important goal for me’. The extent to which the 
patient is committed to taking their medication correctly was measured using 3-items, for 
example, ‘Even if taking my medication correctly is difficult, I will not give up on it’. Conflict 
with other personal goals was measured using 3 items, for example, ‘Taking my medication 
correctly conflicts with other goals I find important’. The extent to which the patient feels 
competent in achieving their goal of medication adherence was measured using 3 goal self-
efficacy items, for example ‘I am capable of taking my medication in the correct way’. Each 
item was scored on a scale of 1 (totally disagree) to 5 (totally agree). Factor analysis (data 
not shown) demonstrated a 3 factor structure: importance and commitment (Cronbach’s α 
= .75); self-efficacy (Cronbach’s α = .84); and goal conflict (Cronbach’s α =.90). Mean scores 
were calculated per subscale. 
Illness perceptions 
The Brief Illness Perceptions Questionnaire (B-IPQ) [31] was used to measure the way in 
which patients perceive their transplant. The 9-item questionnaire measures the cognitive 
representations of perceived consequences, timeline, personal control, treatment control, 
comprehensibility, identity, and causes and the emotional representations of concerns and 
emotional response. The first 8 items are rated on a scale from 0–10. The wording of the 
items was adapted to fit the context of kidney transplantation. An example is ‘How much 
control do you feel you have over the functioning of your kidney graft’. The final open-ended 
question measures perceived causes of illness; this was adapted to perceived causes of graft 
rejection. The B-IPQ has demonstrated good test–retest reliability and concurrent validity 
among renal patients and other patient groups [31]. 
Beliefs about medication 
The Beliefs about Medicines Questionnaire [32] was used to measure perceived necessity 
of and concerns specifically about IM. An example of an item on the necessity subscale is 
‘Without my medicines I would become very ill’. An example of an item on the concerns 
subscale is ‘I sometimes worry about the long-term effects of my medicines’. Each item was 
rated on a 5-point scale ranging from 1 (totally disagree) to 5 (totally agree). Each 5-item 
subscale was summed resulting in a score ranging from 5 to 25. Satisfactory reliability and 
validity have previously been demonstrated [32]. A necessity–concerns differential can also 
be calculated by subtracting the concerns subscale from the necessity subscale [18]. This 
demonstrates a cost–benefit analysis where-by a positive value indicates that the perceived 
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benefits outweigh the costs. 
Sociodemographic and medical characteristics 
The following characteristics were recorded and dichotomized for use in the analyses: gender 
(M/F), employment (paid work versus no paid work), ethnicity (Dutch versus non-Dutch), 
marital status (married/living together versus single/widowed/divorced), type of donor 
(living versus deceased), pre-emptive transplantation (yes/no) and number of transplants 
(0 = 1; 1 ≥ 1). Education was categorized into low, middle and high. Age was recorded as a 
continuous variable. 
Statistical analysis 
Perceived causes of kidney rejection (B-IPQ) were coded independently by two raters (EM 
and DB). After the initial rating, items with differing categorization were discussed and 
the coding was refined. Measurement of agreement was tested using Cohen’s kappa. For 
univariate analyses, chi-squared and independent samples t-tests were conducted to assess 
differences between independent groups for nominal and continuous variables respectively. 
When data were not normally distributed the Mann–Whitney test was conducted. Paired 
t-tests were used to test change over time in related samples. Pearson’s correlation or 
Spearman’s rho (for non-normal data) were used to test for associations between continuous 
variables. The McNemar test for related dichotomous variables was used to assess changes 
in adherence classification. For multivariate analyses, binomial logistic regression analyses 
were conducted to assess the extent to which change in psychological variables (delta scores) 
was related to adherence/nonadherence controlling for sociodemographic variables. Delta 
scores were used in order to take into account the prospective nature of the data. The model 
was built in blocks: (1) socio-demographic and medical variables; (2) psychological variables. 
A stepwise backward elimination process of non-significant variables was employed to 
generate the most parsimonious model. Independent variables with a p-value less than .10 
were entered into the model. Only significant variables (p < .05) are presented in the final 
model. Analyses were carried out using the Statistical Package for Social Sciences, version 
20.0 (IBM Corporation, Armonk, NY, USA). 
Results 
Descriptive and univariate analyses 
Sociodemographic characteristics 
Sociodemographic characteristics of the 113 participants at T1 are presented in Table 1. 
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Table 1 Demographic characteristics of participants at baseline (N=113)
Variable Total Adherent group 
(n=94)
Nonadherent group 
(n=19)
Age: median (range) 53 (19-75) 52.5 (19-75) 57.0 (22-72)
Gender: % men (n) 64.6 (73) 66.0 (62) 57.9 (11)
Marital status: % (n)
Single/divorced/widowed
Married/living together
26.5 (30)
73.5 (83)
24.5 (23)
75.5 (71)
36.8 (7)
63.2 (12)
Ethnicity: % (n)
Dutch
Non-Dutch
84.1 (95)
15.9 (18)
84.0 (79)
16.0 (15)
84.2 (16)
15.8 (3)
Employment: % (n)
Paid employment (full/part-time)
Not in paid employment
45.2 (51)
54.9 (62)
41.5 (39)
58.5 (55)
63.2 (12)
36.8(7)
Education: % (n)  
Low
Middle
High
23.9 (27)
56.6 (64)
19.5 (22)
23.4 (22)
55.3 (52)
21.3 (20)
26.3 (5)
63.2 (12)
10.5 (2)
Donor type: % (n)
Living 
Deceased
78.8 (89)
21.2 (24)
77.7 (73)
22.3 (21)
84.2 (16)
15.8 (3)
Relationship of the living donor to the 
patient: % (n)a
Partner
Parent
Child
Sibling
Aunt/uncle/cousin
Family-in-law
Non-family
National Kidney Exchange
Anonymous
17.7 (20)
13.3 (15)
8.8 (10)
9.7 (11)
1.8 (2)
1.8 (2
7.1 (8)
14.2 (16)
6.2 (7) 
19.1 (18)
13.8 (13)
8.5 (8)
9.6 (9)
2.2 (2)
2.1 (2)
7.4 (7)
10.6 (10)
6.4 (6)
10.5 (2)
10.5 (2)
10.5 (2)
10.5 (2)
0.0
0.0
5.3 (1)
31.6 (6)
5.3 (1)
Pre-emptive transplantation: % (n) 36.3 (41) 34.0 (32) 47.4 (9)
Number of transplants: median (range) 1 (1-5) 1 (1-2) 1 (1-5)
Duration hospital admission: median (range) 13 (8-59) 13 (9-59) 12 (8-41)
a22 missing
Eighty-one percent (n = 91) had undergone a primary kidney transplant where as 22 patients 
had undergone re-transplantation. Three patients had previously undergone another type 
of transplant (2 liver, 1 lung). The large majority of 87% (n = 98) reported co-morbidity (such 
as high blood pressure, diabetes, cardiovascular problems, cerebrovascular accident). There 
were no significant differences in sociodemographic characteristics of responders and non-
responders (data not shown). 
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Adherence 
Adherence classification (BAASIS Part 1). Table 2 shows adherence at T1 and T2. Six weeks 
after transplantation 17% (n = 19) were nonadherent. Six months after transplantation, this 
increased to 27% (n = 29). Nonadherence was greatest for the timing dimension. At both 
time points there were very few or no individuals who skipped more than two doses in a 
row, altered the dose themselves or stopped taking the medication altogether. 
Table 2 Adherence at six weeks (T1) and six months (T2) after transplantation 
T1 (n=113)
n (%)
T2 (n=106)
n (%)
BAASIS part 1
1a. Taking dimension: Do you remember missing a dose of your 
IM in the past 4 weeks?
9 (8.0) 13 (12.3)
Once 8 (7.1) 12 (11.3)
Twice 1 (0.9) 1 (0.9)
1b. Drug holidays: Do you remember having skipped two or more 
doses of your IM in a row in the past 4 weeks?
0 0
2. Timing dimension: Do you remember having taken your IM 
more than 2 h before or after the prescribed dosing time in the 
past 4 weeks?
12 (10.6) 20 (18.9)
Once 10 (8.8) 14 (13.2)
2-3 times 1(0.9) 2 (1.8
4-5 times 1 (0.9) 3 (2.8)
Every 2 to 3 days 0 0
Almost daily 0 1 (0.9)
3. Reduction of dose: Have you altered the prescribed amount of 
your IM during the past 4 weeks without your doctor telling you 
to do so?
0 1 (0.9)
4. Persistence: Have you stopped taking your IM completely in the 
past 4 weeks without your doctor telling you to do so?
0 0
Categorised as nonadherent 19 (16.8) 29 (27.4)
BAASIS part 2
5. Overall adherence rating median
(range; interquartile range)
100 (77-100;5) 99 (50-100;10)
With regard to changes in BAASIS classification over time, 68 patients were classified ad-
herent at both T1 and T2; 9 patients changed from being nonadherent at T1 to adherent at 
T2; 22 patients changed from being adherent at T1 to nonadherent at T2; and 7 patients were 
nonadherent at both time points. Therefore, in total 38 (34%) patients were nonadherent at 
some point in the study. The McNemar test showed that significantly more patients became 
nonadherent over time (χ2 = 4.65, p < .05). 
At T1 and T2 there were no significant differences between the adherent and nonadherent 
groups on gender, ethnicity, marital status, education level, employment, type of donor, 
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or pre-emptive transplantation. No difference was found in age between the adherent 
and nonadherent groups at T1. At T2 those categorised as nonadherent were significantly 
younger (M = 44.72, SD = 13.33) than those categorised as adherent (M = 53.13, SD = 12.70), 
t(104) = 2.99, p < .01. At T1 there was no difference between adherent and nonadherent 
groups according to number of kidney transplants. At T2 those categorised as nonadherent 
were more likely to have undergone re-transplantation, χ2 = 7.16, p < .01. 
Overall adherence scale (BAASIS Part 2). Table 2 shows that the median overall adherence 
rating is generally high but significantly decreases over time (z = −3.18, p < .001). The 
Wilcoxon signed-rank test showed that 36 patients had a negative ranking (T2 adherence 
lower than T1), 20 patients had a positive ranking (T2 adherence higher than T1) and 50 
patients had a tied ranking (same ranking at T1 and T2). Overall adherence rating at T1 
was significantly positively correlated with age (Spearman’s rho = .21, p < .05): younger 
participants rated themselves as less adherent. Also at both T1 and T2 patients who were 
undergoing their first transplant reported higher overall adherence, p < .05. No other 
associations with sociodemographic or medical characteristics were found. 
Personal goal cognitions 
The mean scores presented in Table 3 show that medication taking is an important personal 
goal, patients feel capable of achieving this goal and report low goal conflict. 
Table 3 Paired t-tests for changes in goal cognitions, illness perceptions and treatment beliefs
T1 Mean (SD) T2 Mean (SD) z
Goal cognitions a
Goal importance 4.62 (0.45) 4.52 (0.49) -2.10*
Goal conflict 1.44 (0.72) 1.55 (0.71) -1.77
Goal self-efficacy 4.74 (0.45) 4.63 (0.60) -2.05*
 T1 Mean (SD) T2 Mean (SD) t
Beliefs about medicines
Necessity 22.77 (2.5) 22.02 (3.0) 2.46*
Concerns 10.47 (4.1) 11.08 (3.8) -1.80
N-C Differential b 12.30 (4.9) 10.94 (5.0) 2.97**
Illness perceptions
Consequences 7.64 (2.6) 7.29 (2.6) 1.37
Timeline 8.00 (1.8) 8.21 (1.8) -0.99
Personal control 7.64 (2.0) 7.81 (1.6) -0.75
Treatment control 8.99 (1.1) 9.00 (1.1) -0.08
Identity 2.69 (2.4) 2.93 (2.4) -0.98
Concerns 5.72 (2.9) 5.74 (3.1) -0.06
Coherence 7.39 (2.4) 7.61 (2.3) -0.94
Emotional response 3.89 (3.1) 3.47 (2.8) 1.47
a Due to non-normally distributed delta’s, Wilcoxon signed-rank tests were conducted. 
b N-C differential = necessity-concerns differential. 
* p < .05; ** p < .01.
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Table 3 also shows that on average, importance of adherence to medication as a personal 
goal and self-efficacy to achieve that goal, significantly decreased over time. Greater goal 
importance was positively correlated with overall adherence rating (T1: rho = .31, p < .001; 
T2: rho = .47, p < .001). Self-efficacy at T2 also correlated with overall adherence (rho = .30, 
p < .01). Goal conflict did not significantly correlate with overall adherence. There were no 
significant differences in goal cognitions between the adherent and nonadherent groups at 
T1 and T2. 
Beliefs about medicines 
Patients reported high perceived necessity of IM and relatively lower concerns as indicated 
by the positive necessity–concerns differential (see Table 3). Perceived necessity of the 
IM to maintain the current health status significantly decreased over time. This translated 
into a significant decrease in the necessity–concerns differential. We note that the value of 
the necessity–concerns differential remains positive indicating that the perceived benefits 
outweigh the costs at both T1 and T2. There were no significant differences in beliefs about 
medicines between the adherent and nonadherent groups at both time measurements 
(data not shown). 
Illness perceptions
At T1, timeline (rho = .22, p < .05) was positively correlated with overall adherence rating; 
patients who think that their graft will last longer reported higher overall adherence. There 
was a trend for greater adherence to be related to greater personal control (rho = .18, p = .06) 
and emotional response (rho = .18, p = .06). At T2, greater perceived treatment control was 
related to higher overall adherence (rho = .24, p < .05). These correlations were significant 
but nevertheless weak. There were no associations between change in illness perceptions 
and change in overall adherence rating (r = −.14–.08, p > .05). There were no significant 
differences in illness perceptions between the adherent and nonadherent groups at T1 (data 
not shown). At T2, the consequences scale (impact of transplantation on life) was rated as 
significantly higher by the nonadherent group (M = 8.03, SD = 1.82) than the adherent group 
(M = 7.01, SD = 2.78), t(78) = −2.2, p < .05. Illness perceptions did not significantly change 
between T1 and T2 (see Table 3). 
On the final question of the IPQ, participants were requested to report 3 possible 
causes of allograft rejection. Inter-rater agreement was high for the categorisation of these 
causes at T1 (Cohen’s kappa = .95–.97) and T2 (Cohen’s kappa = .95–.96). Nonadherence 
to IM was reported as a cause of allograft rejection by 83% of patients at both time points, 
however, the remaining patients failed to report nonadherence as a potential cause of 
allograft rejection. There was no significant relationship between naming IM nonadherence 
as a cause of rejection and adherence categorisation or overall adherence rating at T1 or 
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T2. Other commonly reported causes of graft rejection were unhealthy lifestyle (T1 37%; 
T2 36%), poor nutrition and fluid maintenance (T1 34%; T2 25%), and bacteria, infection 
or illness (T1 19%; T2 14%). Causes that were reported less frequently (<10%) were bad 
luck/uncontrollable factors, immune response, smoking, poor graft match/compatibility, 
natural deterioration of graft functioning over time, inadequate contact with health care 
professionals, stress, poor fitness, weight, and alcohol or drug use. A small minority (T1 6%; 
T2 3%) could not name any causes of allograft rejection. 
Multivariate analyses 
Logistic regression was carried out to investigate the association between changes in 
cognitions over time and adherence classification at T2. Table 4 shows the final model in 
which only variables with a significant association are presented. This final model correctly 
classifies 74.5% of patients. When controlling for adherence at T1, an increase in the 
perceived longevity of the graft was related to 1.32 greater odds of nonadherence at T2. 
Conversely, greater age was related to lower odds of nonadherence at T2. Results were the 
same when using timing and taking dimensions separately (data not shown). 
Table 4 Logistical regression with adherence classification six month after transplantation as the 
 dependent variable
95% CI for Exp(B)
B (SE) Wald Exp(B) Lower Upper
Constant 2.27 (1.06) 4.62 9.71
Adherence
  Classification T1
-0.94 (0.62) 2.30 0.39 0.13 1.32
Age -0.05 (0.02)** 8.97 0.95 0.92 0.98
IPQ2 Timeline Δ 0.27 (0.13)* 4.64 1.32 1.03 1.69
Note: R2 = .21 (Nagelkerke). Model χ2 (3) = 16.20, p < .001. * p < .05; ** p < .01.
Linear regression was also conducted to investigate the association between changes in 
cognitions over time and self-reported overall adherence rating at T2. However, when 
controlling for overall adherence rating at T1, none of the change variables were significantly.
Discussion 
This study adds new insights into changes in adherence and the relationship with changing 
cognitions over time. Clinically speaking, a nonadherence rate of 17% as early as six weeks 
after transplantation is cause for concern. Nonadherence as early as the first weeks after 
discharge has also previously been reported [6]. Moreover, this rate increased to 27% six 
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months after transplantation. Previous studies have shown that declining adherence over 
time is related to higher risk of poorer clinical outcomes [10,11]. There is thus a clear need 
for early intervention and research into modifiable factors that are related to nonadherence. 
In line with previous literature [7,20,33], younger patients in this study were more likely 
to be nonadherent six months after transplantation. Nonadherence has typically been 
demonstrated to be an issue among adolescent patients, however since our participants 
were all over the age of 18, this finding highlights the need for continued attention 
to medication adherence beyond adolescence and into young adulthood. Therefore, 
within adult nephrology services, young adults form a risk group for nonadherence and 
interventions should be tailored to this group. Furthermore, patients who showed an 
increase in perceived allograft longevity were more likely to be nonadherent six months 
after transplantation. Opposite effects of timeline have been found among dialysis patients 
whereby the perceived temporary nature of their illness was related to lower adherence 
[16,17]. This demonstrates the context and treatment specificity of beliefs and the 
importance of investigating these specific beliefs in each patient population. We speculate 
that after transplantation an increasing, unrealistic belief regarding the expected graft 
survival may undermine medication taking. Unrealistic beliefs regarding longevity of the 
graft could offer a potential target for intervention aimed at maintaining adherence over 
time. In the clinic, nephrologists should be vigilant to correct beliefs that the graft will last 
an entire lifetime, particularly among younger patients. 
One issue that may have affected our results is that of underreporting leading to 
nonadherent participants assigned to the adherent group. In order to take this into account 
we employed the BAASIS interview, which was developed to take underreporting into 
consideration. Given that even small deviations in the regime are linked to poorer outcomes 
[9] this strict approach to defining adherence in this population appears justified. Part of 
our approach was also to measure self-reported adherence using a personal, confidential 
interview as advocated by Butler and colleagues [34], although social desirability is difficult 
to avoid in a clinical environment. Another issue may be that of inadequate power to find 
differences between the adherent and nonadherent groups, given the lower number of 
nonadherent patients for statistical analyses. 
Despite the high level of self-reported nonadherence, we also found high levels of 
motivation for medication adherence and perceived ability to carry out this behavior 
successfully. Furthermore, the level of conflict with other personal goals was low. Therefore, 
other factors must play a role in nonadherence in this early stage. These baseline cognitions 
appear to be adaptive as we know from previous research that self-efficacy relates to 
better self-management including medication adherence [35]. Similarly in this study, in the 
univariate analyses, greater goal importance was related to greater self-reported overall 
adherence. However, these cognitions changed over time: the importance of medication 
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adherence as a personal goal and perceived ability to carry out this behavior successfully 
(self-efficacy) significantly decreased over time. In the first six months post-transplant 
there was no evidence for a relationship between changing goal cognitions and adherence 
classification. The question remains as to how these cognitions will develop longer after 
transplantation. One study among haemodialysis patients has shown the potential impact 
of a goal-based intervention on adherence [36] however this is yet to be translated to 
the post-transplant period. Given the high baseline level of motivation and self-efficacy, 
strategies such as motivational interviewing may prove useful tools for interventions that 
aim to promote maintenance of motivation for medication adherence over time. 
In general, transplantation was reported to have a large impact on the patient’s lives 
(consequences). Patients perceived high control over the functioning of the graft and even 
higher treatment control. Self-reported complaints from the transplant were relatively low. 
In comparison to illness perceptions and treatment beliefs among lung, heart and liver 
transplant recipients [19], kidney transplant patients reported on average greater perceived 
necessity of the medication and lower concerns about the effects of the medication, but also 
greater consequences of transplant on their lives, greater concerns about the transplant and 
lower coherence [Broadbent 2012, personal communication]. In this study we did not find 
differences between adherent and nonadherent groups on illness perceptions and beliefs 
about medicines whereas Kung and colleagues did [19]. It is possible that the difference 
between findings is related to time since transplantation as previous studies were cross-
sectional and thus included patients with varying time (often years) since transplantation. 
Early post-transplant patients are still recovering from surgery, rehabilitating, and establishing 
new self-management routines. Therefore, some beliefs may be more pertinent to 
adherence immediately after transplantation while others may become pertinent later after 
transplantation. For example, an increase in timeline was related to greater self-reported 
nonadherence in the early post-transplant period in our study whereas lower treatment 
control and higher symptom distress were related to nonadherence among patients years 
post-transplant in the study by Kung and colleagues. Illness perceptions and beliefs are 
dynamic in nature: perceptions are shaped by experiences and appraisal of coping efforts, 
these appraisals in turn influence subsequent actions in an on-going iterative process. It 
is therefore important to investigate how perceptions change over time in order to gain 
insights into these dynamic processes and how changes may influence adherence behavior. 
Conflict of interest
The authors have no conflicting interests to report. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Goal cognitions, illness perceptions and treatment beliefs and self-reported adherence
67
5
Acknowledgments 
This study was supported by an internal Erasmus MC grant ‘Evidence Based Care by Nurses’. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 5
68
References 
[1]  Ruppar TM. Medication adherence research: more theory-driven interventions are needed. 
West J Nurs Res 2010;32:847–8. 
[2]  DiMatteo MRP. Variations in patients’ adherence to medical recommendations: a quantitative 
review of 50 years of research. Med Care 2004;42:200–9. 
[3]  Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people 
with chronic conditions: a review. Patient Educ Couns 2002;48:177–87. 
[4]  Dew MA, DiMartini AF, De Vito Dabbs A, Myaskovsky L, Steel J, Unruh M, et al. Rates and 
risk factors for nonadherence to the medical regimen after adult solid organ transplantation. 
Transplantation 2007;83:858–73. 
[5]  Loghman-Adham L. Medication noncompliance in patients with chronic disease: issues in 
dialysis and renal transplantation. Am J Manag Care 2003;9:155–71. 
[6]  Nevins TE, Matas AJ. Medication noncompliance: another iceberg’s tip. Transplantation 
2004;77:776–8. 
[7]  Denhaerynck K, Dobbels F, Cleemput I, Desmyttere A, Schäfer-Keller P, Schaub S, et al. Prevalence, 
consequences, and determinants of nonadherence in adult renal transplant patients: a literature 
review. Transpl Int 2005;18:1121–33. 
[8]  Vlaminck H, Maes B, Evers G, Verbeke G, Lerut E, Van Damme B, et al. Prospective study on 
late consequences of subclinical non-compliance with immunosuppressive therapy in renal 
transplant patients. Am J Transplant 2004;4:1509–13. 
[9]  De Geest S, Abraham I, Moons P, Vandeputte M, van Cleemput J, Evers G, et al. Late acute 
rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. 
J Heart Lung Transplant 1998;17:854–63. 
[10]  Nevins TE, Kruse L, Skeans MA, Thomas W. The natural history of azathioprine compliance after 
renal transplantation. Kidney Int 2001;60:1565–70. 
[11]  Nevins TE, Thomas W. Quantitative patterns of azathioprine adherence after renal 
transplantation. Transplantation 2009;87:711–8. 
[12]   De Geest S, Denhaerynck K, Dobbels F. Clinical and economic consequences of non-adherence 
to immunosuppressive drugs. In: Grinyó J, editor. International Transplantation Updates. 
Barcelona, Spain: Permanyer Publications; 2011.  
[13]   Cleemput I, Kesteloot K, Vanrenterghem Y, Sabina De G. The economic implications of non-
adherence after renal transplantation. Pharmacoeconomics 2004;22:1217–34.  
[14]   Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR. Transplant 
outcomes and economic costs associated with patient noncompliance to immunosuppression. 
Am J Transplant 2009;9:2597–606.  
[15]   Leventhal H, Brissette I, Leventhal EA. The common-sense model of self-regulation of health and 
illness. In: Cameron LD, Leventhal H, editors. The self-regulation of health and illness behaviour. 
London: Routledge; 2003. p. 42–65.  
[16]   Chilcot J, Wellsted D, Farrington K. Illness representations are associated with fluid nonadherence 
among hemodialysis patients. J Psychosom Res 2010;68:203–12.  
[17]   O’Connor SM, Jardine AG, Millar K. The prediction of self-care behaviors in end-stage renal 
disease patients using Leventhal’s Self-Regulatory Model. J Psychosom Res 2008;65:191–200.  
[18]   Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to 
treatment in chronic physical illness. J Psychosom Res 1999;47:555–67.  
[19]   Kung M, Koschwanez HE, Painter L, Honeyman V, Broadbent E. Immunosuppressant 
nonadherence in heart, liver, and lung transplant patients: associations with medi-  cation 
beliefs and illness perceptions. Transplantation 2012;93:958–63.  
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Goal cognitions, illness perceptions and treatment beliefs and self-reported adherence
69
5
[20]   Chisholm-Burns M, Pinsky B, Parker G, Johnson P, Arcona S, Buzinec P, et al. Factors related 
to immunosuppressant medication adherence in renal transplant recipients.  Clin Transplant 
2012;26:706–13.  
[21]  Butler JA, Peveler RC, Roderick P, Smith PWF, Horne R, Mason JC. Modifiable risk factors for 
non-adherence to immunosuppressants in renal transplant recipients: a  cross-sectional study. 
Nephrol Dial Transplant 2004;19:3144–9.  
[22]   Lennerling A, Forsberg A. Self-reported non-adherence and beliefs about medication in a 
Swedish kidney transplant population. Open Nurs J 2012;6:41–6.  
[23]   Austin JT, Vancouver JB. Goal constructs in psychology: structure, process, and content. Psychol 
Bull 1996;120:338–75.  
[24]   Boersma SN, Maes S, Joekes K, Dusseldorp E. Goal processes in relation to goal attainment: 
predicting health-related quality of life in myocardial infarction patients. J Health Psychol Dec 
2006;11:927–41.  
[25]  Cleemput I, Dobbels F. Measuring patient-reported outcomes in solid organ transplant recipients: 
an overview of instruments developed to date. Pharmacoeconomics 2007;25:269–86. 
[26]  Dobbels F, Berben L, De Geest S, Drent G, Lennerling A, Whittaker C, et al. The psycho- metric 
properties and practicability of self-report instruments to identify medication nonadherence in 
adult transplant patients: a systematic review. Transplantation 2010;90:205–19. 
[27]  Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical 
trials and clinical practice. Clin Ther 1999;21:1074–90. 
[28] Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to 
antiretroviral therapy are consistent with electronic data and virological treat- ment outcome. 
AIDS 2002;16:269–77. 
[29]  Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer H, et al. Correlates of self-
reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort 
Study. J Acquir Immune Defic Syndr 2006;41:385–92. 
[30]  Pomaki G, Maes S, ter Doest L. Work conditions and employees’ self-set goals: goal pro- cesses 
enhance prediction of psychological distress and well-being. 2004;30:685–94. 
[31]  Broadbent E, Petrie KJ, Main J, Weinman J. The Brief Illness Perception Questionnaire. J 
Psychosom Res 2006;60:631–7. 
[32]  Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the de- velopment 
and evaluation of a new method for assessing the cognitive representa- tion of medication. 
Psychol Health 1999;14:1–24. 
[33]  Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN. Ad- herence to 
the immunosuppressive regimen in pediatric kidney transplant recipi- ents: a systematic review. 
Pediatr Transplant 2010;14:603–13. 
[34]  Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug regimens 
after renal transplantation: comparison of self-report and clinician rating with electronic 
monitoring. Transplantation 2004;77:786–9. 
[35]  Curtin RB, Walters BAJ, Schatell D, Pennell P, Wise M, Klicko K. Self-efficacy and self-management 
behaviors in patients with chronic kidney disease. Adv Chronic Kidney Dis 2008;15:191–205. 
[36]  Christensen AJ, Moran PJ, Wiebe JS, Ehlers SL, Lawton WJ. Effect of a behavioral self-regulation 
intervention on patient adherence in hemodialysis. Health Psychol 2002;21:393–7. 

6
Discrepancies Between Beliefs and Behavior: A Prospective 
Study Into Immunosuppressive Medication Adherence 
After Kidney Transplantation 
Emma K. Massey1,
 
Mirjam Tielen1,
 
Mirjam Laging1,
 
Reinier Timman2,
 
Denise K. Beck1,
 
Roshni Khemai1,
 
Teun van Gelder3,
 
and Willem Weimar1
1 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
2 Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
3 Departments of Internal Medicine and Hospital Pharmacology, Erasmus Medical Center, 
Rotterdam, The Netherlands.
Transplantation 2015; 99 (2): 375-380
Abstract
Background: Nonadherence to immunosuppressive medication after kidney transplantation 
is a behavioral issue and as such it is important to understand the psychological factors 
that influence this behavior. The aim of this study was to investigate the extent to which 
goal cognitions, illness perceptions, and treatment beliefs were related to changes in self-
reported immunosuppressive medication adherence up to 18 months after transplantation. 
Methods: Interviews were conducted with patients in the outpatient clinic 6 weeks (T1; n = 
113), 6 months (T2; n = 106), and 18 months (T3; n = 84) after transplantation. Self-reported 
adherence was measured using the Basel Assessment of Adherence to Immunosuppressive 
Medications Scale Interview. Psychological concepts were measured using the Brief Illness 
Perceptions Questionnaire, Beliefs about Medicines Questionnaire, and questions on the 
importance of adherence as a personal goal, conflict with other goals, and self-efficacy for 
goal attainment. 
Results: Nonadherence significantly increased over time to 31% at T3. Perceived necessity 
of medication, perceived impact of transplant on life (consequences) and emotional 
response to transplantation significantly decreased over time. Participants who reported 
low importance of medication adherence as a personal goal were more likely to become 
nonadherent over time. 
Conclusions: Illness perceptions can be described as functional and supportive of adherence, 
which is inconsistent with the pervasive and increasing nonadherence observed. There 
appears therefore to be a discrepancy between beliefs about adherence and actual behavior. 
Promoting (intrinsic) motivation for adherence goals and exploring the relative importance 
in comparison to other personal goals is a potential target for interventions. 
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Introduction
Immunosuppressive medication is a lifelong requirement after organ transplantation and 
an important component of self-management. Numerous studies have demonstrated early 
and pervasive immunosuppressive medication nonadherence (IMNA) after transplantation.
(1-6) Recipients of a kidney, in comparison to recipients of other organs, demonstrate the 
highest level of IMNA,(6) which in turn is related to poorer clinical outcomes.(3,7) Despite 
the established prevalence of IMNA, there are few studies that investigate potential 
modifiable targets for intervention to promote adherence among transplant patients. 
Improving adherence is a key target in improving long-term transplant outcomes.(8) 
In the area of health psychology, the common sense model of self-regulation has often been 
applied to the study of adherence behavior. The theory posits that individuals develop illness 
and treatment representations in an attempt to make sense of and guide management 
of the illness.(9–11) Illness perceptions include the perceived cause(s) of the illness, 
the label it is given (identity), timeline (chronic, acute, or cyclical), personal control over 
outcomes, the effectiveness of treatment to control outcomes, understanding of the illness, 
and concerns about, and emotional reaction to the illness. Treatment beliefs include the 
perceived necessity of treatment to maintain the current health state and concerns about 
the treatment. These perceptions inform goals set and actions undertaken to cope with 
the illness, such as medication taking. To understand transplant patients and their health 
behaviors, it is important to understand how they perceive their illness and medication as 
well as how this medication regime fits into, or conflicts with, the person’s goals in life. 
Research among diabetes(12) and dialysis patients has suggested support for a relationship 
between medication adherence and illness and treatment perceptions.(11,13,14) 
Among solid organ transplant recipients, evidence is mixed. Some studies demonstrated 
a relationship between perceptions and adherence(4,15–17) while one did not.(18) One 
major limitation of these studies is the cross-sectional design, which precludes investigation 
of changes over time and causal relationships. 
In this study, we add to the literature by contributing a prospective study on the extent to 
which illness and treatment perceptions and goal cognitions predict adherence up to 18 
months after transplantation. Analyses on the data from the first 2 timepoints revealed that 
patients were highly motivated to take their medication, felt efficacious in doing so, and 
understood the necessity for the medication to maintain current health state. However, goal 
importance, self-efficacy to achieve this goal and perceived necessity for the medication 
decreased significantly over time. Lower age and an increase in perceived longevity of the 
graft were related to nonadherence at 6 months.(19) For this analysis on all 3 timepoints 
up to 18 months, we formulated the following research questions: (1) Does adherence 
level change over time? (2) Do illness and treatment perceptions change over time? (3) Do 
perceptions predict IMNA in the first 18 months after transplantation? 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 6
74
Materials and methods 
Participants 
Consecutive patients who received a kidney transplant at the Erasmus University Medical 
Centre, Rotterdam, between August 24, 2010, and October 26, 2011, were invited to 
participate. Inclusion criteria were as follows: older than 18 years, sufficient physical and 
mental ability to participate, and sufficient command of the Dutch language. 
Procedure 
Patients who met the inclusion criteria received a Patient Information Form and Informed 
Consent Form during a consultation with the nurse practitioner before discharge from 
the hospital. Patients who returned the signed consent form were contacted to make an 
appointment; however, those who experienced graft failure by week 6 after transplantation 
were excluded. Interviews were conducted individually and were combined with the 
scheduled visit to the outpatient clinic to maximize participation. Interviews at T1, T2, and 
T3 were conducted by a nurse practitioner (M.T.), a psychologist (E.M., M.L.), or psychology 
student (R.K., D.B.). During the face-to-face interview, the questionnaires used in this 
study were administered. The study was approved by the Medical Ethics Committee of the 
Erasmus Medical Centre (MEC-2010-257). 
Measurements 
Medication Adherence 
Adherence to the immunosuppressive medication regime was measured using the Basel 
Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS Interview),(20) 
which consists of 4 questions on the taking and timing of medication, drug holidays, 
reduction of the dose, and persistence. We chose the BAASIS to measure medication (non)
adherence because it was specifically developed for immunosuppressive medications 
and consequently takes into consideration timing as well as taking. An affirmative answer 
to any of the first 4 items results in assignment to the nonadherent group. This scoring 
is intentionally strict due to an assumption of under-reporting of nonadherence.(21) The 
BAASIS measure is a brief, reliable, and valid instrument.(22,23) 
Goal Cognitions 
Goal cognition items were adapted from earlier measures of goal cognitions.(24,25) 
The extent to which patients endorse immunosuppressive medication adherence as an 
important personal goal was measured using 2 items, for example, “Taking my medication 
at the correct time is an important goal for me.” Goal commitment was measured using 3 
items, for example, “Even if taking my medication correctly is difficult, I will not give up on 
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it.” Conflict with other personal goals was measured using 3 items, for example, “Taking my 
medication correctly conflicts with other goals I find important.” Confidence in achieving 
their medication goal was measured using 3 goal self-efficacy items, for example, “I am 
capable of taking my medication in the correct way.” Each item was scored on a scale of 1 
(totally disagree) to 5 (totally agree). Principle components analysis on the baseline data 
(not shown) demonstrated a 3-factor structure: importance and commitment (Cronbach α = 
0.75), self-efficacy (Cronbach α = 0.84), and conflict (Cronbach α = 0.90). Mean scores were 
calculated per subscale (range 1–5). 
Illness Perceptions 
The Brief Illness Perceptions Questionnaire,(26) a widely implemented questionnaire to 
measure illness perceptions, was adapted to measure the way in which patients perceive 
their transplant. The first 8 items used here measure the perceived consequences, timeline, 
personal control, treatment control, comprehensibility, identity (symptoms), concerns 
(about rejection), and emotional response. Items were rated on a scale from 0 to 10. 
The Brief Illness Perception Questionnaire is brief and has demonstrated good test-retest 
reliability and concurrent validity among (renal) patients.(26) 
Beliefs About Medication 
The Beliefs about Medicines Questionnaire(27) was used to measure perceived necessity of, 
and concerns specifically about, immunosuppressive medication. Each item was rated on a 
5-point scale ranging from 1 (totally disagree) to 5 (totally agree). Each 5-item subscale was 
summed resulting in a score ranging from 5 to 25. Horne and colleagues(27) demonstrated 
satisfactory reliability and validity. 
Sociodemographic and Medical Characteristics 
The following characteristics were recorded and dichotomized for use in the analyses: sex 
(male/female), employment (paid work versus no paid work), ethnicity (Dutch versus non-
Dutch), marital status (married/living together versus single/widowed/divorced), type of 
donor (living versus deceased), preemptive transplantation (yes/no), number of transplants 
(1/>1), and comorbidity (yes/no). Education was categorized into low, middle, and high. Age 
and duration of hospital admittance were recorded as a continuous variable. 
Time 
For purpose of analysis and to accurately represent the length of time between 
measurements, timepoints were coded 0 at baseline (T1), 1 at 6 months follow-up (T2), and 
3 at 18 months follow-up (T3). 
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Statistical Analysis 
To answer the first 2 research questions, multilevel logistic and linear regression analyses 
were conducted on adherence and psychological variables, respectively, with time and the 
quadratic function of time as the predictors. To answer the third research question, multilevel 
logistic regression analyses were conducted to assess the contribution of psychological 
factors and time and the interactions of these factors to adherence categorization. Multilevel 
logistic regression corrects for bias when absence of data is dependent on characteristics 
that are present in the models (missing at random).(28) Time was entered into the analyses 
to investigate the linear effects of time on outcomes. A significant linear effect implies an 
increase or decrease in the outcome over time. Additionally, the quadratic function of time 
was entered as a predictor to investigate the nonlinear effects of time (eg, a U-shaped 
regression line). Level 1 data was time and level 2 was participants. All predictors were 
entered into the model, and backward elimination was used to exclude nonsignificant 
predictors. Only significant models are presented. Analyses were carried out using the 
Statistical Package for Social Sciences, version 21 (IBM Corporation, Armonk, NY). 
Results
Participant Characteristics 
During the inclusion period, 212 patients underwent transplantation, of which 44 (21%) did 
not satisfy the inclusion criteria. Of the remaining 168 patients, 113 participated at T1 (67% 
response rate). Reasons for refusal included fatigue (n = 26), no interest (n = 20), logistical 
reasons (n = 7), and other (n = 2). At T2, 106 patients participated (94% retention). At T3, 84 
patients participated (74% retention). Of the 29 dropouts, 4 patients died, 4 patients had 
graft failure, and 21 had health issues or did not wish to participate further. 
Sociodemographic and medical characteristics of participants are presented in Table 1. 
The majority (87%) reported comorbidity, such as diabetes and cardiovascular problems. 
There were no significant differences in sociodemographic or medical characteristics of 
responders and nonresponders.(29) 
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Table 1.  Baseline socio-demographic and medical characteristics
Characteristic Total group (N=113)
Age: median (range) 53 (19-75)
Gender: % men (n) 64.6 (73)
Marital status: % (n)
Single / Divorced / Widowed
Married / living together
26.5 (30)
73.5 (83)
Ethnicity: % (n)
Dutch
Non-Dutch 
84.1 (95)
15.9 (18)
Employment: % (n)
Paid employment (full/part-time)
Not in paid employment
45.2 (51)
54.9 (62)
Education: % (n) a
Low
Middle
High
12.4 (14)
63.7 (72)
21.2 (24)
Donor type: % (n)
Living
Deceased
79.6 (90)
20.4 (23)
Pre-emptive transplantation: % (n) 36.3 (41)
Number of transplants: median (range) 1 (1-5)
Duration of hospital admission: median (range) 13 (8-59)
a 3 missing
Change in Adherence 
The number of participants categorized as nonadherent significantly increased from 17% 
(19/113) at T1 to 27% (29/106) at T2 to 31% (26/84) at T3. Multilevel logistic regression 
showed that time was a significant predictor of nonadherence: B = 0.045; 95% CI, 0.007-
0.082, Wald χ2 (1) = 5.313; P = 0.021. 
Change in Psychological Factors 
Mean scores of psychological factors at each timepoint are presented in Table 2. Multilevel 
linear regression demonstrated significant linear (P = 0.008) and quadratic (P = 0.009) effects 
of time on necessity for medication. Perceived necessity of immunosuppressive medication 
decreased in the first 6 months and subsequently increased at 18 months. Perceived 
consequences (p = .016) and emotional response (p = .033) significantly decreased over 
time. Table S1 (SDC, http://links.lww.com/TP/B117) presents the full multilevel model for 
each psychological variable. 
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Table 2.  Means and standard deviations per timepoint for illness perceptions, treatment beliefs 
 and goal cognitions.
T0 (n=113)
Mean (SD)
T1 (n=106)
Mean (SD)
T2 (n=84)
Mean (SD)
Significant 
linear effect 
of time
Significant 
quadratic effect 
of time
Goal cognitions
Goal importance 4.62 (0.46) 4.52 (0.50) 4.53 (0.46)
Goal conflict 1.44 (0.72) 1.55 (0.71) 1.58 (0.82)
Goal self-efficacy 4.75 (0.45) 4.63 (0.60) 4.63 (0.50)
Beliefs about medicines
Necessity 22.76 (2.52) 22.03 (3.03) 22.42 (2.32) p = 0.008 p = 0.009 
Concerns (medication) 10.47 (4.09) 11.08 (3.75) 11.21 (3.96)
Illness perceptions
Consequences 7.64 (2.56) 7.29 (2.59) 6.87 (2.65) p = 0.016
Timeline 8.01 (1.81) 8.21 (1.84) 7.80 (2.08)
Personal control 7.64 (2.15) 7.81 (1.63) 7.94 (1.70)
Treatment control 8.99 (1.13) 9.00 (1.09) 8.81 (1.41)
Identity 2.69 (2.44) 2.93 (2.45) 3.17 (2.75)
Concerns (rejection) 5.72 (2.86) 5.74 (3.10 5.32 (3.07)
Coherence 7.39 (2.34) 7.61 (2.27) 7.17 (2.80)
Emotional response 3.89 (3.04) 3.47 (2.85) 3.21 (2.81) p = 0.033
Prediction of Nonadherence 
In step 1, the relationships between sociodemographic and medical characteristics were 
explored. These analyses showed that younger age (P = .03) and being in paid employment 
(trend, P = .06) were related to greater nonadherence. Pearson residuals were saved from 
this analysis and used as the dependent variable for the subsequent step (this procedure 
is equivalent to blocks in hierarchical regression). In step 2, controlling for age and 
employment, the psychological variables were entered. Nonsignificant (p > .05) variables 
were subsequently removed in a backward procedure. In the final parsimonious model, 
time, and the interaction between time and goal importance were significantly related 
to adherence categorization (see Table 3). There was no main effect of goal importance, 
however, as the interaction term is nested in this variable it was not removed from the 
model. To gain better understanding of this relationship, we divided goal importance 
according to the median split and plotted participants categorized as nonadherent per time 
point (Figure 1). The figure shows that participants who scored low on goal importance were 
more likely to become nonadherent over time.
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Table 3.  Multilevel logistical regression with IMNA as outcome
Parameter B Std. Error
95% Wald Confidence 
Interval Hypothesis Test
Lower Upper Wald Chi-
Square
       df  Sig.
(Intercept) 0.106 0.3256 -0.532 0.745 0.107 1 0.744
Time 0.616 0.1817 0.260 0.972 11.501 1 0.001
GI -0.034 0.0703 -0.172 0.104 0.233 1 0.629
Time* GI -0.127 0.0391 -0.204 -0.051 10.630 1 0.001
GI = Goal Importance
 98 
Figure 1. This figure demonstrates the predicted nonadherence values at each time point for 
participants who scored either high or low on goal importance.  
DISCUSSION  
Illness and treatment perceptions in the first 18 months after kidney transplant can be 
described as functional. Adherence was seen as an important personal goal, well integrated 
with other goals (as indicated by low goal conflict), and self-efficacy to achieve the goal was 
high. Patients reported high-perceived necessity and had relatively few concerns about their 
immunosuppressive medication. Transplantation was reported to have a large impact on 
patients' lives, however, this diminished over time. There was a good understanding of the 
transplant process, high personal and treatment control, low symptoms, and emotional 
response to the transplant. The latter further reduced over time. Concerns about rejection 
were fairly common; however, patients believed that the graft would last a relatively long time. 
This may reflect the large proportion of participants that received a living donor kidney (some 
Figure 1. This figure demonstrates the predicted nonadherence values at each time point for 
participants who scored either high or low on goal importance. 
Discussion 
Illness and treatment perceptions in the first 18 months after kidney transplant can be 
described as functional. Adherence was seen as an important personal goal, well integrated 
with other goals (as indicated by low goal conflict), and self-efficacy to achieve the goal 
w s high. Patients repor ed h gh-perceived nec ssity and h d relatively few concerns about 
their immunosuppressive medication. Transplantation was reported to have a large impact 
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on patients’ lives, however, this diminished over time. There was a good understanding of 
the transplant process, high personal and treatment control, low symptoms, and emotional 
response to the transplant. The latter further reduced over time. Concerns about rejection 
were fairly common; however, patients believed that the graft would last a relatively long 
time. This may reflect the large proportion of participants that received a living donor kidney 
(some preemptively), which in general has greater longevity than a deceased donor kidney. 
These functional illness and treatment perceptions were inconsistent with the 
behavioral findings. Nonadherence was pervasive and increased significantly over time 
with almost one third of participants categorized as nonadherent at 18 months after 
transplantation. There appears therefore to be a discrepancy between the way in which 
patients perceive the transplantation and medication on the one hand and their medication 
taking behavior on the other. These findings support those of Lennerling and Forsberg(18) 
that there is no relationship between beliefs about immunosuppressive medication and 
adherence in kidney transplant recipients. We add that perceptions about the transplant, 
such as personal and treatment control over graft functioning were unrelated to adherence 
behavior. These findings highlight the disease and treatment specificity of perceptions.(30) 
A previous study that focused on promoting self-efficacy after kidney transplantation was 
ineffective in increasing adherence over and above the increases found in the control group.
(31) Our findings may help explain this as self-efficacy was generally high and unrelated to 
nonadherence over time. 
Of the psychological variables investigated, importance of adherence as a personal goal 
was related to adherence. Participants who scored low on goal importance were more 
likely to become nonadherent over time. Exploring patients’ personal goals (such as work, 
relationships, and health) and the relative importance and integration of self-management 
goals could be one way of promoting adherence after transplantation. Few interventions 
have been effective in stimulating greater adherence in transplant patients.(32) Personal goal 
cognitions and self-regulatory skills may also be potential targets for adherence-enhancing 
interventions. Goal cognitions including perceived goal ownership, difficulty, support from 
the environment, and timeframe for achievement. Goal pursuit or self-regulatory skills 
include goal setting, planning, monitoring, revision, and emotion regulation.(33) There is a 
clear need for studies investigating the development and testing of adherence-promoting 
interventions after transplantation. 
One of the strengths of this study is the prospective design, which allows consideration 
of how perceptions and behavior change over time. A number of limitations can also be 
highlighted. The patients captured in this study may not represent all patients due to 
exclusion, nonresponse, and attrition rates. Inclusion bias may have influenced our findings 
because 21% (44/212) of the potential participant pool did not satisfy the inclusion criteria. 
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Patients were required to speak sufficient Dutch to be included, and this was the largest 
group that was excluded. Further research is needed to explore predictors of nonadherence 
in these hard-to-reach groups, such as those who do not speak the dominant language, 
are illiterate, or have low health literacy. Thirty-three percent (55/168) declined to 
participate due to lack of interest or ill health; however, given the lack of difference in socio-
demographic or medical characteristics between responders and nonresponders, we have 
no reason to believe this influenced the findings. A further 26% (29/113) of participants 
dropped out during the study, mainly for health reasons, which remains an issue when 
studying chronically ill patients. Regarding the method of assessing adherence, we focused 
on a self-report measure. Adherence is notoriously sensitive to method of measurement, 
and there is no gold standard.(21) In this study, we expected that self-reported adherence 
would have the largest relationship with illness and treatment perceptions, and this guided 
our choice to focus on self-report. Future studies could consider triangulation of findings 
from multiple, valid, and subjective and objective measures. Finally, we recognise that we 
focussed exclusively on patient-related factors.(34) In the future, a broader investigation 
into modifiable health system, social economic, condition, and therapy-related factors is 
likely to uncover other potential targets for promoting adherence after transplantation. 
With regard to the clinical implications of our findings, clinicians are advised to take a 
holistic view to adherence support after kidney transplantation with attention for important 
personal goals and how medication taking fits into the patient’s life. Clinical interactions 
and interventions often focus on the provision of medical information and education, which 
although important, is insufficient to bring about behavioral change.(32) Motivational 
interviewing is one potential tool that could be used to promote importance of adherence 
as a personal goal.(36,37) Exploring and helping maintain high motivation for medication 
adherence may help prevent deteriorating adherence over time. Given time restrictions of 
doctors and the psychosocial nature of this issue, it is likely that nurse practitioners could 
play an important role in offering this self-management support.(35) Finally, (barriers to) 
medication adherence should be something clinicians routinely explore not only immediately 
after transplantation but also longer after transplantation as our findings showing adherence 
is likely to deteriorate over time. 
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Abstract
Background: Nonadherence to medication is a common problem after kidney transplantation. 
The aim of this study was to explore attitudes towards medication, adherence and the 
relationship with clinical outcomes. Findings could inform development and tailoring of 
education and intervention programmes. 
Method: Kidney recipients were invited to participate in a Q-methodological study 6 weeks 
after transplantation. As a measure of medication adherence, respondents completed 
the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS©-
interview). Moreover, the intra-patient variability in the pharmacokinetics of tacrolimus was 
calculated, which measures stability of drug intake. Data on graft survival was retrieved from 
patient records up to 2 years after transplantation.
Results: 113 renal transplant recipients (19-75 years old) participated in the study. Results 
revealed three attitudes towards medication adherence: attitude 1; “Confident & Accurate”, 
attitude 2; “Concerned & Vigilant”, and attitude 3; “Appearance oriented & Assertive”. 
We found association of attitudes with intra-patient variability in pharmacokinetics of 
tacrolimus, but not with self-reported nonadherence or graft survival. However, self-
reported nonadherence immediately after transplantation was associated with lower two-
year graft survival.
Conclusion: These preliminary findings suggest that nonadherence shortly after kidney 
transplantation may be a risk factor for lower graft survival in the years to follow. The 
attitudes to medication were not a risk factor.
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Introduction
Kidney transplant patients are required to take lifelong immunosuppressive medication 
to prevent graft rejection. Nonadherence to immunosuppressive medication is a common 
issue and increases over time. Both dosage and timing of medication are crucial. Failure to 
take the medication as prescribed is a risk factor for (late) acute rejection, (late) graft failure/
loss, and patient mortality (1-4).
Among renal transplant patients, on average 36% of patients per year are reported to be 
nonadherent to immunosuppressive medication with estimates ranging from 2 to 67% (2, 
5-7). A number of patient, practitioner and regime related factors have been shown to be 
related to adherence after renal transplantation. The number and frequency of medication, 
as well as the relationship, communication and trust between the patient and health care 
provider are likely to influence adherence (3). Nonadherence is particularly a problem among 
adolescent transplant recipients. Rates of nonadherence have also found to be related to 
factors such as level of social support, education and socioeconomic status (3, 8). There is 
also evidence that nonadherence prior to transplantation is an independent predictor of 
nonadherence after transplantation (5, 9).
As nonadherence is a behavioral rather than a medical issue, many studies have focused 
on exploring possible psychological and other modifiable predictors (2, 3, 10). Psychological 
well-being, such as depression, can affect the extent to which an individual is adherent to 
the medication regime (11). In a previous study we reported clusters of attitudes which may 
indicate risk of poorer adherence to medication among young adult renal transplant patients 
(12). This was a population of young adults who had varying time since transplantation. 
Evidence suggests that adherence immediately after transplantation is often high but 
gradually declines over time (2), although some authors suggest nonadherence might be 
‘early and pervasive’ among renal transplant patients (4). Schmid-Mohler et al. (10) used 
the integrative model of behavioral prediction and found that forgetfulness/interruption 
of daily routine was the only significant predictor for non-adherence. In their later work 
(13) they found that nonadherence was significantly associated with patients beliefs about 
their immunosuppressive medicines. The aim of this study was to gain greater insight 
into attitudes towards the immunosuppressive medication regime shortly after kidney 
transplantation. And what is the relationship with adherence to medication and clinical 
outcomes in the years subsequent to transplantation. 
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Methods
Participants
All consecutive patients who received either a living or deceased donor kidney transplant 
in the Erasmus Medical Centre, Rotterdam, between August 2010 and October 2011 were 
invited to participate in the study. The inclusion criteria required that kidney transplant 
patients were older than 18 years, had a functioning graft six weeks post-transplant and had 
a sufficient level of understanding and speaking of the Dutch language. For clinical endpoints 
we had a follow-up time of at least two years after transplantation (until 31th of Oct 2013). 
All participants provided written consent for participation and the study was approved by 
the Medical Ethics Committee of the Erasmus Medical Centre. 
Measures and procedure
To explore attitudes towards medication after kidney transplantation we used 
Q-methodology. This is a method that combines aspects of qualitative and quantitative 
methods and provides a foundation for the systematic study of subjectivity (e.g., peoples’ 
viewpoints or beliefs, in this case attitudes to the immunosuppressive medication regime 
after kidney transplantation) (14, 15). The results of a Q-methodological study can be used 
to describe a population of viewpoints, not a population of people (16, 17). In previous 
studies we generated statements for young adults and elderly using the WHO dimensions of 
adherence (8, 18): socioeconomic-related factors, health care team or health system-related 
factors, condition-related factors, treatment-related factors and patient-related factors. This 
was done based on an iterative procedure and consensus (12). For the current study the 
statements were tailored for more general use with patients of all ages. The final Q-set 
consisted of 37 statements (Table 1), which were randomly numbered and printed on cards. 
Respondents were invited to participate in face-to-face interviews. Patients were 
interviewed at 6 weeks after transplantation during which they were asked to rank-order the 
37 statements, using a quasi-normal grid ranging from -3 to +3 (Figure, see page 21) (12). 
In addition, participants were asked to explain the ranking of the 2 statements that they 
agreed with (+3) and disagreed (-3) the most. The individual rankings of statements were 
analysed using by-person factor analysis so as to reveal a limited number of corresponding 
patterns in the way the statements were sorted by respondents. Correlation between 
individual rankings of statements is viewed as an indication of similarity in attitude.
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The outcome variable was nonadherence. To study nonadherence effectively we used 
a combination of measurement methods, as proposed by Farmer (19). Firstly, we used 
the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS©-
interview) (20, 21). This scale is a self-report instrument that consists of 4 questions on 
the taking and timing of medication, drug holidays, reduction of the dose and persistence 
over the past month (Table 2). An affirmative answer to any of the first 4 questions results 
in assignment to the nonadherent group. This scoring is intentionally strict due to an 
assumption of under-reporting of nonadherence. Patients also rated their own adherence 
using a Visual Analogue scale from 0% (medication never taken as prescribed) to 100% 
(medication always taken as prescribed). The BAASIS measure was selected as it is short, 
reliable, valid and sensitive to both timing and taking which is of particular importance for 
the immunosuppressive regime after kidney transplantation (20). A number of studies have 
demonstrated support for the validity of both parts of the instrument (22, 23). Specificity 
and sensitivity of the visual analogue scale have been shown to be high (22).
Table 2:  Adherence 6 weeks after transplantation as measured with the BAASIS© interviewa 
 (n=113). 
Part 1b Response 
n (%)
Categorized as 
nonadherent 
n (%)
1a Taking dimension: Do you remember missing a dose of your 
immunosuppressive medication (IM) in the past 4 weeks?
9 (8.0)
	 Once 8 (7.1)
	 2-3 times 1 (0.9)
1b Drug holidays: Do you remember having skipped two or more doses of 
your IM in a row in the past 4 weeks?
0
2 Timing dimension: Do you remember having taken your IM more than 
2 h before or after the prescribed dosing time in the past 4 weeks?
12 (10.6)
	 Once 10 (8.8)
	 2-3 times 1 (0.9)
	 4-5 times 1 (0.9)
3 Reduction of dose: Have you altered the prescribed amount of your IM 
during the past 4 weeks without your doctor telling you to do so?
0
4 Persistence: Have you stopped taking your IM completely in the past 4 
weeks without your doctor telling you to do so?
0
Total 19 (16.8)
Part 2c median (range)
5 Overall adherence rating 100 (77-100)
Note: a © University of Basel, Leuven-Basel Adherence Research Group, Institute of Nursing Science, 
University of Basel, Belgium, 2005. Permission & conditions to use the BAASIS® can be obtained from 
sabina.degeest@unibas.ch. b Response categories for questions 1 to 4 are given on a 6-point scale: 
(0) no; (1) once; (2) 2-3 times; (3) 4-5 times; (4) every 2-3 days; (5) almost daily. c Visual Analogue 
scale ranging from 0% (medication never taken as prescribed) to 100% (medication always taken as 
prescribed).
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Secondly, we calculated patient intra-individual variability in the pharmacokinetics of 
immunosuppressive medication, in this case tacrolimus (Prograft®) (24). Whole blood 
tacrolimus concentrations in different measurements over time within patients were used 
to calculate intra-individual variability. Patients with a high intra-patient variability have 
tacrolimus concentrations that are often outside the therapeutic window. Under-exposure 
may lead to immune activation, and over-exposure can result in CNI-induced nephrotoxicity. 
Both could affect long-term outcome. Borra et al.(24) showed that high intra-individual 
variability in the pharmacokinetics of tacrolimus leads to reduced graft survival. One of 
the most likely causes for intra-patient variability is medication nonadherence. To calculate 
the intra-patient variability in tacrolimus concentrations we used the method previously 
described by Borra et al (24). 
For the clinical endpoints, we collected information about rejection (yes/no) and graft 
failure (yes/no) two years after transplantation. 
Statistical analysis
Independent t-tests and chi-squared analyses were conducted to test differences between 
responders and non-responders. As the BAASIS overall rating scale was negatively skewed, 
a Mann-Whitney test was used to test the difference on this scale between adherent 
and nonadherent patients. One-way ANOVA and chi-squared tests were used to test the 
association between attitudes and adherence. When cell values were small, fisher’s exact 
tests were used to test 2x2 associations. Survival analyses were calculated with Kaplan-Meier 
and lifetable. Analyses were carried out using the Statistical Package for Social Sciences, 
version 20.0. Q-methodological data were analysed using PQMethod 2.11 (Schmolck & 
Atkinson, 2002).
Results
Demographic characteristics
Between August 2010 and October 2011, 212 kidney transplantations were carried out in 
our centre. Of these 212 patients 44 were excluded for the following reasons: not able to 
speak the Dutch language sufficiently (n=23), a mental or physical disability (n=9); death 
prior to inclusion (n=4); graft loss (n=4), primary non-function (n=3) and follow-up at another 
centre (n=1). Of the 168 kidney patients who were eligible to participate, 113 patients were 
included (67.3%). Fifty-five kidney transplant patients (32.7%) did not want to participate 
because they were not interested (n=20) or did not want to stay longer at the outpatient 
clinic for the study (n=26). Seven did not want to participate for logistical reasons and 2 were 
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discontent with their treatment and decided not to participate. Demographic characteristics 
of respondents and non-respondents are shown in Table 3. Of the 113 participants we had 
a minimum follow-up of two-years; 35 experienced graft rejection and 5 graft failures (1 
unknown, 4 due to rejection) and 6 patients died with a functioning graft. 
Table 3:  Patient characteristics of respondents and non-respondents
Respondents 
(n=113)
Non-respondents
(n=55)
Demographics n (%) n (%) p-value
Age (years)
 18-29
 30-45
 46-64
 65+
9   (8%)
27 (23.9%)
59 (52.2%)
18 (15.9%)
5 (9.1%)
8 (14.5%)
34 (61.8%)
8 (14.5%)
0.804
0.161
0.240
0.816
Gender
 Male
 Female
73 (64.6%)
40 (35.4%)
37 (67.3%)
18 (32.7%)
0.733
Education level
 High
 Middle
 Low
 Unknown
22 (19.5%)
64 (56.6%)
27 (23.9%)
5   (9.1%)
28 (50.9%)
17 (30.9%)
5 
0.134
0.940
0.180
Ethnicity
 Caucasian
 Asian
 African
 Turkish
 Other
 Unknown
86 (76.1%)
9   (8%)
10 (8.8%)
2 (1.8%)
2 (1.8%)
4  
40 (72.7%)
4 (7.3%)
4 (7.3%)
3 (5.4%)
3 (5.4%)
1 
0.489
0.851
0.705
0.195
0.195
Kidney transplant
 Living donor
 Deceased donor
 Number of transplants   
(median, range)
89 (78.8%)
24 (21.2%)
1 (1-5)
42 (76.4%)
13 (23.6%)
1 (1-3)
0.725
0.690
Marital status
 Married
 Living together
 Single
 Divorced
 Widow/widower
 Other
69 (61%)
14 (12.3%)
16 (14.2%)
8  (7.1%)
2  (1.8%)
4  
28 (50.9%)
5  (9.1%)
19 (34.5%)
1  (1.8%)
1  (1.8%)
1 
0.161
0.502
0.003
0.149
0.994
Attitudes
The analysis of the Q-methodological study revealed three distinct attitudes towards 
medication adherence (Table 1). Of the 113 participants 23 did not load significantly on 
any of these attitudes, or on more than one. Of the remaining 90 participants 40 patients 
defined factor 1, 38 factor 2 and 12 factor 3.
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Patients defining the first factor find it important to take their medication exactly every 
twelve hours (statement 29). They take good care of their kidney (statement 20) and have 
no worries about the future (statement 9) and are not afraid they have to go on dialysis again 
(statement 10). They find it reassuring their kidney function is checked regularly (statement 
34); these patients feel the least gloomy or depressed (statement 13). They do not mind 
taking multiple medicines every day (statement 21) but also indicate not to experience 
many side-effects (statement 14). This factor was labeled “Confident & Accurate”. These 
quotes from participants defining this factor illustrate this attitude profile: “this kidney was 
given to me by my wife, I have an obligation to take good care of this kidney”; “You don’t 
have any influence on things going wrong; I will do the best I can”. 
Patients defining the second factor also found it reassuring that their kidney function is 
checked regularly (statement 34), but this is more out of fear of graft loss. They are 
concerned that their kidney will be rejected (statement 8) and are afraid to go (back) on 
dialysis (statement 10). Therefore they are careful and they do not think it is wise to forget 
medication, even if it is only now and then (statement 2). They would rather be adherent 
than to enjoy their life to the fullest (statement 3). This factor was labeled ‘Concerned & 
Vigilant’. These quotes illustrate this attitude: “I’m always so worried, after my check-up 
I always call my doctor for the test results”; “Rejection is always on my mind, this has an 
impact on my life”; “It is so important to stay focused on the regime, I don’t want to blame 
myself for ruining this kidney, you have to follow the rules”. 
Patients defining the third factor find their appearance important (statement 11) and are 
afraid that the medication will influence their appearance negatively (statement 12). They 
do not want their lives to revolve around their disease (statement 5), although they indicate 
experiencing side effects (statement 14). Nevertheless they do not feel the need to be 
extra careful with their kidney from a loved one (statement 20), and they are not really 
concerned they will have to go (back) on dialysis (statement 10). They want their own say 
in their treatment (statement 35) and feel they are able to manage their medication and 
appointments themselves (statement 15). Therefore this factor was labeled ‘Appearance 
oriented & Assertive’. These quotes illustrate this attitude: “I don’t feel sick, not everybody 
knows I have a kidney transplant”; “I have been a kidney patient for 40 years now, and I 
want to be involved”; “In the future I want to do things without thinking about my disease”; 
“This kidney is from my mum and that is special to me, but I am not extra careful with my 
kidney because it is from my mum”.
There was general consensus between participants regarding a number of statements. 
In none of the attitudes patients were ashamed of their transplantation, minded others 
knowing about their kidney transplant (statement 1), or experienced problems with 
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swallowing larger pills (statement 23). All attitudes were neutral about having a healthy 
lifestyle (statement 7), taking their medication with them when they go out of the house 
(statement 30) and letting the doctor know if they took a wrong dose of the medication 
(statement 37). 
Adherence
The BAASIS-interview revealed that six weeks after transplantation, 17% (n=19) were 
classified as nonadherent (missed a dose or >2 hours earlier or later than prescribed in the 
past 4 weeks). Nine patients (8%) had missed a dose in the past month. Twelve patients 
(11%) had taken their dose 2 hours before or after the prescribed time; and two patients had 
either missed a dose or taken their dose 2 hours before or after the prescribed time. None 
of the patients had altered their dose or completely stopped taking their medication in the 
past four weeks (Table 2). Demographic characteristics of the self-reported nonadherent 
patients versus the self-reported adherent patients are shown in Table 4. There were no 
significant differences in age, gender, education level, donor kidney, ethnicity or social 
status between these groups. 
Patients also rated their own overall adherence from 0 to 100%. A Mann-Whitney test 
revealed a significant difference between groups: the adherent group had a median of 100% 
and the nonadherent group had a significantly lower median of 95% (p <.01). 
Of the 19 patients who were classified as nonadherent, 8 patients loaded on attitude 
1, 4 patients on attitude 2, 2 patients on attitude 3 and 5 patients did not load on any 
specific attitude. There was no significant association between attitudes and self-reported 
nonadherence classification (X2(2)= 1.344 p=.476).
In order to calculate the intra-patient variability in tacrolimus we used a minimum of 3 
tacrolimus measurements per patient (n=4) and a maximum of 5 measurements per patient 
(n=87). For 7 patients we were not able to calculate the intra-patient variability because of 
missing data. The median intra-patient variability was 14.5% (range 1.12-86.3%). As a cut-
off we divided the group in tertiles and split the patients into a group with low intra-patient 
variability (the patients in the lowest tertile 0-11.7%) and a group with high variability (the 
patients in the highest tertile, 18.02-100%). This resulted in 34 patients in the low-variability 
group, with a mean variability of 8.9%, and 35 patients with high-variability, with a mean 
variability of 27.0%. The intra-patient variability was significantly correlated with attitude 
profile (X2(2)= 6.799 p=.036). Patients with a high variability loaded more often on the 
attitude “Concerned & Vigilant”, while those with a low variability loaded more often on the 
attitude “Confident & Accurate”. Intra-patient variability was not correlated with the BAASIS 
classification of adherent versus nonadherent patients (X2(1)= 2.88 p=.110). 
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Table 4: Demographics self-reported nonadherent versus adherent patients
Nonadherent
(n=19)
Adherent
(n=94)
Demographics n (%) n (%) p-value
Age (years)
 18-29
 30-45
 46-64
 65+
2 (10.5%)
3 (15.8%)
11 (57.9%)
3 (15.8%)
7 (7.4%)
24 (25.5%)
48 (51.1%)
15 (16%)
0.651
0.364
0.587
0.985
Gender
 Male
 Female
11(57.9%)
8 (42.1%)
62 (66%)
32 (34%)
0.503
Education level
 High
 Middle
 Low
2 (10.5%)
12 (63.2%)
5 (26.3%)
20 (21.3%)
52 (55.3%)
22 (23.4%)
0.280
0.529
0.786
Ethnicity
 Caucasian
 Asian
 African
 Turkish
 Other
 Unknown
15 (78.9%)
0 (0%)
3 (15.8%)
0 (0%)
1 (5.3%)
0
71 (75.5%)
9 (9.6%)
7 (7.4%)
2 (2.1%)
1 (1.1%)
4 
0.995
0.150
0.272
0.512
0.220
Kidney transplant
 Living donor
 Deceased donor
Number of transplant 
(median, range)
16 (84.2%)
3 (15.8%)
1 (1-2)
73 (77.7%)
21 (22.3%)
1 (1-5)
0.524
1.000
Marital status
 Married
 Living together
 Single
 Divorced
 Widow/widower
 Other
12 (63.2%)
0 (0%)
4 (21.1%)
1 (5.3%)
1 (5.3%)
1 (5.3%)
57 (60.6%)
14 (14.9%)
12 (12.8%)
7 (7.4%)
1 (1.1%)
3 (3.2%)
0.837
0.072
0.345
0.735
0.205
0.656
Clinical endpoints
Patients that reported nonadherence in the BAASIS©-interview (n=19) had a lower two-
year graft survival (failure n=3) compared to the adherent group (failure n=2) (84% versus 
98% respectively (X2(1)=6.409 p=0.038). See Figure 2. Graft failure was not related to 
attitudes (p=0.532) or intra-patient variability (p=0.159). Patients with rejection (n=35) had 
no significantly lower graft survival (p=.167), graft rejection was not correlated with self-
reported adherence (X2(1)=.004 p=.574), the three attitudes (X2(2)=2.391 p=.347) or intra-
patient variability (X2(1)=2.947 p=.074).
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Figure 2: Kaplan Meier Graft survival. The nonadherent group consisted of 19 patients (3 graft failures) 
and the adherent group consisted of 94 patients (2 graft failures).
Discussion
This Q-methodological study revealed three distinct attitudes toward medication 
nonadherence as early as six weeks after transplantation: (1) Confident & Accurate, (2) 
Concerned & Vigilant, and (3) Appearance oriented & Assertive. We observed association 
between these attitudes, but not with self-reported adherence and clinical outcomes 2 years 
after transplantation. Patients with the attitude ‘Confident & Accurate’ appeared not to 
have any problems with medication adherence. They were confident about managing their 
medication regime 6 weeks after transplantation and these patients had significantly lower 
variability of tacrolimus in their blood. Earlier research has suggested that lower variability 
indicates greater adherence (24). In the attitude ‘Concerned & Vigilant’ we found evidence 
for a relationship between anxiety about the medication regime and nonadherence, as 
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indicated by the significantly higher variability of tacrolimus in the blood of these patients. 
DiMateo et al. (25) also found a difference in risk of nonadherence between anxious and 
non-anxious patients. They argued that patients were worried about their future and 
that this translated into frequent monitoring, fear of forgetting and non-compliance. In 
our study, significantly more patients with a high-intra patient variability loaded on this 
‘Concerned and Vigilant’ attitude. These findings suggest that individuals characterised by 
anxiety about their medication regime may be less adherent or, alternatively, that patients 
who have more problems with their medication are more worried. This association between 
attitude and adherence was, however, only found when adherence was measured using 
levels of medication found in the blood, not when using self-report. Although the patients 
defining attitude 2 seem to indicate they are reliable in their medication taking, their intra-
patient variability suggests differently. This discrepancy suggests potential under-reporting 
of nonadherence in this group on the self-report measure. Several studies before have 
found differences between self-reported nonadherence, which is simpler to measure but 
more susceptible to error, and direct measures for defining nonadherence such as drug 
levels or a clinical indicator, which are more objective and accurate but expensive (19, 26, 
27). Patients with the attitude ’Appearance oriented & Assertive’ want to live a normal life, 
be in control and think they are capable of taking care of their kidney, but are also the 
patients that indicate to experience side effects. Although their intra-patient variability of 
tacrolimus was not elevated, we speculate that these patients may have a higher risk of 
nonadherence in the future because they are concerned about (cosmetic) side effects of 
their medication regimen.
The Q-methodology study thus uncovered different attitudes towards medication 
adherence, which were associated with intra-patient variability of tacrolimus but not 
with self-reported nonadherence and with clinical endpoints such as graft rejection or 
graft survival. In contrast, self-reported nonadherence 6 weeks after transplantation was 
associated with graft failure in the subsequent 2-year period, but variability of tacrolimus 
was not. 
The findings reported should be interpreted in the light of a number of limitations. Firstly, 
as discussed, there is a possibility of under-reporting of nonadherence given the clinical 
setting of the study and the possibility of socially desirable answers. The BAASIS scale was 
developed with this phenomenon in mind and is therefore intentionally strict in its scoring 
mechanism: even a small deviation in the regime leads to a classification as nonadherent 
(20). However, these scores were not associated with intra-patient variability of tacrolimus, 
a direct and potentially more objective measure for adherence, so that under-reporting 
cannot be dismissed. Secondly, patients who did not have sufficient mastery of the Dutch 
language were excluded and an other group of patients declined to participate. It is possible 
that these harder-to-reach patients demonstrate yet another attitude, not identified here. 
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Findings therefore cannot be generalised to these patients. Finally, this study was conducted 
among a limited number of patients in a single centre. Replication of this study in different 
centres, with particular attention to inclusion of the harder-to-reach patients as well, is 
therefore advised. 
There are a few clinical implications of these findings. We found that Q-methodology 
was a useful tool for nurses in their interactions with patients, as it helped patients to talk 
freely about a difficult clinical topic. This approach offered patients the opportunity to 
(visually) structure their thoughts and nurse researchers the opportunity to investigate such 
pertinent issues in greater depth and to develop and tailor education programmes for this 
patient population. In any case, the finding that self-reported nonadherence was related to 
likelihood of graft failure suggests that a dialog between nurse and patient on medication 
adherence early in the transplant recovery period could be a useful tool to flag up individuals 
at risk of graft failure. Future research is also needed to further explore the (reciprocal) 
relationship between worry/anxiety and nonadherence and its clinical consequences. 
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This thesis investigated immunosuppressive medication nonadherence after kidney 
transplantation; in particular the psychosocial aspects of nonadherent behavior. The goal 
was to gain knowledge that would help nurse practitioners in their daily practice. We gained 
greater insight into patients’ medication taking behavior, the way patients perceive their 
illness and medication and how this medication regime fits into their daily lives. 
The main research questions were: 
(1) What is the rate of nonadherence among our population of kidney transplant recipients 
and does this change over time?
(2) What are the attitudes, beliefs and goals of kidney transplant recipients towards the 
medication regime?
(3) To what extent are these attitudes, beliefs and goals related to nonadherence? 
(4) To what extent is nonadherence related to graft survival?
In the general discussion these questions will be addressed.
Nonadherence and clinical outcomes
The rate of nonadherence was consistent over the studies in this thesis. We found a 
nonadherence rate of 31% in our cross-sectional study with elderly where the median time 
after transplantation was 5 years, this is consistent with our findings in our later prospective 
studies in which we found a nonadherence rate of 31% after 18 months. Our findings are 
comparable to other studies among kidney transplant patients, describing nonadherence in 
approximately one third of the patients (1-3). 
Nonadherence was found early after kidney transplantation. Our hypothesis was that 
patients who are recently transplanted are well informed and motivated to take their 
medication, but there was already a 17% nonadherence rate 6 weeks after transplantation. 
This is in line with other authors that suggest that nonadherence is ‘early and pervasive’ 
among kidney transplant patients (4). Moreover, the rate of nonadherence increased 
further over time. The perception of the necessity of medication decreases as time since 
transplantation goes by, as reported in chapter 6 (1, 5, 6). In our prospective studies we found 
that timing issues, as opposed to taking issues, were the most commonly reported form of 
nonadherence. Kidney transplant patients are required to take their immunosuppressive 
medication on time every 12 or 24 hours. Barriers to taking medication can include the 
complexity of the regime. The higher the number of pills or the more taking moments 
during the day, the more difficult it will be to be adherent (7, 8). Side effects can play a role 
in nonadherence but also, depression, younger age, health literacy, lack of understanding, 
patient beliefs, or having a living donor kidney (2, 9-12). Anxiety symptoms often co-
occur with depressive symptoms (13). While depression is indicated as a risk factor for 
nonadherence (14-17), we found the opposite that the gloominess about future prospects 
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translated in a high need of control and adherence in young adult recipients (chapter 2). This 
is comparable to another study that found nonadherent young adult recipients had fewer 
symptoms of depression than adherent recipients (18). In one study they found intentional 
non-adherence that was related to depression (19). Most studies focus on unintentional 
nonadherence; e.g. practical barriers to adherence, forgetfulness and missing medication 
when one’s routine is different (19-21). It is likely that patients forget medication to which 
they attach lower priority or importance to adherence.
In this thesis it is clear that nonadherence occurs amongst all groups of kidney transplant 
patients. Many studies have associated nonadherence with lower age and adolescence (12). 
This thesis showed that there is a significant difference in graft survival in young adults 
compared to older adults (chapter 2), nonadherence is likely to play a role in this although 
other factors may also contribute. We were able to categorize young adults that were 
suggested to be at risk of being nonadherent according to their attitude profile. Moreover 
each specific subgroup of young adults demands a specific tailored approach from a health 
care professional. Because this particular study was cross-sectional it had its limitations and 
we also did not measure adherence behavior. In addition to the findings on young adults 
(chapter 2), our studies also showed that in elderly patients (chapter 4) and in a cohort study 
of kidney transplant patients of all ages (chapters 5,6,7) nonadherence is present. Age alone 
is therefore not an accurate indicator of (non)adherence. We also found some young adults 
that were very adherent.
We demonstrated in chapter 7 that nonadherent patients according to the BAASIS 
scale also scored themselves lower on the overall adherence rating scale. Another study 
found the opposite between self-reported nonadherence according to the BAASIS (high) 
and the self-rating overall adherence (high) in young adults (18). This could be typical for 
young adults, we detected in interviews with young adults that they feel invulnerable to 
the effects of discontinuing immunosuppressive drugs and find it quite normal to take 
immunosuppressive drugs late and do not perceive any problem in doing so (chapter 3). 
Advantages of the BAASIS-interview or questionnaire are that it is a quick tool to asses self-
reported non-adherence and it measures both taking and timing issues. 
There is no gold standard for measuring nonadherence; we used self-report adherence 
scales (chapters 4 and 5,6,7) and intra-patient variability (chapter 7). The limitation of self-
reported adherence is that patients could give socially desirable answers. In elderly patients 
(>65 years) we used the Siegal scale for self-reported non-adherence, this scale is limited 
to issues of taking medication but does not measure issues of the timing of medication. In 
contrast, the BAASIS is a validated scale and measures the taking, timing and dosing of the 
medication. It is therefore possible that we did not capture timing issues in elderly patients 
due to the Siegal scale as opposed to the BAASIS.
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Better medication adherence improves health outcomes and results in lower healthcare 
costs (22, 23). Our findings suggest that nonadherence shortly after kidney transplantation 
may be a risk factor for lower graft survival in the years to follow (chapter 7). This is in line 
with the study of Nevins et al, that found that early declining medication nonadherence in the 
first two months was associated with adverse clinical outcomes, such as rejection and graft 
loss in the following 5-8 years (24). A study by Vlaminck et al found an association between 
non-adherence 1 year after transplantation and an increased risk for late acute rejection 
in the next 5 years (25). We demonstrated that patients who are already nonadherent at 
such a short time after kidney transplantation have worse clinical outcomes after kidney 
transplantation (4, 24). Therefore, maximizing medication adherence is a target for care to 
improve the long-term transplant outcomes. 
Nonadherence in our studies was substantial and was related to poorer clinical outcomes, 
however, we do not know the extent to which our findings are generalizable to those who 
did not participate. In order to avoid participant-bias, we did not mention to the patient 
that our aim was to investigate nonadherence, but that we wanted to know about their 
attitudes towards and beliefs about the medication regime and how kidney disease and 
transplantation fitted into their lives. We do not know if patients are more or less adherent in 
the group of non-responders. For logistical reasons, we excluded patients who did not speak 
or understand Dutch. Maybe these patients are at even higher risk of being nonadherent. 
There is some evidence that patients with racial/ethnic differences in demographics are less 
adherent (26, 27). In elderly patients we included a group of 65 years and older who were 
fit enough to receive a kidney transplantation, these were therefore already survivors and 
thus a select group (28-30). Patients who were in nursing homes, had cognitive limitations, 
or were on dialysis were not included. 
Attitudes and beliefs towards the medication regime
In this thesis attitudes were explored in kidney transplant recipients of different ages: young 
adults, the elderly, and in a group of all ages. The reason we wanted to explore attitudes 
of particularly younger and older patients was because nonadherence was believed to be 
associated with younger age (31-34). Moreover, there was little research on elderly kidney 
transplant patients who might experience difficulties due to deteriorating cognitive functions. 
In general, there is limited research on psychosocial factors associated with nonadherence 
among kidney transplant patients (21, 35). This was the first time that Q-methodology was 
used to investigate attitudes towards the medication regime after kidney transplantation. 
Q-methodology is a mixed method and combines the strength of qualitative and quantitative 
research, and is regarded a more robust technique than alternative (mixed) methods for the 
measurement of attitudes (36-40).
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There were some similarities in attitude profiles found in the various studies, and some 
differences. With Q-methodology we were able to categorize young adult kidney transplant 
patients in 4 distinct attitude profiles (chapter 2). One attitude profile was suggested to 
be at risk of being nonadherent, namely ‘easy going & pliable’. This group of ‘easy going 
and pliable’ young adults finds it more important to live their life to the fullest than to be 
adherent. Massey et al. found a high level of nonadherence (64.5%) in a group of young adult 
transplant recipients similar in age to the participants in chapter 2 (18). While adolescence 
and young adulthood are often associated with more nonadherence, we also found a profile 
in young adults that was very adherent and precise. This indicates that age is not always 
indicative of nonadherence and it is important to explore attitudes.
In addition, elderly patients could be categorized into two attitude profiles (chapter 4). 
One group labelled ’satisfied & easy going’ was focused on leading a normal and enjoyable 
life who were not fearful or worried about the consequences of not taking their medication 
correctly. While the other group labelled ‘reserved & concerned’ experienced more physical 
and psychological complaints and were more fearful of the consequences of not taking 
medication correctly. We did not find any differences in adherence between the patients 
in these two attitude profiles (chapter 4). While in young adults there was also a group 
that was fearful of the consequences of being nonadherent, this was suggested to translate 
into more adherence. Also we found fewer attitude profiles among elderly recipients, 
presumably missing the more experimental or appearance-focused attitudes that typify 
younger age. This could be due to the fact that the more experimental group of young 
adults is not represented in the elderly group, or in other words; the patients in the ‘easy 
going & pliable’ group who found it more important to live their life to the fullest than to be 
adherent may be less likely to survive. 
In our prospective study (chapter 5,6,7) we found 3 attitude profiles. Patients in the 
‘Confident and accurate’ group take medication very accurately and feel confident in doing 
so. The second profile ‘Concerned and vigilant’, is similar to the ‘reserved & concerned’ 
profile found in elderly, these patients find it reassuring to check their kidney function 
regularly, but this is more out of fear of graft loss, while in the ‘Confident and accurate’ 
profile patients also find it reassuring to check their function regularly but their motivation 
is to confirm that they are doing well. The third profile ‘appearance oriented and assertive’ 
was also found both in the prospective study in all ages and in the study with young adults 
(chapter 2). These patients do not want their lives to revolve around their disease and have 
difficulties with the (cosmetic) side effects of the medication. 
In conclusion 3 attitude profiles were repeatedly found in kidney transplant patients. 
First, an attitude profile that is concerned and afraid of graft loss but appears to be taking 
medication as prescribed, second, an attitude profile that is confident and not worried about 
graft loss and wants to live a normal life, and third, an attitude profile that found appearance 
important and experience side-effects of the medication. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Discussion
107
8
In addition to attitudes we also investigated patients’ beliefs about medication and the 
transplant and how post-transplant lifestyle and medications fits into patients’ daily lives. 
Adherence was an important goal for patients, and kidney transplantation a real life-event. 
Our cohort study among kidney transplant patients (chapter 5,6,7) shows that patients 
report high-perceived necessity of immunosuppressive medication and relatively lower 
concerns about the medication in the beginning after transplantation. Lennerling et al. 
also found that patients had a high necessity of immunosuppressive medication and low 
concerns (35). Because our work was prospective, we were able to see this changes over 
time; some changes appear functional while others may be less functional. In the first six 
months post-transplant, perceived necessity of immunosuppressive medication decreased 
and belief in one’s ability to carry out the regime decreased (chapter 5). In the longer 
follow-up, up to 18 months post-transplant, perceived necessity for the immunosuppressive 
medication continued to decrease, although the perceived impact of transplantation and 
negative emotional reaction to this decreased over time (chapter 6). 
Associations with nonadherence
We did not find an association between the attitude profiles and self-reported 
nonadherence; this was equally distributed over the profiles. Thus, we did not find evidence 
for relationship between attitudes and behavior. Attitude alone is not a predictive factor 
of nonadherent behavior of patients; this finding highlights the discrepancy between the 
beliefs regarding transplantation and medication on the one hand and medication taking 
behavior on the other. Similarly to Lennerling and Forsberg who found a high necessity of 
immunosuppressive treatment and a high adherence rate on the VAS scale of the BAASIS. 
They found a nonadherence rate of 36% when scoring the BAASIS as we did in our studies. 
(35). This shows that actual behavior can be different than what the beliefs and attitude 
of patients are. What we did find was an association between attitudes and intra-patient 
variability in the pharmacokinetics of Tacrolimus (chapter 7). High intra-patient variability, 
i.e. high variability in blood trough levels of Tacrolimus, could be the result of variable 
Tacrolimus intake. Patients with the attitude ‘concerned & vigilant’ had a high intra-patient 
variability, and the patients with attitude ‘ confident & accurate’ had a low intra-patient 
variability. This also suggests discrepancy between beliefs and actual behavior of patients. 
However, intra-patient variability was not related to clinical consequences (graft survival) 
whereas self-reported nonadherence was. This might be due to the short time after 
transplantation, the fact that patients are not yet stable and are not always well adjusted 
to their medication. Moreover a high intra-patient variability can also have other causes 
than nonadherence (41, 42). Which can make the intrapatient-variability measurement less 
accurate for nonadherence. 
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We found that patients who believed their graft would last longer were more likely to 
be nonadherent 6 months after transplantation (chapter 5). Patients with an unrealistic 
expectation that their graft will last a lifetime may underestimate the importance of 
medication in maintaining graft functioning. And those who reported a decreasing personal 
goal importance to adherence were more likely to become nonadherent over time (chapter 
6).
With regard to socio-demographic characteristics, we found an association between 
nonadherence and being in paid employment. Ortega et al. found patients working outside 
the home reported lower levels of global satisfaction and convenience. Patients who were 
satisfied with their treatment show better compliance with prescriptions and play an active 
role in their own care (43). In our studies we found evidence that the most common reason 
for being classified as nonadherent was timing, not taking of the medication. We speculate 
that patients who have a job have difficulties with timing of medication because of they 
forget, having difficulties taking medication when with colleagues, or due to a busy schedule. 
Furthermore we found an association between nonadherence and younger age. This is a 
continue variable, so we do not have a cut-off point of what age patients are at risk. The 
literature suggests that younger age can be a risk factor for nonadherence (11). The same 
goes for patients who make a transition from children’s hospital into the adult care (34, 44). 
We also found no relationship between nonadherence and perceived necessity for or 
concerns about medication. What we did find was an increase in nonadherence over time 
parallel to a decrease in perceived need for medication. However there was no significant 
relation between these two factors. In contrast Hugon et al. found in a prospective study 
in a population of solid organ transplant recipients that negative beliefs (concerns) towards 
medications were shown to be an independent risk factor of poor adherence. The stronger 
the belief that medicines in general are harmful and overprescribed, the less adherent 
patients are likely to be (21).
Practical/clinical implications
In this thesis we were not able to pinpoint one single factor that was consistently predictive 
of nonadherence. Nevertheless specific attitudes profiles were (repetitively) found that 
give a unique insight into patient’s perspectives on their medication regime. We now know 
the preferences of the patients with a certain attitude, and can as healthcare professionals 
interact with our patients according to their preferences and tailor the medical regime for 
them. The profiles can be used in clinical practice by making a short description of each of 
the profiles and asking the patient which profile they identified the most with (an example 
can be found in the appendix). This can help health care providers in adapting their care. 
Similarly Dwarswaard et al. underlined, in a thematic synthesis about self-management 
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needs, that patients vary in the extent to which they want to be involved in medical decision 
making and that changing the traditional (hierarchical) professional-patient relationship into 
a collaborative partnership is key (45). Our findings indicate that patients in each attitude 
profile demand a specific approach. For example the ‘appearance oriented and assertive’ 
patients are likely to thrive from a collaborative partnership where shared decision-making 
is central. With the right information and knowing the pros and cons they can contribute to 
decision-making regarding choice of medication. In young adults we now know that some 
patients with attitude ‘opinionated & independent’ want to be confronted by healthcare 
professionals with their nonadherent behavior in order to boost their motivation for 
adherence again. In addition to using short descriptions of the Q-profiles, when necessary 
the Q-sorting of the statements can be used as an intervention to communicate with young 
adults. The sorting of the statements can stimulate the young adult to think about his/her 
preferences/priorities with regards to treatment. We found in Q-methodology a tool to 
speak to young adults about complex issues such as nonadherence. The same experience 
was shared in other studies (46, 47). On the other hand Q-methodology was time consuming 
with elderly and therefore not that suitable for intervention in clinical practice for that 
specific group. 
Younger age was found to be a risk factor for nonadherence, but among young adults 
there can also be a difference in attitude and behavior. Healthcare professionals should 
always be extra alert for nonadherence if patients are younger; nevertheless this thesis 
showed that nonadherence is present among kidney transplant patients of all ages. 
The maintenance and persistence of the regime is an important target for intervention. 
Vrijens et al. describes the different stages of nonadherence; initiation, implementation, 
and discontinuation, but also the persistence is important (48). In the beginning (initiation 
phase) the majority of patients are well motivated but this decreases over time, especially if 
patients have unrealistic beliefs about the survival of their graft. Patients who assigned less 
importance to the goal adherence were more likely to become nonadherent. Additionally, 
these cognitions changed over time: the importance of medication adherence as a personal 
goal and perceived ability to carry out this behavior successfully (self-efficacy) significantly 
decreased over time. Patients need to be motivated to take their immunosuppressive 
medication. Motivation for adherence should be discussed regularly after transplantation 
and not only in the first months after transplantation as our findings showing adherence is 
likely to deteriorate over time. Also motivated patients can be nonadherent due to other 
factors. My own clinical experience is that every patient who has ever experienced graft 
loss due to nonadherence has his or her regrets. Based on this thesis, healthcare providers 
are recommended to discuss not only the need for and taking of medication but also the 
attitude, beliefs, motivation and expectations for the future. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 8
110
As nonadherence is not a one-time event but an ongoing process, addressing 
nonadherence with the patient should be part of the routine of a healthcare professional 
during a patient consultation. The BAASIS-interview is a relatively easy and brief way of 
addressing the issue nonadherence in the outpatient clinic. Important considerations are how 
the questions are asked and the relationship between patient and healthcare professional. 
In addition the BMQ could be used to screen patients for negative beliefs towards their 
immunosuppressive medications (21). With this instrument the healthcare provider gains 
an inside in the way patients thinks about the needs and concerns about the medication. 
This could help healthcare professionals to discuss this feelings with the patient about their 
regime. This could increase the shared-decision making on how the regime best fits into a 
patient’s life with the best outcomes. It is important to involve patients in the management 
of their own disease if they able to do so, and to encourage adherence as a personal goal. 
Healthcare professionals should also be vigilant to correct unrealistic beliefs that the graft 
will last an entire lifetime, particularly amongst younger patients, and emphasize that they 
can optimise their graft survival by good medication adherence.
All the major items are summarized in the box below. 
The major items for nurse practitioners concerning non adherence after kidney transplantation are:
1. Nonadherence should be considered in ALL patients;
2. The most common form of nonadherence is the TIMING of medication;
3. Nonadherence is pervasive IMMEDIATELY after transplantation, and increases over time;
4. Discussing adherence with patients in the outpatient clinic should be part of ROUTINE care;
5. The BAASIS-interview or questionnaire is a recommended tool to quickly and effectively 
MEASURE non-adherence; 
6. ATTITUDE towards medication adherence can differ from actual adherence BEHAVIOR;
7. Adherence should be stimulated as an important personal GOAL;
8. Be vigilant to correct UNREALISTC EXPECTATIONS that a kidney transplant will last a lifetime;
9. The sorting of the Q-statements can be used as an intervention to COMMUNICATE with 
uncommunicative young adults;
10. Short descriptions of the Q-profiles can be used to explore ATTITUDES towards the regime.
Future directions
Our research showed early and increasing nonadherence after kidney transplantation. 
One third of kidney transplant patients are not always adherent to the medication regime. 
Patients have to take lifelong immunosuppressive drugs to prevent rejection of the graft and 
adhere to lifestyle changes. Future research should focus on two things. First, continuing to 
look for factors associated with adherence as targets for interventions. Not all determinants 
of nonadherence are known yet, so we are not able to identify specific groups of patients 
at risk for nonadherence. We need more follow-up time after transplantation to see if 
certain profiles are at risk for poorer clinical outcomes. Also we need to focus on other 
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dimensions than patient-related and therapy-related factors (10). We should also address 
health system/health care team factors and critically assess if multidisciplinary teams are 
involved in addressing nonadherence. Other factors to be investigated are the influence of 
the interaction between healthcare professionals and patients on adherence. Furthermore, 
are healthcare professionals such as nurse practitioners/doctors well trained enough to 
address the subject nonadherence. In a qualitative study by Been et al. nurses had divergent 
perceptions about self-management and their actual role in promoting this. Sufficient 
tools and training could help nurses operationalize self-management support in their daily 
working routine (49). More evidence is needed what kind of tools and training nurses can 
use to best contribute to the problem of nonadherence and self-management support in 
general. 
Secondly, we have to develop interventions in the clinic to promote adherence. 
Interventions that help patients find a way to cope with their disease and adhere to the 
medication and lifestyle changes that comes with a kidney transplant. Interventions on 
improving adherence after kidney transplantation are scarce (50-52). Effective interventions 
are even more scarce. Nonadherence is present amongst the different groups of kidney 
transplant patients, this makes it hard to make an intervention that applies to the whole 
group of (non)adherent patients. An intervention should be tailored to the individual patient 
preferences. In a review about interventions for enhancing adherence in HIV patients, the 
authors found few interventions that successfully improved both adherence and clinical 
outcomes, with annotation that interventions based on theory of behavior would stand 
a better chance of improving adherence, but they found no evidence to support this (53). 
Motivational interviewing is one potential tool that could be used to promote importance 
of adherence as a personal goal (54, 55). Exploring and helping maintain high motivation 
for medication adherence may help prevent deteriorating adherence over time. Especially 
nurse practitioners are trained for balancing care and cure and can play an important 
role in adherence promotion (56). Therefore nurse practitioners may be a good choice as 
interventionists. Effective nurse-led interventions to enhance adherence are essential in 
order to achieve the best long-term clinical outcomes including quality of life after kidney 
transplantation. 
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Summary 
Patients with end stage renal disease (ESRD) benefit from kidney transplantation as the best 
renal replacement therapy. Kidney transplantation is the best option due to the advantages 
for patient survival and quality of life. There are two choices in renal transplantation; a 
living donor kidney transplantation (LDKT) or a deceased donor kidney transplantation 
(DDKT). A LDKT is the most favourable, because of the advantages for graft and patient 
survival. Patients have to take immunosuppressive medication after kidney transplantation 
to prevent rejection of the graft. According to the World Health Organization (WHO) 
adherence is defined as “the extent to which a person’s behavior corresponds with the 
agreed recommendations from a health care provider”. This thesis investigated patients’ 
adherence behavior and attitudes and beliefs about the immunosuppressive regime.
Chapter 1 gives a general introduction about what kind of therapy and lifestyle is required 
after kidney transplantation. Patients have to be adherent to their immunosuppressive 
medication regime. This most commonly consists of two intake moments of medicine a day, 
although patients are likely to have other additional medication for other comorbidities 
making this regime even more complex. There are five interacting dimensions that affect 
adherence according to the world health organization (WHO). The first is ‘social and 
economic factors’, for example poverty, race, age, and insurance. The second dimension is 
‘the health care team and system-related factors’, such as patient-provider relationship. The 
third dimension ‘condition-related factors’ is the severity of symptoms or disease and how 
they influence patients’ perception of risk if they deviate from the prescribed regime. The 
fourth dimension is ‘therapy-related factors’ like the complexity of the medical regime and 
the side effects of that regime. The fifth and last dimension is ‘patient-related factors’ which 
represents the resources, knowledge, attitudes, beliefs, perceptions, and expectations of 
the patient. 
This chapter also describes nonadherence among kidney transplant patients and how 
this is monitored. Furthermore there are many factors that can have an influence on the 
graft survival; nonadherence is a potential contributing factor.
At the end of this chapter the aim of this thesis and specific research question are 
presented. The aim of the thesis was to gain a better understanding of (change in) 
immunosuppressive medication nonadherence and in particular the psychosocial aspects 
of behavior after kidney transplantation in order to inform the care that nurse practitioners 
can offer in the clinic. The research questions in this thesis were: (1) What is the rate of 
nonadherence among our population of kidney transplant recipients and does this change 
over time? (2) What are the attitudes, beliefs and goals of kidney transplant recipients 
towards the medication regime? (3) To what extent are these attitudes, beliefs and goals 
related to nonadherence? (4) To what extent is nonadherence related to graft survival?
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Chapter 2 describes a cross sectional study on attitudes toward s the medication regime 
among young kidney transplant patients. A Q-methodological (mixed-methods) study was 
conducted among 26 young adults (18-25 years). Four distinct attitude profiles concerning 
post-transplant health lifestyle were found: (i) concerned & controlled, (ii) appearance 
orientated, (iii) opinionated & independent, and (iv) easy going & pliable. (For the four short 
descriptives see appendix).
The young adults loading on the first factor (i) ‘concerned & controlled’ worry that their 
kidney will be rejected and are concerned about their future. They are careful about their 
medication and their health behavior, and find it more important to be adherent than to 
have a good life now. Non-adherence leads to feelings of guilt. Young adults loading on 
the second factor (ii) are ‘appearance-orientated’, do not wish their life to revolve around 
their disease, and believe that after transplantation they can live a normal life. The risk 
for non-adherence seems relatively small in these young adults, but the fear for cosmetic 
side-effects of immunosuppressant’s, and the tendency to be uncommunicative about their 
transplant in their social environment, may interfere with adherence. Young adults loading 
on the third factor (iii) ‘opinionated & independent’ believe strongly about not wanting to go 
back on dialysis again and do not wish their life to revolve around their disease. They seek a 
normal life, with the least possible limitations from their regime. More than in other groups, 
these young adults are scared of a rejection because of nonadherence. Young adults loading 
on the fourth factor (iv) ‘easy going & pliable’ find it more important to live a good life now 
than to be compliant and think nothing bad will happen if they forget their medication. 
These young adults seems to be uninformed or uninterested in their illness and regime, and 
not to foresee or accept the risks of their nonadherent behavior. We speculate therefore 
that their risk of nonadherence is high. Thirty-four young adult transplant recipients were 
subsequently asked to what extent they identified themselves with these 4 profiles. Self-
categorization on these attitudes seems feasible and may be a useful screening aid to 
identify young adults at risk of non-adherence. 
Chapter 3 describes the results of the Q-methodology in-depth interview study in 
Chapter 1 focusing on the four statements related to the medication regime. Statement 1; 
“If you forget your medication, nothing really bad will happen”. Statement 2; “I never forget 
my medication”. Statement 3; “When I stay in bed late, I just take my medication later”, and 
statement 4; “When I am out with friends, I am not very punctual with medication”. Ten 
of the 26 patients felt that forgetting medication would not lead to serious consequences. 
They had developed all kind of theories about why there would be no serious consequences. 
Half of the respondents (48%) stated that they never forget their medication. Most young 
adults (80%) have no problems with taking medication when with friends. Remarkably, 72% 
of the young adults admitted not always taking their medication on time. After going out 
with friends the day before, they forget to take their medication on the prescribed time. 
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Especially during the weekend young adults experience problems with the regular intake 
of immunosuppressive medication. Apparently, young adults are not too accurate with 
the medication, especially when it does not fit in with their life style and with important 
social activities such as going out with friends. This study is very relevant for healthcare 
professionals because it helps to understand the motivation behind nonadherence behavior 
among young adult transplant recipients. 
Chapter 4 describes a study that investigated attitudes towards the post-transplant 
regime of immunosuppressive medication among the elderly kidney transplant recipients 
(>65 years). Two distinct attitudes were found: ‘satisfied & easy going’ and ‘reserved & 
concerned’. Satisfied and easy-going patients focus on leading a normal and enjoyable life and 
are not fearful or worried about the consequences of not taking their medication correctly. 
Reserved and concerned elderly patients experience more psychical and psychological 
complaints are more fearful of consequences of not taking their medication correctly. 
These attitudes imply different needs for assistance, monitoring and risk of nonadherence. 
The proportion of elderly that forgets their medication is considerable, but not different 
between the two attitude profiles. 
Chapter 5 describes a prospective cohort study where we investigated whether changes 
in goal cognitions, illness perceptions, and treatment beliefs were related to self-reported 
medication adherence six months after kidney transplantation. The cohort consisted of 
113 kidney transplant patients at baseline 6 weeks after transplantation. We found that 
self-reported nonadherence increased significantly between 6 weeks and 6 months after 
transplantation from 17% to 27%. Importance of medication adherence as a personal goal 
and self-efficacy to successfully carry out this goal was high but decreased significantly over 
time. Perceived necessity of immunosuppressive medication was also high but significantly 
decreased over time. Concerns about the medicines were low. There were no significant 
changes in illness perceptions or concerns over time. An increase in perceived graft longevity 
(timeline) was related to higher likelihood of nonadherence six months post-transplant. 
Furthermore, younger adult patients were more likely to be nonadherent six months after 
transplantation. The self-reported nonadherence levels found in this study so soon after 
transplantation demonstrate the need for early and continued intervention after kidney 
transplantation in order to maximize adherence. Changes in (unrealistic) beliefs regarding 
the longevity of the graft may offer a potential target for intervention among nonadherent 
patients. 
Chapter 6 describes the 18-month follow-up of the prospective cohort study presented 
in chapter 5. Here we see nonadherence significantly increased from 17% at 6 weeks to 31% 
at 18 months after transplantation. Perceived necessity of medication, perceived impact of 
transplant on life (consequences) and emotional response to transplantation significantly 
decreased over time. Participants who reported low importance of medication adherence 
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as a personal goal were more likely to become nonadherent over time. Illness perceptions 
can be described as functional and supportive of adherence, which is inconsistent with 
the pervasive and increasing nonadherence observed. There appears therefore to be a 
discrepancy between beliefs about adherence and actual behavior. Promoting (intrinsic) 
motivation for adherence goals and exploring the relative importance in comparison to 
other personal goals is a potential target for interventions. 
Chapter 7 describes attitudes towards medication adherence 6 weeks after 
transplantation using Q-methodology in the same cohort described in chapters 5 and 6. 
The three attitudes found were 1; “Confident & Accurate”, 2; “Concerned & Vigilant”, and 
3; “Appearance oriented & Assertive”. Patients with the attitude ‘Confident & Accurate’ 
were confident about managing their medication regime 6 weeks after transplantation and 
had significantly lower variability of tacrolimus in their blood. Patients with the attitude 
‘Concerned & Vigilant’ reported anxiety about the medication and nonadherence and 
were significantly related to higher variability of tacrolimus in the blood compared to the 
‘confident & accurate’ patients. These findings suggest that individuals characterized by 
anxiety about their medication regime may be less adherent or, alternatively, that patients 
who have more problems with their medication are more worried. This association between 
attitude and adherence was, however, only found when adherence was measured using 
levels of medication found in the blood, not when using self-report. Patients with attitude 
’Appearance oriented & Assertive’ want to live a normal life, be in control and think they 
are capable of taking care of their kidney, but also experience side effects. Although their 
intra-patient variability of tacrolimus was not elevated, we speculate that these patients 
may have a higher risk of nonadherence in the future because they are concerned about 
(cosmetic) side effects of their medication regimen. 
The Q-methodology study thus uncovered different attitudes towards medication 
adherence that requires different approaches from healthcare professionals. We found an 
association between attitudes and intra-patient variability in pharmacokinetics of tacrolimus, 
but not with self-reported nonadherence or graft survival and with clinical endpoints such 
as graft rejection or graft survival. In contrast, self-reported nonadherence 6 weeks after 
transplantation was associated with graft failure in the subsequent 2-year period. These 
findings suggest that nonadherence shortly after kidney transplantation may be a risk 
factor for lower graft survival in the years to follow. The attitudes towards medication were 
not related to adherence behavior, but nurses experienced the interview method used as 
helpful to interact with patients about this difficult clinical topic. These results will inform 
the development and tailoring of self management programmes for patients shortly after 
transplantation.
Chapter 8 describes the general discussion and gives an integration of all the study 
results. With the following major items for nurse practitioners regarding non-adherence. 
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The major items for nurse practitioners concerning non adherence after kidney transplantation 
are:
1. Nonadherence should be considered in ALL patients;
2. The most common form of nonadherence is the TIMING of medication;
3. Nonadherence is pervasive IMMEDIATELY after transplantation, and increases over time;
4. Discussing adherence with patients in the outpatient clinic should be part of ROUTINE care;
5. The BAASIS-interview or questionnaire is a recommended tool to quickly and effectively 
MEASURE non-adherence; 
6. ATTITUDE towards medication adherence can differ from actual adherence BEHAVIOR;
7. Adherence should be stimulated as an important personal GOAL;
8. Be vigilant to correct UNREALISTC EXPECTATIONS that a kidney transplant will last a lifetime;
9. The sorting of the Q-statements can be used as an intervention to COMMUNICATE with 
uncommunicative young adults;
10. Short descriptions of the Q-profiles can be used to explore ATTITUDES towards the regime.
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Voor patiënten met eindstadium nierfalen is niertransplantatie de beste nierfunctie 
vervangende therapie. Niertransplantatie is de beste optie omdat het de beste kwaliteit van 
leven geeft ten opzichte van de andere nierfunctie vervangende therapieën en zorgt voor 
de beste patiënten overleving. Er zijn twee verschillende vormen van niertransplantatie: een 
levende donornier transplantatie of een postmortale donornier transplantatie. Een levende 
donornier transplantatie heeft de voorkeur, vanwege de voordelen voor het transplantaat 
(nier) en de overleving van de patiënt. Patiënten dienen na een niertransplantatie 
immunosuppressiva in te nemen om afstoting van de donornier te voorkomen. Volgens de 
World Health Organization (WHO) is de definitie van therapietrouw: “de mate waarin iemands 
gedrag correspondeert met de overeengekomen aanbevelingen van een zorgverlener”. Dit 
proefschrift onderzocht de houding en overtuigingen van patiënten ten opzichte van hun 
medicatie regime en therapietrouw gedrag na niertransplantatie.
Hoofdstuk 1 geeft een inleiding over wat voor therapie en levensstijl nodig is na een 
niertransplantatie. Patiënten moeten zich houden aan de medicatie voorschriften van de 
immunosuppressiva. Deze immunosuppressiva dient normaliter op twee momenten per dag 
te worden ingenomen, maar deze patiënten hebben vaak nog meer medicatie ten gevolge 
van co morbiditeit en dat maakt het medicatieregime nog complexer. Therapieontrouw 
heeft een negatieve invloed op de niertransplantaatoverleving op de lange termijn. Volgens 
de World Health Organization (WHO) zijn er 5 interactieve dimensies die de therapietrouw 
kunnen beïnvloeden. De eerste zijn ‘sociale en economische factoren’, denk aan armoede, 
etniciteit, leeftijd en zorgverzekering. De tweede dimensie is ‘het gezondheidszorg team en 
systeem gerelateerde factoren’, zoals de behandelrelatie tussen de patiënt en zorgverlener. 
De derde dimensie ‘conditie gerelateerde factoren’ is de ernst van de symptomen van 
de ziekte en welk risico patiënten nemen als ze afwijken van het voorgeschreven regime. 
De vierde dimensie is ‘therapie gerelateerde factoren’ zoals de complexiteit van het 
medicatieregime en de bijwerkingen van de medicatie. De vijfde en laatste dimensie is 
‘patiënt gerelateerde factoren’ wat de kennis, houding, overtuiging en verwachtingen 
van een patiënt vertegenwoordigd. In dit hoofdstuk wordt ook therapieontrouw onder 
niertransplantatie patiënten beschreven en de diverse methoden om dit te meten. Verder 
zijn er veel factoren die invloed kunnen hebben op de transplantaatoverleving waaronder 
therapieontrouw.
Het doel van dit proefschrift was om inzicht te krijgen over (veranderingen in) 
therapieontrouw en voornamelijk meer inzicht in de psychosociale factoren die van invloed 
zouden kunnen zijn op therapieontrouw gedrag. Zodat verpleegkundig specialisten de 
poliklinische zorg voor patiënten kunnen verbeteren.
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De onderzoeksvragen van dit proefschrift waren: (1) Hoe vaak komt therapieontrouw 
voor onder onze populatie niertransplantatiepatiënten en verandert dit over de tijd? (2) 
Wat zijn de houdingen, overtuigingen en doelen van een niertransplantatiepatiënt ten 
opzichte van zijn medicatie regime? (3) Zijn houdingen, overtuigingen en doelen van 
patiënten van invloed op de therapieontrouw? (4) Is therapieontrouw van invloed op de 
niertransplantaatoverleving?
Hoofdstuk 2 beschrijft een crossectionele studie over houdingen ten aanzien van de 
medicatie onder jong volwassen niertransplantatiepatiënten. Deze Q-methodologische 
(gecombineerde methode kwalitatief/kwantitatief) studie werd verricht onder 26 jong 
volwassenen (18-25 jaar). Vier afzonderlijke factoren van houdingen ten opzichte van het 
medicatie regime en het leven na een niertransplantatie werden gevonden: (i) bezorgd & 
gecontroleerd, (ii) uiterlijk georiënteerd & gesloten, (iii) relaxed, eigenwijs & zelfstandig, en 
(iv) makkelijk & meegaand. (Zie de bijlage voor 4 korte beschrijvingen). De jong volwassenen 
die op de eerste factor laden (i) ‘bezorgd & gecontroleerd’ zijn bezorgd dat de donornier zal 
afstoten en maken zich zorgen om hun toekomst. Ze zijn zorgvuldig met de medicatie en 
leven gezond, zij vinden het belangrijker om volgens de regels te leven dan nu te genieten. 
Therapieontrouw leidt tot schuldgevoelens. Jong volwassenen die laden op de tweede factor 
(ii) zijn ‘uiterlijk georiënteerd & gesloten’, zij willen niet dat hun leven om de ziekte draait, 
zij geloven dat ze na een niertransplantatie gewoon een normaal leven kunnen leiden. Het 
risico op therapieontrouw bij deze jong volwassenen lijkt redelijk klein, maar de angst voor 
cosmetische bijwerkingen van de immunosuppressiva en de neiging om gesloten te zijn over 
hun niertransplantatie in hun sociale omgeving zal mogelijk invloed kunnen hebben op de 
therapietrouw. Jong volwassenen die laden op de derde factor (iii) ‘relaxed, eigenwijs & 
zelfstandig’ willen absoluut niet (terug) naar de dialyse en willen ook niet dat hun leven om 
de ziekte draait. Zij willen een normaal leven en geen beperkingen ervaren ten aanzien van 
hun medicatie regime. Meer dan in de andere factoren zijn deze jong volwassenen bang voor 
afstoting als gevolg van therapieontrouw. Jong volwassenen die laden op de vierde factor (iv) 
‘makkelijk & meegaand’ vinden het belangrijker om nu lekker te leven dan om therapietrouw 
te zijn. Zij denken dat er niks ergs gebeurt als je af en toe je medicijnen vergeet. Deze jong 
volwassenen lijken niet goed geïnformeerd of ongeïnteresseerd in hun aandoening te zijn en 
bijbehorende regime en lijken niet goed in staat om hun risico’s te overzien of te accepteren 
na therapieontrouw gedrag. Wij speculeren dat het risico op therapieontrouw bij deze 
jongeren hoger zal zijn. 34 jong volwassen niertransplantatiepatiënten werden vervolgens 
gevraagd of zij zichzelf konden identificeren met deze 4 factoren. Zelf categorisatie op deze 
factoren lijkt uitvoerbaar en kan een nuttig instrument zijn om jongeren te identificeren 
voor een risico op therapieontrouw. 
Hoofdstuk 3 beschrijft de resultaten van de diepte-interviews van de Q-methodologie 
studie in hoofdstuk 1 gericht op de 4 stellingen die direct gerelateerd waren aan het 
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medicatie regime. Stelling 1; “Als je een paar keer je medicijnen vergeet, zal er echt niets 
gebeuren”. Stelling 2; “Ik vergeet mijn medicijnen eigenlijk nooit”. Stelling 3; “Als ik uitslaap, 
neem ik mijn medicijnen gewoon wat later in”, en stelling 4; “Als ik met vrienden ga stappen 
of op vakantie ben, neem ik het niet zo nauw met mijn medicijnen”. Tien van de 26 patiënten 
dachten dat het vergeten van medicatie geen consequenties zou hebben. Ze hadden diverse 
theorieën ontwikkeld waarom dat geen serieuze consequenties kon hebben. De helft van 
de respondenten (48%) verklaarden dat zij nooit hun medicatie vergaten. De meerderheid 
van de jong volwassenen (80%) had geen moeite met het innemen van medicatie in het 
bijzijn van vrienden. Opmerkelijk was dat 72% van de jong volwassenen toegaven dat ze 
hun medicatie niet altijd op de voorgeschreven tijd innamen, vooral als ze de dag daarvoor 
met vrienden waren uit geweest. Vooral tijdens het weekend ervaren jong volwassenen 
problemen met het op tijd innemen van de immunosuppressiva. Blijkbaar zijn jong 
volwassenen niet altijd even accuraat met de voorgeschreven medicatie, vooral als het 
niet in hun levensstijl past en interfereert met belangrijke sociale activiteiten zoals uitgaan 
met vrienden. Deze studie is van belang voor zorgverleners omdat het inzicht geeft over de 
motivatie achter therapieontrouw gedrag van jong volwassen niertransplantatiepatiënten.
Hoofdstuk 4 beschrijft een studie over houdingen ten aanzien van het medicatie regime 
van immunosuppressiva onder de oudere niertransplantatiepatiënten (>65 jaar). Twee 
onderscheidende houdingen werden gevonden: ‘tevreden & ontspannen’ en ‘gereserveerd 
& bezorgd’. Tevreden en ontspannen patiënten richten zich op een normaal en plezierig leven 
en zijn niet angstig of bezorgd over de consequenties als ze de medicatie niet goed innemen. 
Gereserveerde en bezorgde oudere patiënten ervaren meer psychische en psychologische 
klachten en zijn angstiger voor de consequenties als ze de medicatie niet goed innemen. 
Deze houdingen impliceren verschillende behoeftes voor begeleiding, bejegening en risico 
op therapieontrouw bij oudere patiënten. De hoeveelheid ouderen die de medicatie vergeet 
is aanzienlijk, maar niet verschillend tussen de twee verschillende houdingen. 
Hoofdstuk 5 beschrijft een prospectieve cohort studie waar we onderzochten of 
veranderingen in doel en, ziektepercepties, en overtuigingen ten aanzien van de behandeling 
van invloed waren op zelf-gerapporteerde medicatie therapieontrouw 6 maanden na 
niertransplantatie. Aan het beginpunt, 6 weken na niertransplantatie, bestond het cohort 
uit 113 niertransplantatiepatiënten. Zelf-gerapporteerde therapieontrouw nam significant 
toe tussen 6 weken en 6 maanden na transplantatie van 17% tot 27%. Het belang van 
therapietrouw als een persoonlijk doel en zelfredzaamheid om zelfstandig dit doel uit te 
voeren was hoog maar dit nam significant af in de loop van de tijd. De ervaren noodzaak 
van immunosuppressiva was hoog maar ook dit daalde significant in de loop der tijd. Zorgen 
over de medicatie waren laag. Er waren geen significante veranderingen in ziektepercepties 
of zorgen over transplantatie over de tijd. Een toename in verwachte levensduur van het 
niertransplantaat door de patiënt is gerelateerd aan een hogere kans op therapieontrouw 
zes maanden na niertransplantatie. 
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Verder hadden jongere volwassenen meer kans op therapieontrouw 6 maanden na 
niertransplantatie. In deze studie laat de mate van zelf-gerapporteerde therapieontrouw 
zo vroeg na niertransplantatie een noodzaak zien voor een vroege en continue interventie 
om de therapietrouw te verbeteren. Veranderingen in (onrealistische) overtuigingen ten 
opzichte van de verwachte levensduur van het transplantaat kan een belangrijk doel voor 
interventie zijn onder therapieontrouwe patiënten.
Hoofdstuk 6 beschrijft de 18 maanden follow-up van het cohort van de prospectieve studie 
zoals beschreven in hoofdstuk 5. Hier zien we dat de therapieontrouw significant toeneemt 
van 17% op 6 weken tot 31% op 18 maanden na transplantatie. De ervaren noodzaak voor 
de medicatie, waargenomen effect van het transplantaat op het leven (consequenties) en 
de emotionele reactie op de transplantatie daalde significant over de tijd. Deelnemers die 
therapietrouw niet als persoonlijk doel beschouwen hadden meer kans om therapieontrouw 
te worden over de tijd. Ziekte percepties kan beschreven worden als functioneel en 
bevorderend voor therapietrouw, wat inconsequent is met de alomtegenwoordige en 
toenemende therapieontrouw die is waargenomen. Er lijkt een discrepantie te bestaan 
tussen overtuigingen over therapietrouw en werkelijk gedrag. Bevordering van (intrinsieke) 
motivatie voor naleving van de doelstellingen en het verkennen van het relatieve belang in 
vergelijking met andere persoonlijke doelen zijn potentiele doelwitten voor interventies.
Hoofdstuk 7 beschrijft houdingen ten aanzien van de naleving van de medicatie 6 weken 
na de transplantatie met behulp van Q-methodologie in dezelfde cohort beschreven in 
de hoofdstukken 5 en 6. De drie houdingen die werden gevonden zijn, 1; “zelfverzekerd 
& precies”, 2; “bezorgd & waakzaam”, en 3; “uiterlijk georiënteerd & assertief”. Patiënten 
met de houding “zelfverzekerd & precies” waren zelfverzekerd over het regelen van hun 
medicatie regime 6 weken na transplantatie en hadden significant lagere variabiliteit van 
tacrolimus concentraties in hun bloed. Patiënten met de houding “bezorgd & waakzaam” 
rapporteerden angst over de medicatie en therapieontrouw en waren significant gerelateerd 
aan een hogere variabiliteit van tacrolimus concentraties in het bloed in vergelijking met 
de patiënten met houding “ zelfverzekerd & precies”. Deze bevindingen suggereren dat 
individuen gekenmerkt door angst over hun medicatie regime mogelijk minder therapietrouw 
zijn of, andersom beredeneerd, dat patiënten die meer problemen met hun medicatie 
hebben meer bezorgd zijn. Deze associatie tussen houding en therapietrouw is echter 
alleen gevonden wanneer therapietrouw werd gemeten met behulp van tacrolimusspiegels 
in het bloed, niet bij de zelf gerapporteerde therapieontrouw. Patiënten met de houding 
“uiterlijk georiënteerd & assertief” willen een normaal leven leiden, de regie houden en 
denken dat ze goed in staat zijn om voor hun transplantaatnier te zorgen, maar ervaren ook 
bijwerkingen. Hoewel hun intra-patiënten variabiliteit van tacrolimus niet gestegen was, zijn 
wij van mening dat deze patiënten mogelijk in de toekomst een hoger risico hebben op 
therapieontrouw omdat ze zich zorgen maken om de (cosmetische) bijwerkingen van het 
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medicatie regime. De Q-methodologie studie toont dus verschillende houdingen ten aanzien 
van de medicatie en therapie waarvoor verschillende benaderingen van beroepsbeoefenaren 
in de gezondheidszorg worden gevraagd. We vonden een samenhang van de houdingen van 
patiënten met intra-patiënten-variabiliteit in farmacokinetiek van tacrolimus. We vonden 
geen samenhang van houdingen van patiënten met zelf-gerapporteerde therapieontrouw of 
transplantaatoverleving en klinische eindpunten zoals afstoting of transplantaatoverleving. 
In tegenstelling tot zelf-gerapporteerde therapieontrouw 6 weken na transplantatie dat 
werd geassocieerd met transplantaatverlies in de daaropvolgende periode van 2 jaar. Deze 
bevindingen suggereren dat therapieontrouw kort na niertransplantatie een risicofactor 
kan zijn voor een lagere transplantaatoverleving in de jaren die volgen. De houdingen 
ten opzichte van het medicatie regime waren niet gerelateerd aan therapietrouw gedrag, 
maar verpleegkundigen ervaren de interview methode die wordt gebruikt als een nuttig 
instrument om te communiceren met patiënten over dit moeilijke klinische onderwerp. 
Deze resultaten worden gebruikt voor het verder informeren en ontwikkelen van een 
zelfmanagementprogramma voor patiënten kort na transplantatie. 
Hoofdstuk 8 beschrijft de algemene discussie en geeft een integratie van alle 
studieresultaten. Onderstaand de belangrijkste aandachtspunten voor verpleegkundig 
specialisten samengevat. 
Belangrijke aandachtspunten voor verpleegkundig specialisten met betrekking tot 
therapieontrouw na niertransplantatie
1. Bij ALLE patiënten dient men alert te zijn op therapieontrouw;
2. Het niet innemen van medicatie op de voorgeschreven TIJD is de meest voorkomende vorm 
van therapieontrouw;
3. Therapieontrouw kan DIRECT na transplantatie voorkomen en neemt toe in de loop van de tijd;
4. Het bespreken van therapietrouw met patiënten in de polikliniek moet deel uitmaken van de 
STANDAARD zorg;
5. De BAASIS-interview/vragenlijst is een aanbevolen hulpmiddel om snel en effectief 
therapieontrouw te METEN; 
6. HOUDING ten aanzien van therapietrouw kan verschillen van therapietrouw GEDRAG; 
7. Therapietrouw dient gestimuleerd te worden als een persoonlijk DOEL; 
8. Corrigeer patiënten die ONREALISTISCHE VERWACHTIGINGEN hebben over de levensduur van 
de donornier;
9. Het rangschikken van de Q-stellingen kan worden gebruikt als een interventie om te 
COMMUNICEREN met ontoegankelijke jong volwassenen;
10. Korte beschrijvingen van de Q-profielen kunnen worden gebruikt om inzicht te krijgen in de 
HOUDING van een patiënt ten aanzien van de therapie en de zorg daarop aan te passen.
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PhD Portfolio
1. Phd-training year hrs ECTS
Seminars and workshops
-7th Annual conference V&VN VS, Papendal; workshop 
statistics
-LWTV (Landelijke werkgroep transplantatie 
verpleegkundige) workshop, Wolfheze (including 
nonadherence)
2015
2015
4
7
International Presentations
-Ethical, Legal and Psychosocial Aspects of organ 
Transplantation, Rotterdam, The Netherlands
-29th Annual Q Conference, Amsterdam, The Netherlands
-28th Annual Q Conference, Pittsburgh, USA
-The Transplantation Society, Berlin, Germany
-European Society for Patient Adherence,COMpliance
and Persistence, Utrecht, The Netherlands
-International Transplant Nurses Society, Gothenburg, 
Sweden
-International Transplant Nurses Society; Minneapolis, USA
-International Transplant Nurses Society; Montreal, USA
-American Transplant Congress; Boston, USA
-International Transplant Nurses Society; St Louis, USA
-International Transplant Nurses Society; Denver, USA
-American Transplant Congress; San Francisco, USA
- Ethical, Legal and Psychosocial Aspects of organ 
Transplantation, Rotterdam, The Netherlands
-International Transplant Nurses Society; Rotterdam, The 
Netherlands: workshop presenter
-American Transplant Congress; Seattle, USA
-European Society of Transplant, Geneva, Switzerland
Presentation
Oral
Oral
Oral
Oral
Oral
Oral
Oral (2)
Oral
Poster
Poster
Oral
Oral
Oral
Oral
Poster
Oral
2013
2013
2012
2012
2011
2011
2010
2009
2009
2007
2007
2007
2007
2006
2005
2005
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
National Presentations
-7th Annual conference V&VN VS, Papendal 
-Annual conference NTV (bootcongres), Leiden
-5th Annual conference V&VN VS, Papendal 
-Annual conference NTV (bootcongres), Maastricht
-Annual conference NTV (bootcongres), Rotterdam
-Annual workshop Zeist; workshop presenter
Presentation
Oral
Laptop
Oral
Oral
Oral
Oral
2015
2014
2013
2012
2010
2009
1
1
1
1
1
1
2. Teaching 
Lecturing
-Lectures at meetings for patients 
-Lectures for professionals
-Minor for students
2006-2015
2006-2015
2015
8
12
Supervision
-Supervision of masterthesis MANP student
-Nurse teacher of MANP student
2014
2011-2013
2
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3. Other activities
Professional memberships 
- ITNS (international transplant nurses society)
- LWTV (landelijke werkgroep transplantatie 
verpleegkundige)
-V&VN VS (Verpleegkundigen & Verzorgenden Nederland, 
platform Verpleegkundig Specialist)
2008-2015
2008-2015
2004-2015
Committee memberships
-Board member of foundation OWVS (stichting 
ondersteuning wetenschappelijk onderzoek voor 
verpleegkundig specialisten)
-Secretary of the nurse practitioners Erasmus MC group
-Chair of the LWTV (landelijke werkgroep transplantatie 
verpleegkundige)
-Chair of the Nurse Practitioners Erasmus MC group
2012-2015
2010-2015
2008-2013
2004-2010
Grants 
-Researchgrant; EBCN (Evidence Based Care for Nurses; 
€20.000)
2011
Awards
-Best presentation NTV annual congress 2012
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Mirjam Moors-Tielen was born on May 31, 1977 in Eindhoven, the Netherlands. After 
completing secondary school at Kempenpoort, Eindhoven in 1996, she qualified as a 
Registered Nurse in 2001 at the Hogeschool Rotterdam. She started working at the transplant 
unit of the University Medical Center of Rotterdam in 2001 as a RN. There she developed an 
interest in kidney transplantation and applied to the department to create a position as nurse 
practitioner in the field of kidney transplantation. The request was accepted in 2004 and 
Mirjam completed her Master in Advanced Nursing Practice in 2006. This was the first class 
of students to graduate with the MANP degree in Rotterdam. She is now a nurse practitioner 
with more than 10 years’ experience in the field of kidney transplantation for adult patients 
at the Erasmus University Medical Center in Rotterdam. She has a special interest in 
immunosuppressive medication adherence and Q-methodology. She is an active member of 
several nursing organizations and was, for example, the President of the Dutch Workgroup 
of Transplant Nurses for 5 years. Currently, she is a board member of the nurse practitioner 
group in the Erasmus Medical Center and is also board member of the foundation of OWVS 
since 2013 (Ondersteuning Wetenschappelijk onderzoek Verpleegkundig Specialist). In her 
work as a nurse practitioner she works mainly at the outpatient clinic, evaluating transplant 
candidates and their living donors as well as providing post-transplant care. She lives in 
Breda with her husband Xavier Moors and their three children, Evi (2008), Dex (2012) and 
Cas (2014). 
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Short Q-descriptive used in young adult renal transplant patients
Which profile fits the most?
A
    
B
C
D 
 168 
Short Q-descriptive used in young adult renal transplant patients 
Which profile fits the most? 
 
 
 
 
 
I am always worried that my kidney will reject. I think it is important to 
check my kidney function in the outpatient clinic regularly, so I make 
sure I’m doing all right. I worry about the future, how long will my graft 
survive. That kind of questions keep me occupied. I am sometimes 
gloomy. I take good care of myself and I am very sparingly with my 
kidney. In comparison with other people I’m tired more. I have side-
effects of the medication. I can say no to friends. Sometimes I feel guilty 
when I eat too much. I hardly forget my medication and I am always on 
time with taking my pills. 
 
 
I think that the way I look is very important, and I don’t like the scars 
after my kidney transplantation. It is frustrating that you gain weight 
after transplantation or can’t lose it. I think I have side-effects of the 
medication. Nevertheless, I can do everything and live a normal life. 
Sometimes I am insecure whether I can find a relationship. I rather don’t 
tell I have a kidney transplant. Sometimes it is hard to  tell where my 
boundaries are, because I want to be normal. I hardly forget my 
medication. I think it is possible to do something that is not always the 
healthiest way.  
 
 
 
I never want to go back on dialyses, that was horrific. I hate living by too 
many rules. I am open about telling of my kidney transplant, but I don’t 
shout it out. I don’t need contact with other patients with a kidney 
transplant, I am like anybody else. I am independent and try to do my 
best with taking my medication, sometimes it is hard to comply. It is 
important for healthcare professionals to remind you of the importance 
of your medication, so you try harder. I can do anything and do not feel 
limitations. I trust that the doctor knows what is best.  
 
 
I think it is more important to live my life than to be compliant. I am not 
so accurate with my medication, I sometimes forget. I think you can 
forget your pills sometimes, nothing bad will happen. I find it difficult to 
say no to my friends, I want to do the same things like they do. My life is 
all about my disease enough. I have side-effects of the medication. My 
doctor or nurse may confront me with my noncompliance, so I start 
realizing what I am doing. My parents are interfering to much with my 
life. I don’t worry about the future, my life is now.  
 
 
Not at                                          Very 
All          not     A little   good    good 
Not at                                          Very 
All          not     A little   good    good 
Not at                                          Very 
All          not     A little   good    good 
Not at                                          Very 
All          not     A little   good    good 
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Dankwoord
Eindelijk is het dan zover, ook ik mag een dankwoord schrijven. Het voltooien van een 
proefschrift is een hele ‘bevalling’. Het dankwoord biedt mij een gelegenheid om stil te 
staan en dankbaar te zijn voor de mensen die mij geholpen hebben in mijn carrière, of een 
inspiratie bron of rolmodel zijn geweest, vaak zonder dat diegene zich daar bewust van is 
geweest. 
Allereerst ben ik dank verschuldigd aan alle niertransplantatiepatiënten die hebben 
deelgenomen aan de studies, letterlijk van jong tot oud. Jullie hebben me een kijkje gegeven 
in jullie leven en dank voor de eerlijke openhartige gesprekken over het moeilijke onderwerp 
therapietrouw. 
Zonder mensen te kort willen doen wil ik toch een aantal mensen in het bijzonder noemen 
die ik dankbaar ben. 
Mijn ‘serieuze’ carrière begon op de middelbare school waar mijn toenmalige leraar Engels 
meneer De Vries zei dat ik vast achter de kassa van de HEMA zou eindigen. Nu heb ik niks 
tegen het beroep caissière, maar ik heb altijd in mijn achterhoofd het idee gehad dat mijn 
tijd nog zou komen, dankzij meneer de Vries ben ik toch niet die richting opgegaan. Al heb ik 
wel enige jaren met veel plezier bij de HEMA gewerkt om wat bij te verdienen. 
Na de middelbare school volgde de HBO-V opleiding (duaal leren/werken) in Rotterdam 
en ben ik gaan werken als verpleegkundige op transplantatieafdeling 10 midden. Wat een 
fantastische tijd heb ik daar mogen beleven met veel bijzondere mensen, enkelen die ik daar 
ontmoet heb blijken vriendinnen voor het leven te zijn (Annemiek, Femke & Debbie). 
Na een open sollicitatie werd ik door professor Weimar aangenomen en ben ik de opleiding 
tot Master of Advanced Nursing Practice (MANP) gaan volgen in 2004. In 2006 afgestudeerd 
als nurse practitioner, waarna ik mij in 2012 volgens de wet verpleegkundig specialist mocht 
noemen.
Mijn promotor, Prof.dr. W. Weimar, beste Willem, allereerst bedankt dat ik het vertrouwen 
kreeg om als eerste nurse practitioner (nu verpleegkundig specialist) te mogen beginnen 
op de afdeling niertransplantatie. Bedankt voor alle kansen die u mij gegeven hebt. Ik weet 
nog goed dat u tegen me zei we gaan iets onderzoeken en dan ga je daar een abstract over 
schrijven. Ik wist niet eens wat een abstract was. Vele abstracts en mooie congresreizen 
later is hier dan het resultaat. Soms had ik wat overredingskracht nodig, er waren immers 
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nog zoveel andere leuke dingen, maar nu dan toch de eerste verpleegkundig specialist van 
het Erasmus MC die mag promoveren. Bedankt voor de mooie tijd, ik ben er trots op dat u 
mijn promotor bent, ik had geen andere willen hebben!
Mijn copromotor, dr. Emma Massey, wat fijn om jou als collega te hebben en dat je mijn 
copromotor wilde zijn. Ik heb enorm veel van je geleerd, ik ken je als een ambitieuze vrouw 
waar ik een voorbeeld in zie. Je weet jezelf en daarmee het hele team op de kaart te zetten. 
Verder wil ik je bedanken voor onze fijne samenwerking, waarbij ik meer over de praktische 
vraagstukken nadenk en jij over de theorie. Je maakt altijd tijd voor me vrij. Ook bedankt 
voor het corrigeren van mijn Engels, dat moet soms best grappig zijn geweest. 
Willij Zuidema, ik had het in het begin best lastig in mijn nieuwe functie als pionier 
en kon altijd bij je terecht. Bedankt daarvoor, ook heb ik dankzij jou veel mensen leren 
kennen en stimuleerde je mijn betrokkenheid bij bepaalde werkgroepen buiten de eigen 
niertransplantatieafdeling en stond je er voor open dat ik voorzitter van de LWTV (landelijke 
werkgroep transplantatie verpleegkundigen) werd. 
Ook Adela den Breejen was een steun voor me tijdens mijn opleiding tot verpleegkundig 
specialist, bedankt dat je mijn verpleegkundig leermeester wilde zijn. 
Tijdens de opleiding tot verpleegkundig specialist kwam ik in contact met Susan Jedeloo en 
AnneLoes van Staa van de Hogeschool Rotterdam. Zij waren diegenen die me begeleiden 
tijdens de masterthese en met hen heb ik mijn eerste artikel gepubliceerd, waarvoor dank. 
Met AnneLoes ben ik altijd contact blijven houden, en ik hoop dat we nog vele jaren blijven 
samenwerken. Ik vind het een eer om jou in de commissie te hebben.
Via Susan leerde ik Job van Exel kennen, de Nederlandse expert op het gebied van 
Q-methodologie (samen met Gjalt). Job bedankt voor al je advies en geduldige uitleg en 
de gezellige Q-congressen. Ik kan altijd een beroep op je doen! Ik heb veel van je geleerd.
Prof.dr. Teun van Gelder, jij was de eerste nefroloog die het wel aandurfde om zijn 
transplantatiepatiënten te delen met de verpleegkundig specialist, waarvoor dank. Ook al 
heb je het druk, ik krijg altijd een reactie van je via telefoon, mail of de app. Ook dat je mijn 
stukken naleest en van feedback voorziet. Wat fijn dat je in de commissie zit.
Prof.dr. Jan van Busschbach, Prof.dr. Sabina de Geest, Prof.dr. Jan van Saase en Prof.dr. Jan 
IJzermans bedankt dat jullie in de commissie willen deelnemen en tijd hebben gemaakt om 
mijn proefschrift door te nemen.
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Alle verpleegkundig specialisten in het Erasmus MC bedankt voor jullie inzet om de functie 
verpleegkundig specialist neer te zetten binnen het ziekenhuis, vorderingen lijken soms zo 
langzaam te gaan, maar als we terugblikken hebben we met z’n allen al zo veel voor elkaar 
gekregen. Ik ben er trots op om als eerste verpleegkundig specialist te mogen promoveren 
binnen het Erasmus MC, ik hoop dat nog velen van jullie mij volgen! 
Bedankt alle collega’s binnen het LWTV netwerk voor de fijne contacten, gezellige workshops, 
adviezen, bedankt voor het vertrouwen en dat ik jullie voorzitter mocht zijn. 
Verder wil ik al mijn (oud) collega’s bedanken voor de gezelligheid, de fijne gesprekken, en 
de “printer” praatjes. 
De dames van de poli; Heidi, Linda, Marja, Saskia en Silvana.
De coördinatoren; Annette, Ingrid, Jacqueline, Karin, Saliha en Sandra, bedankt voor onze 
prettige samenwerking. Ook maatschappelijk werker Nico Tronchet bedankt voor de 
samenwerking. 
De research(verpleegkundigen): Nelly, Monique, Marieken en Brigitte, bedankt voor de 
gezelligheid en interesse in mijn onderzoek. Ook voor de Nederlandse les waar ik regelmatig 
om vraag. 
De database club; Judith, Mirjam en Tessa. Judith, ik kan altijd bij je aankloppen indien 
ik weer een nieuw lijstje met eisen uit de database wil, en jij tovert dit dan zo weer in 
elkaar. Bedankt daarvoor (en blijf daar vooral mee doorgaan). Mirjam wil ik in het bijzonder 
bedanken voor het mede afnemen van de Q-methodologie, nuttige tips over Endnote tot 
alle vragen over de Kaplanmeier. 
Verder dank aan Marry (voor de ervaringsverhalen), Saida, Mathilde, Frederike, Lotte (een 
mooi voorbeeld hoe te promoveren), Dorthe en Marian voor de gezelligheid. 
De D-gang mannen: Paul en Jan, bedankt voor jullie humor. Jan, jij ziet alles, of ik het nu leuk 
vind of niet, en Paul bedankt voor het vertrouwen dat jij wel gewoon bij me in het vliegtuig 
stapt, dat durft niet iedereen.  
Alle nefrologen bedank ik voor de prettige samenwerking, met in het bijzonder de pre-
transplantatie nefrologen Jacqueline, Joke en Marcia. Ook Martijn dank ik voor zijn 
onderwijsmomenten en ondersteuning bij mijn post transplantatiepoli. Michiel Betjes 
bedankt voor de vrijheid om te promoveren. Ook alle medewerkers van het transplantatielab 
bedankt voor het afnemen van de spiegelbepalingen die ik gebruikt heb in mijn onderzoek. 
Alle medewerkers van de afdeling heelkunde voor de prettige samenwerking. 
Dit proefschrift zou er nooit gekomen zijn zonder de hulp van psychologiestudenten Denise 
Beck en Roshni Khemai, dankzij de EBCN (Evidence Based Care for Nurses) beurs konden 
zij de data verzamelen en kon ik rustig met zwangerschapsverlof. Dankzij de kundigheid en 
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accuraatheid van deze dames kon ik dat met een gerust hart overlaten. Denise wat leuk dat 
je na je afstuderen een collega van mij geworden bent en de verpleegkundig specialist nu 
een belangrijke rol in jouw onderzoeksproject speelt. 
Dan wil ik in het bijzonder mijn paranimfen bedanken, mijn 2 collega’s Louise en Marleen. 
Heb altijd gezegd dat mocht ik ooit gaan promoveren dat zij mijn paranimfen mochten zijn. 
Nu is het dan eindelijk zover. Ook jullie hebben een bijdrage geleverd aan dit proefschrift 
met het afnemen van de Q. Mijn werk begon pas echt leuk te worden toen ik jullie als 
collega’s kreeg. Ik ben nu eenmaal een teamplayer en heb mensen in mijn omgeving nodig 
die me stimuleren. Mede dankzij jullie kunnen we de functie en continuïteit van ons beroep 
pas goed vorm geven. Ik ben er trots op als je ziet wat we in die jaren allemaal al bereikt 
hebben. We zijn alle drie verschillend maar dat maakt onze samenwerking des te sterker, 
we vullen elkaar aan en zijn een hecht team. Ook buiten het werk kunnen we het goed met 
elkaar vinden. Ik hoop met jullie nog lang samen te mogen werken. Bedankt dat jullie achter 
me willen staan op deze belangrijke dag. 
In mijn persoonlijk leven dank ik al mijn vrienden en familie voor een luisterend oor en de 
interesse die jullie in mijn onderzoek hebben getoond. Thijs, bedankt voor het maken van 
de mooie kaft. Mijn hechte vriendenkring bedank ik voor de gezelligheid en gekkigheid die 
we uithalen, mijn BFF Hedwig, Femke & Kevin, Debbie & Hans, Annemiek & Michiel. Jullie 
geven me energie!
Mijn broer Remco en schoonzus Marit, bedankt voor jullie interesse. Mijn andere schoonzus 
Chantalle en zwager Paul. We hebben samen al heel wat doorstaan. Mijn lieve oma, die trots 
is op alles wat ik bereikt heb. 
Overige vrienden, familie, kennissen, bedankt voor jullie interesse. 
Mijn ouders dank ik voor de fijne warme jeugd die ze me gegeven hebben. Ze hebben me 
geleerd om een zelfstandige sterke vrouw te zijn met een eigen mening. Ik weet dat jullie 
trots op me zijn, wie had gedacht dat ik ooit zou promoveren. Mijn doorzettingsvermogen 
heb ik van jullie. Jullie hebben me altijd gestimuleerd om de kansen te grijpen die er liggen. 
Ik weet dat ik altijd op jullie kan terugvallen, tegelijkertijd hebben jullie mij geleerd dat ik het 
wel red. Wat fijn dat we in het mooie Brabant zijn gaan wonen en we iets dichter bij elkaar 
wonen. Wat heerlijk mam om te zien hoe je elke week op onze kinderen past en hen leert 
wat je mij hebt geleerd, ik hoop nog heel lang van jullie beiden te genieten.
Xavier bedankt, met jou deel ik mijn leven, reislust, hobby’s, verdriet, geluk, huishouden, 
blijdschap, humor (gedeeltelijk dan) en nog veel meer. Wij kunnen alles aan zolang we het 
samen blijven doen. Je hebt me altijd gestimuleerd om dit boekje te schrijven en vertelt het 
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trots tegen iedereen die het maar wil horen, want je vindt het maar wat stoer om straks een 
doctor als vrouw te hebben. 
We hebben samen al heel wat meegemaakt, en ik weet dat je mijn rugzak altijd de Machu 
Picchu op zal dragen. The sky is the limit, maar niet voor ons…. 
Samen hebben we drie prachtige kinderen gekregen, waar we intens van genieten. Ze zijn 
alle drie unieke temperamentvolle kinderen, dat moet ook wel met ons als ouders. 
Lieve Evi, Dex & Cas, mama houdt van jullie! 
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